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ABSTRACT 
               The organic anion transporting polypeptides (human: OATP; other: Oatp) 
form a mammalian transporter superfamily that mediates the transport of structurally 
unrelated compounds across the cell membrane. Members in this superfamily 
participate in the absorption, distribution and excretion of many endogenous and 
exogenous substances including a number of medications and environmental 
toxicants. Polymorphisms of OATPs have been shown clinically to give rise to inter-
individual variabilities of drug efficacy and/or toxicity. Furthermore, as multi-specific 
transporters, they are potential sites for drug-drug interactions. Therefore, 
understanding the mechanism of OATP/Oatp mediated transport of endo- and 
xenobiotics will not only help to improve drug efficacy but also to improve the 
prediction and prevention of toxicity. The overall goal of this dissertation is 
identifying key amino acids that may play an important role in OATP/Oatp-mediated 
transport and investigating the spatial size of the substrate binding/translocation 
pocket. In this dissertation, I defended three specific aims. In the first specific aim, I 
evaluated the hypothesis that conserved positively charged amino acids play important 
roles in OATP1B1 transport function. To address this aim, site-directed mutagenesis 
was employed and the mutants of several conserved positively charged amino acids were 
studied. The two extracellular amino acids R57 and K361 were found to be important in 
OATP1B1 mediated transport of estradiol-17β-glucuronide, estrone-3-sulfate and BSP. 
In the second specific aim, I evaluated the hypothesis that quantifying transport 
activities of different substrates mediated by chimeras between rat Oatp1a1 and 
 vi
Oatp1a4 in combination with site-directed mutagenesis should allow us to identify 
regions and/or individual amino acids that are important for Oatp1a4-mediated 
substrate recognition and/or transport. The effects of chimeric proteins on transport 
activity were substrate dependent. Extracellular loop 4 and transmembrane domain 8 
were identified to be important in transport of digoxin, taurocholate and estradiol-
17β-glucuronide. The C-terminal half of Oatp1a4 and Oatp1a1 was found to be 
important for BSP transport and the interactions between the N-terminal half and the 
C-terminal half of Oatp1a4 is essential for DPDPE transport. In the third specific aim, 
I evaluated the hypothesis that different rat renal organic anion transporters of the Oat 
and Oatp families selectively transport perfluorinated carboxylates (PFCAs) depending 
on the chain lengths. The purpose of this study was to determine the substrate size 
selectivity of Oats and Oatp1a1. To address this aim, the inhibitory effects of PFCAs with 
chain length from C2 to C18 on transport of model substrates by rat Oat1, Oat2, Oat3, 
Urat1 and Oatp1a1 was quantified. Furthermore, direct uptake of the best inhibitors was 
characterized. The best substrates for Oats were C7 and C8, whereas Oatp1a1 transported 
longer PFCAs such as C9 and C10 better than C8 and C7. Altogether, this dissertation 
reveals that (1) some conserved positively charged amino acids and the C-terminal half 
are important for OATP/Oatp mediated transport of certain substrates; (2) OATP/Oatps 
have several binding/translocation sites for different substrates and (3) the preferred 
substrate size for OATP/Oatps is slightly bigger than that for Oats.    
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 CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
 
I.    INTRODUCTION TO MEMBRANE TRANSPORTERS 
          Membrane transporters are proteins with the ability to move molecules 
across biological membrane borders in living cells. They control both intercellular 
and intracellular exchange of nutrients, ions, metabolites, signaling molecules and 
xenobiotics. The essential physiological roles of transporters are supported by the 
fact that transporters are ubiquitously present in bacteria, archaea and eukarya 
(Saier, 2000).  
     
          Organic anion transporting polypeptides (human OATPs; rodent Oatps) 
form a superfamily of membrane transporters that mediate the movement of a 
wide range of amphipathic organic compounds across plasma membranes 
(Hagenbuch and Meier, 2003; Hagenbuch and Meier, 2004). Together with 
organic anion transporters (OATs), they control most organic anion uptake in all 
mammalian organisms. The aim of the studies presented in this dissertation is to 
understand the structural requirements of the transporter and the structural 
requirements of the substrates for the transport activities of OATP/Oatps in the 
context of their physiological, pharmacological and toxicological roles.  
 
            In this dissertation, I will first introduce the classification systems and 
related nomenclatures of transporters that will be helpful later in understanding 
both the published studies and the primary research reported in this dissertation.  
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 Then I will provide some details regarding the OATP/Oatp superfamily focusing 
on their biological and toxicological roles as well as on structure-function 
characterizations.   From the review of published literature, I will build the 
framework required for designing the primary research reported in subsequent 
chapters.  In conjunction with other published results, these data begin to reveal 
some critical structural features of both transporters and substrates required for 
OATP/Oatp mediated transport.   
 
 
II.    CLASSIFICATION OF TRANSPORTERS 
          Due to the various transport mechanisms and diversified substrate spectra, 
there are multiple classification systems for membrane transporters.   Based on 
mechanisms and energy source, membrane transporters can be divided into 2 
broad classes: passive transporters and active transporters. Passive transporters 
include ion channels (such as Na+ channels) and facilitated diffusion transporters 
(such as the glucose transporters of the GLUT family). Active transporters can be 
further divided into primary active and secondary active transporters. Primary 
active transporters such as the Na+/K+ ATPase directly use ATP as energy source. 
Secondary active transporters, such as the Na+/ amino acid symporters and the 
Na+/H+ exchanger, use ion gradients established, for example, by the Na+/K+ 
ATPase as their energy source (Saier, 2000).   
 
            The two largest superfamiles of membrane transporters are the ATP-
binding cassette (ABC) superfamily and the major facilitator superfamily (MFS). 
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 ABC transporters generally have multiple transmembrane components, capable of 
transporting both small molecules and macromolecules in response to ATP 
hydrolysis. Members of the ABC superfamily are primary active transporters such 
as the human ABCB1 (MDR1) (Jones and George, 2004). The MFS transporters 
are single-polypeptide carriers capable of transporting small solutes. Members of 
the MFS superfamily can be either active transporters, such as the glycerol-3-
phosphate transporter, or passive transporters, such as GLUT2 (Pao et al., 1998).   
 
          All genes encoding mammalian transporters either belong to SLC (Solute 
Carrier) families or non-SLC families based on substrate specificity and amino 
acid sequence identities. A transporter belongs to a specific SLC family if it has at 
least 20–25% amino acid sequence identity to existing members in that family 
(Hediger et al., 2004). SLC families include genes encoding passive transporters, 
ion-coupled transporters and exchangers for different kinds of substrates. A list of 
current SLC families is shown in Table 1-1.  Examples of SLC transporters include 
glucose transporters, metal transporters, and organic anion transporters.  Examples 
of non-SLC transporters include ABC transporters, ion channels, and water 
channels.  
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 Table 1-1: The HGNC solute carrier family series 
  SLC1: The high affinity glutamate and neutral amino acid transporter family  
  SLC2: The facilitative GLUT transporter family
  SLC3: The heavy subunits of the heteromeric amino acid transporters 
  SLC4: The bicarbonate transporter family 
  SLC5: The sodium glucose cotransporter family 
  SLC6: The sodium- and chloride- dependent neurotransmitter transporter family  
  SLC7: The cationic amino acid transporter/glycoprotein-associated family
  SLC8: The Na+/Ca2+ exchanger family
  SLC9: The Na+/H+ exchanger family
  SLC10: The sodium bile salt cotransport family
  SLC11: The proton coupled metal ion transporter family 
  SLC12: The electroneutral cation-Cl cotransporter family 
  SLC13: The human Na+-sulfate/carboxylate cotransporter family
  SLC14: The urea transporter family 
  SLC15: The proton oligopeptide cotransporter family
  SLC16: The monocarboxylate transporter family
  SLC17: The vesicular glutamate transporter family 
  SLC18: The vesicular amine transporter family 
  SLC19: The folate/thiamine transporter family 
  SLC20: The type III Na+-phosphate cotransporter family
   SLCO: The organic anion transporting family 
  SLC22: The organic cation/anion/zwitterion transporter family
  SLC23: The Na+-dependent ascorbic acid transporter family
  SLC24: The Na+/(Ca2+-K+) exchanger family 
  SLC25: The mitochondrial carrier family 
  SLC26: The multifunctional anion exchanger family 
  SLC27: The fatty acid transport protein family
  SLC28: The Na+-coupled nucleoside transport family 
  SLC29: The facilitative nucleoside transporter family
  SLC30: The zinc efflux family  
  SLC31: The copper transporter family 
  SLC32: The vesicular inhibitory amino acid transporter family 
  SLC33: The Acety-CoA transporter family 
  SLC34: The type II Na+-phosphate cotransporter family
  SLC35: The nucleoside-sugar transporter family 
  SLC36: The proton-coupled amino acid transporter family 
  SLC37: The sugar-phosphate/phosphate exchanger family 
  SLC38: Family of System A and System N sodium-coupled neutral amino acid transporters 
  SLC39: The metal ion transporter family
  SLC40: The basolateral iron transporter family 
  SLC41: The MgtE-like magnesium transporter family
  SLC42: The Rh ammonium transporter family
  SLC43: Na+-independent, system-L like amino acid transporter family
  SLC44: Choline-like transporter family 
  SLC45: Putative sugar transporter family 
  SLC46: Folate transporter family 
  SLC47: Multidrug and Toxin Extrusion (MATE) family
  SLC48: Heme transporter family 
 
Reprinted by permission from the publisher, Pflugers Arch.: 447: 465-468, 2004  (Copyright © 
Springer); See license in Appendix III 
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   III.    INTRODUCTION TO OATPS 
  A.   Basic information and history 
          Organic anion transporting polypeptides (human: OATPs; all other species: 
Oatps; gene symbol: SLCO/Slco; Old gene symbol: SLC21A/Slc21a) form a 
superfamily within the SLC families that mediate the sodium-independent 
transmembrane transport of a wide range of amphipathic endogenous and 
exogenous organic compounds (Hagenbuch and Meier, 2003; Hagenbuch and 
Meier, 2004). The first Oatp was cloned and characterized from rat liver 
(Oatp1a1) in 1994 (Jacquemin et al., 1994). In 2004, a new nomenclature for this 
superfamily of transporters was introduced (Hagenbuch and Meier, 2004). The 
entire superfamily is classified into 6 families (families OATP1/Oatp1 through 
OATP6/Oatp6) and each family, into subfamilies (e.g., OATP1A, OATP2B). 
Each individual family contains proteins with amino acid sequence identities of 
more than 40%; subfamilies contain proteins with amino acid sequence identities 
of more than 60%. Individual paralogues within a subfamily are indicated by 
different final numbers (e.g., Oatp1a1, OATP1A2, Oatp1a3, Oatp1a4, etc.). More 
than 160 OATP/Oatps have been predicted in at least 25 different species. 
However, only a few OATP/Oatps have been functionally characterized 
(Hagenbuch and Gui, 2008).  
 
          In mammals, many of the OATP/Oatp transporters are distributed in 
multiple cell types or organs, whereas some of them are predominantly expressed 
in one or two cell types or organs. For example, OATP1B1 and OATP1B3 are 
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 considered to be exclusively expressed in human hepatocytes; OATP1A2 has 
strongest expression in brain, whereas it is also expressed in multiple organs such 
as kidney, liver, ciliary body and intestine. OATP/Oatps exhibit broad and 
overlapping substrate specificity. The cell type or organ distribution and model 
substrates of most of the common OATP/Oatps are summarized in several reviews 
(Hagenbuch and Meier, 2003; Hagenbuch and Meier, 2004; Konig et al., 2006; 
Hagenbuch and Gui, 2008). Table 1-2 is a list of basic information about the 
OATP1/Oatp1 family, and the primary research presented in later chapters will 
focus on several members in this family.  
 
B.  OATPs and human health 
          The roles of OATPs in human health have been extensively studied in 
various organs such as brain, liver and kidney for the past ten years. These studies 
have addressed the roles of OATPs in the context of physiology, pharmacology 
and toxicology.  
 
(1)  Distribution of OATPs in normal human organs 
          Three OATPs have been shown to be expressed in the brain. OATP1A2 is 
expressed in the endothelial cells of the blood brain barrier (Kullak-Ublick et al., 
1995; Gao et al., 2000). Given the location and broad substrate spectrum of 
OATP1A2, it may be involved in delivering CNS drugs or drugs with CNS side 
effects across the blood-brain barrier. A number of drugs or toxins that exhibit 
either CNS efficacy or toxicity have been shown to be OATP1A2 substrates, such 
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 Table 1-2: Members in OATP1/Oatp1 family 
 
Gene 
symbol 
Protein 
name 
Other 
names 
Species Predominant substrate Organ 
distribution 
Slco1a1 Oatp1a1 Oatp1 Rodent Bile salts, organic 
anions, organic 
cations 
Liver, kidney, 
choroid plexus 
SLCO1A2 OATP1A2 OATP-A Human Bile salts, organic 
anions, organic 
cations 
Brain, kidney, 
liver, ciliary 
body 
Slco1a3 Oatp1a3_v1  
Oatp1a3_v2 
OAT-K1       
OAT-K2 
Rodent Bile salts, organic 
anions 
Kidney 
Slco1a4 Oatp1a4 Oatp2 Rodent Digoxin, bile salts, 
organic anions 
Liver, Brain, 
choroid plexus, 
ciliary body, 
retina 
Slco1a5 Oatp1a5 Oatp3 Rodent Bile salts, organic 
anions 
Jejunum, 
choroid plexus 
      
Slco1a6 Oatp1a6 Oatp5 Rodent   
      
SLCO1B1 OATP1B1 OATP-C, 
LST-1, 
OATP2 
Human Bile salts, organic 
anions 
Liver 
Slco1b2 Oatp1b2 Oatp4,  
Lst-1 
Rodent Bile salts, organic 
anions 
Liver, ciliary 
body 
      
SLCO1B3 OATP1B3 OATP8 Human Bile salts, organic 
anions, digoxin 
 
SLCO1C1 OATP1C1 OATP-F        
OATP-RP5 
Human T3, rT3, BSP Brain, Leydig 
cells 
Slco1c1 Oatp1c1 Oatp14, 
BSAT1 
Rodent   
 
Reprinted by permission from the publisher, Pflugers Arch.: 447: 653-665, 2004 (Copyright © 
Springer); See license in Appendix III. 
 
 7
 as D-penicillamine2,5-enkephalin (DPDPE) (Gao et al., 2000), methotrexate 
(Badagnani et al., 2006), levofloxacin (Maeda et al., 2007) and microsystin 
(Fischer et al., 2005). OATP1C1, a high-affinity thyroxine transporter, is also 
located in the brain (Pizzagalli et al., 2002). OATP1C1 has been suggested to be 
essential for thyroid hormone delivery to the developing brain (Hagenbuch, 2007). 
In addition, a number of nonsteroidal antiinflammatory drugs in the fenamate 
class have been shown to competitively inhibit thyroxine transport mediated by 
OATP1C1 (Westholm et al., 2009). Taken together, OATP1C1 thought to be an 
important thyroid hormone transporter and a potential drug-drug interaction site in 
the brain. OATP2B1 is expressed at the luminal membrane of brain endothelial 
cells (Bronger et al., 2005). OATP2B1 has relatively narrow substrate specificity 
at pH 7.4. OATP2B1 transports bromosulfophthalein (BSP) (Kullak-Ublick et al., 
2001), estrone-3-sulfate and dehydroepiandrosterone-3-sulfate (Pizzagalli et al., 
2003).  However, at lower pH, additional substrates have been reported such as 
taurocholate and statins (Nozawa et al., 2004). Therefore, the pH of the micro 
environment might be important for OATP2B1 transport activity.   
 
          Several OATPs are expressed in liver, the primary detoxification organ. 
OATP1B1, a liver-specific OATP (Abe et al., 1999; Hsiang et al., 1999; Konig et 
al., 2000),  is localized to the basolateral membrane of hepatocytes (Konig et al., 
2000). In addition to transporting endogenous metabolites such as bilirubin (Briz 
et al., 2003) and taurocholate (Abe et al., 1999; Hsiang et al., 1999; Kullak-Ublick 
et al., 2001), OATP1B1 also mediates the liver uptake of a large number of drugs 
 8
 and toxins (Hagenbuch and Gui, 2008). The potential drug-drug interactions via 
OATP1B1 and the impact of OATP1B1 polymorphisms on the pharmacokinetics 
of several drugs such as rifampicin (Vavricka et al., 2002; Tirona et al., 2003; 
Treiber et al., 2007; van Giersbergen et al., 2007), pravastatin, rosuvastatin, 
pitavastatin (Nishizato et al., 2003; Morimoto et al., 2004; Mwinyi et al., 2004; 
Niemi et al., 2004; Simonson et al., 2004; Tachibana-Iimori et al., 2004; Chung et 
al., 2005; Kameyama et al., 2005; Hirano et al., 2006; Maeda et al., 2006; Noe et 
al., 2007; Seithel et al., 2007; Kitamura et al., 2008; Neuvonen et al., 2008; 
Vaidyanathan et al., 2008; Furihata et al., 2009; Qiang et al., 2009) and irinotecan 
(SN-38) (Nozawa et al., 2005; Rohrbacher et al., 2006) have been extensively 
studied in both cell lines and  clinical settings.  
 
          Another liver-specific OATP is OATP1B3, which has 80% amino acid 
identity to OATP1B1 (König et al., 2000; Abe et al., 2001). In addition to many 
substrates shared with OATP1B1, OATP1B3 also has its own specific substrates, 
such as cholecystokinin octapeptide (CCK-8) and the anticancer drugs paclitaxel 
and docetaxel (Ismair et al., 2001; Kullak-Ublick et al., 2001; Smith et al., 2005). 
Oatp1b2 is the rodent orthologue of OATP1B1 and OATP1B3. In 2008, Oatp1b2 
knockout mice were reported (Lu et al., 2008; Zaher et al., 2008).  These mice 
showed no morphological abnormalities. They were used to further characterize 
the role of Oatp1b2 in the pharmacokinetics of pravastatin and rifampin (Zaher et 
al., 2008) and in the hepatic uptake/toxicity of phalloidin and microcystin-LR (Lu 
et al., 2008) in vivo. In addition to the two liver-specific OATPs, several other 
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 OATPs including OATP1A2, OATP2A1, OATP2B1 and OATP4A1 (Hagenbuch 
and Gui, 2008) are also expressed in the liver. Except for OATP2A1, which may 
be involved in the regulation of pericellular prostaglandin levels (Schuster, 2002) 
and OATP1A2 which has been localized to cholangiocytes (Lee et al., 2005), all 
the other OATPs in the liver are thought to play important roles in the absorption 
and disposition of numerous endobiotics and xenobiotics (Hagenbuch and Gui, 
2008).  
 
 
          In contrast to liver, there are only two major OATPs expressed in the 
kidney: OATP4C1 and OATP1A2. OATP4C1 is localized to the basolateral 
membrane of the proximal tubule (Mikkaichi et al., 2004) whereas OATP1A2 is 
localized to the brush border membrane in the distal nephron (Lee et al., 2005). 
OATP4C1 is considered a kidney-specific transporter. In addition to its possible 
function of delivering thyroid hormone, OATP4C1 also transports a number of 
drugs such as digoxin, ouabain and methotrexate into kidney, and thus may play 
an important role in the renal elimination and disposition of these medications. 
OATP1A2 is expressed in multiple organs,  including brain (Gao et al., 2000), 
kidney (Lee et al., 2005) and intestine (Glaeser et al., 2007). Therefore, OATP1A2 
is likely involved in the disposition of a number of drugs and potentially serves as 
a drug-drug and drug-food interaction site. A good example of this phenomenon is 
OATP1A2 mediated uptake of fexofenadine, and its interactions with other 
xenobiotics (Cvetkovic et al., 1999; Dresser et al., 2002; Dresser and Bailey, 
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 2003; Dresser et al., 2005; Kamath et al., 2005; Shimizu et al., 2005; Bressler, 
2006; Kikuchi et al., 2006; Glaeser et al., 2007; Matsushima et al., 2008; 
Greenblatt, 2009; Qiang et al., 2009).  
 
(2)  Expression of OATPs in cancer 
          In addition to the normal expression of OATPs in various organs, several 
types of cancers have recently been shown to overexpress certain OATPs. For 
example, the liver-specific OATP1B3 has been detected in gastrointestinal cancers 
(Abe et al., 2001; Lee et al., 2008), breast cancer (Muto et al., 2007; Wlcek et al., 
2008) and prostate cancer (Hamada et al., 2008).  Another liver-specific 
transporter, OATP1B1 has been found in neoplastic colon tissue (Ballestero et al., 
2006). In addition, OATP1A2 mRNA levels have been shown to be high in breast 
cancer, compared to the adjacent healthy tissue (Meyer zu Schwabedissen et al., 
2008). Because several OATPs, such as OATP1B1, OATP1B3 and OATP1A2 are 
able to transport hormones and hormone conjugates (Hagenbuch and Gui, 2008), 
the expression of OATPs may contribute to  hormone-dependent growth of 
cancerous cells, and anti-apoptotic progression of cancer (Muto et al., 2007; 
Hamada et al., 2008; Lee et al., 2008; Meyer zu Schwabedissen et al., 2008). 
However, OATPs are also able to transport anti-cancer drugs such as methotrexate 
and paclitaxel (Hagenbuch and Gui, 2008). Therefore, OATPs are candidate 
carriers that could deliver anti-cancer drugs to cancer cells. The studies of the 
function and expression of OATPs under pathological conditions are undoubtedly 
very valuable to understand and treat cancers.  
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(3) OATP/Oatp expression in response to endogenous compounds and xenobiotics 
           Hepatocyte nuclear factor 1 alpha has been shown to regulate the liver-
specifc expression of OATP1B1 and OATP1B3 (Jung et al., 2001).  The 
expression of OATP/Oatps is also influenced by endogenous and exogenous 
stimulants. It has been shown that in rodents, sex hormones regulate the sex 
specific expression of Oatps in kidney (Lu et al., 1996; Cheng and Klaassen, 
2006; Cheng and Klaassen, 2009) and liver (Rost et al., 2005; Cheng and 
Klaassen, 2006; Cheng et al., 2006). Prolactin and growth hormone can upregulate 
rat Oatp1b2, and human OATP1B3 gene expression via the Stat5 signal-
transduction pathway (Wood et al., 2005). Growth hormone can also regulate 
Oatp1a1 expression in mouse liver but not in kidney (Cheng et al., 2006). The 
proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) 
(Vee et al., 2009), interferon-gamma (Le Vee et al., 2010), and hepatocyte growth 
factor (Le Vee et al., 2009) down-regulate the expression of several OATPs in 
human hepatocytes. However, using knock-out mouse models, the down-
regulation of Oatp1a1 after lipopolysaccharide (LPS) or bile-duct ligation  
induced cholestasis has been shown to be independent of the individual activity of 
TNF-α, IL-1, IL-6, or NF-κB (Lickteig et al., 2007). These findings suggest that 
physiologically and pathologically, there is more than one pathway involved in the 
regulation of OATP/Oatp expression at the transcriptional level.  
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           In addition to endogenous regulators, a number of xenobiotics can also 
affect the expression of OATP/Oatps. It has been shown in mouse, rats, and 
humans that inducers of the aryl hydrocarbon receptor (AhR), constitutive 
androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-
activated receptor α (PPAR-α), and nuclear factor erythroid 2-related factor 2 
(Nrf2) can modulate the expression of OATP/Oatps in either liver, kidney or 
intestine (Guo et al., 2002; Cheng et al., 2005; Cheng et al., 2006; Jigorel et al., 
2006). In addition, LPS can down-regulate Oatp1b2 in mouse liver through the 
toll-like receptor 4 (TLR4) (Li et al., 2004). Moreover, perfluorooctanoic acid and 
perfluorodecanoic acid can down-regulate Oatps in mouse liver through PPAR-α 
pathways (Cheng and Klaassen, 2008). Kidney Oatps are differentially regulated 
after cisplatin treatment (Aleksunes et al., 2008). 
           
          Compared to the transcriptional regulation mediated by endogenous 
molecules, the body has additional systems to regulate OATP/Oatp expression in 
response to exposure to xenobiotics. For a multispecific transporter superfamily 
that can transport many classes of compounds, including nutrients and toxicants, a 
fine-tuned regulating system is essential for adaptation to the changing 
environment.  
 
          In summary, as a superfamily of multispecific transporters, OATPs are able 
to deliver different classes of substrates, both endogenous and exogenous, to 
different parts of the body. They play important roles in 1) maintaining the normal 
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 physiological metabolite flow in the body, 2) delivering drugs and toxicants to the 
site of action, and 3) defending the body from environmental and biological 
toxins. Furthermore, the abnormal expression of OATPs in cancers may contribute 
to the pathogenesis of cancers, but may also represent a potential mechanism for 
the uptake of anti-cancer drugs. The importance of OATP/Oatps, both 
physiologically and/or pathologically, has inspired many researchers to study this 
superfamily of transporters at the molecular level. In the next section, I will 
review studies performed by several groups analyzing the structure and function 
relationships of OATP/Oatps using different approaches.  
 
C.   Structural features of OATP/Oatps 
          As a superfamily of membrane proteins, there are several common 
structural features that all OATP/Oatps share. First, membrane protein topology 
programs suggest that all OATP/Oatps contain 12-transmembrane (TM) domains, 
with both N- and C- termini inside the cell. This 12-TM topology has been 
verified experimentally for rat Oatp1a1 by immunofluorescence analysis, using an 
epitope-specific antibody designed to differentiate a 10- from a 12-transmembrane 
domain model (Wang et al., 2008). Second, all OATP/Oatps have a large 
extracellular loop between TMs 9 and 10 that contains many conserved cysteine 
residues. Site-directed mutagenesis of these conserved cysteines has been 
performed for OATP2B1. The results suggest that all 10 extracellular cysteines 
normally form disulfide-bonds that are important in the trafficking and function of 
OATP2B1 (Hanggi et al., 2006). Third, there are N-glycosylation sites in 
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 extracellular loops 2 and 5 (Lee et al., 2003). The glycosylation sites of Oatp1a1 
have been mapped to asparagines 124 (extracellular loop 2), 135 (extracellular 
loop 2), and 492 (extracellular loop 5) (Lee et al., 2003; Wang et al., 2008). 
Finally, all OATP/Oatps share the OATP ‘‘superfamily signature’’: a stretch of 
highly conserved consensus amino acids D-X-RW-(I,V)-GAWW-XG-(F,L)-L at 
the border of extracellular loop 3 and TM6 (Hagenbuch and Meier, 2003).  
 
          Several OATP/Oatps, including OATP1A2, OATP2B1 and rat Oatp1a1, 
have a PDZ consensus binding site at their C termini (Wang et al., 2005). 
Oligomerization of Oatp1a1 with PDZK1, via this consensus sequence, has been 
shown using cell lines and PDZK1 knock out mice to be very important for proper 
cell surface localization and function of Oatp1a1 (Wang et al., 2005). PDZK1 is a 
major scaffold protein and is important in determining the location of many 
membrane-associated proteins to defined areas of the plasma membrane (Gisler et 
al., 2003; Kocher et al., 2003). The presence of PDZ consensus binding sites in 
several OATP/Oatps indicates that PDZK1 may play a role in the subcellular 
localization of some OATP/Oatps.  
 
         Figure 1-1 summarizes the general features of OATP/Oatps.  However, more 
information is needed to answer the question: how do these transporters carry 
substrates across the membrane?  
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Figure 1-1   General features of OATP/Oatps. OATP/Oatp proteins are 
predicted to have 12-transmembrane domains with both N- and C- termini inside 
the cell. Highly conserved amino acids among most OATP/Oatps are indicated in 
black. Conserved and charged amino acids (D, E, K, R) are given in gray, and 
conserved cysteines (C) are marked with asterisks. Three potential N-
glycosylation sites (Y) predicted for rat Oatp1a1 are present on extracellular 
protein loops. The OATP superfamily signature is indicated at the border of the 
extracellular loop 3 and the transmembrane domain 6. 
 
Reprinted by permission from the publisher, Biochim Biophys Acta.: 1609: 1-18 
(Copyright © 2002 Elsevier Science B.V.); See license in Appendix III: List of license 
agreements for copyrighted materials. 
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           Scientists have evaluated the transport process using two major approaches. 
One is to investigate how the transporter interacts with its substrates. In other 
words, which parts of the transporter are important for substrate binding, and what 
structural requirements are needed for the transporter to complete the translocation 
process?  The other approach is to concentrate on the substrates. One can 
determine what structural requirements are needed for a molecule to be a 
substrate, and what other molecules are required for the movement of the 
substrate.  In the field of OATP/Oatps, researchers have studied the transport 
mechanisms from both perspectives during the past 15 years. The approaches and 
findings are discussed below in detail.  
 
D.    Structure and function studies of OATP/Oatps 
(1)    Structural requirement of OATP/Oatps for proper transport function.  
 (i)  Crystallography 
           X-ray crystallography is the most direct way to characterize transporter 
protein structures and to study transport mechanisms, especially if the protein can 
be crystallized in the presence of substrates.  However, because of the difficulties 
associated with expression and crystallization of membrane proteins, the crystal 
structures of very few membrane proteins are available. In the major facilitator 
superfamily, only three crystal structures have been solved for 12 TM membrane 
transporters: lactose permease of Escherichia coli (E. coli) (Abramson et al., 
2003), glycerol-3-phosphate transporter of E. coli (Huang et al., 2003) and the 
multidrug transporter EmrD of E. coli (Yin et al., 2006). Despite the low sequence 
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 similarity of these three membrane transporters, the reported structures are highly 
similar with 12-transmembrane helices. This led to the hypothesis that all 
members of the MFS share a similar structure, regardless of their low sequence 
identity (Vardy et al., 2004). The importance of this structural homology will be 
considered in the following discussion on computer modeling and mutagenesis.  
 
(ii)  Computer modeling 
           Computational or in silico methods have been adopted widely to study 
structure-function relationship of transporters, especially in the absence of crystal 
structures. There are two main approaches to modeling the structure-function 
relationship of transporters: transporter-based modeling and substrate-based 
modeling.  I will introduce the transporter-based methods in this section and the 
substrate-based methods will be discussed in later sections. In transporter-based 
modeling, at least one crystal structure of a template protein is required. This 
template must have a high level of homology with the target transporter. The 
homology requirement can be either sequence homology, such as high amino acid 
sequence identities, or structural homology, such as the same number of 
transmembrane domains. After selecting the best fit template, the next step is 
sequence alignment of the target protein with the template. Based on the 
alignment, a 3D structure model of the target protein is then generated, optimized, 
and validated (Chang and Swaan, 2006). Furthermore, using the 3D model of the 
target protein, important amino acids can be predicted, and docking studies can be 
performed. A docking study describes the “best-fit” orientation of a substrate that 
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 binds to the target transporter model, and predicts the putative binding or 
substrate-protein interaction domains.  In recent years,  three dimensional models 
have been generated for more than 20 membrane transporters, such as the human 
apical sodium bile acid transporter (ASBT) (Zhang et al., 2002; Zhang et al., 
2004), the human organic anion transporter 1 (Oat1) (Perry et al., 2006) and 
human OATP1B3 and OATP2B1 (Meier-Abt et al., 2005).   The great advantage 
of generating a computer model is that the model may provide information 
regarding the orientation and spatial position of amino acids that may be important 
in structure or function of the transporter. In other words, a computer model is a 
very powerful hypothesis generator for subsequent studies, such as site-directed 
mutagenesis.   
 
(iii)  Polymorphisms studies 
           Naturally occurring polymorphisms have provided some insights into the 
structure-function relationship for OATP/Oatps. Polymorphisms in OATP/Oatps 
encode the same transporter with one or a few mutated amino acids. The most 
common polymorphism is the single nucleotide polymorphisms (SNPs), which 
results in a point mutation in the primary structure of the transporter. Sometimes, 
a combination of two or more SNPs can also be found in certain populations. 
Studying the transport function of different polymorphisms allows evaluating the 
importance of a particular amino acid for the structure and/or function of the 
transporter. Because OATP1A2, OATP1B1, and OATP1B3 are highly involved in 
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 drug disposition, the effects of polymorphisms on transport activities of these two 
transporters have been examined.  
 
          For OATP1A2, E172D (A516C), N135I (A404T), and T668S (C2003G) 
variants have altered expression of the transporter in the plasma membrane, which 
may contribute to the reduced transport activity (Lee et al., 2005; Badagnani et al., 
2006). The N135I variant has also been shown to have alterations in glycosylation 
status (Lee et al., 2005).  
 
          At least 15 alleles have been identified for OATP1B1 polymorphisms 
(Fahrmayr et al., 2010). OATP1B1*5 (V174A, T521C) and OATP1B1*15 
(V174A, T521C + N130D, A388G) influence the pharmacokinetics or 
pharmacodynamics of drug substrates the most. Extensive clinical research has 
been done to study the effects of these two polymorphisms on efficacy, clearance, 
and toxicity of a number of drugs including statins, rifampicin, and irinotecan 
(Fahrmayr et al., 2010).  In HEK293 and HeLa cell expression systems, 
OATP1B1*5 and OATP1B1*15 have been shown to have decreased transport 
activities.  This reduced transport rate may be due to decreased protein expression 
on the cell surface (Kameyama et al., 2005) or due to impaired translocation 
processes (Iwai et al., 2004).  
 
          Compared to OATP1B1, only a few known polymorphismsare known for 
OATP1B3. S112A (T334G) and M233I (G699A) are the two best characterized 
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 polymorphisms. In stably transfected MDCK II cells, the transport rate of several 
OATP1B3 model substrates is slightly higher in S112A and M233I mutants than 
in wild-type OATP1B3. However, in HEK293 cells, the transport rate is the same 
between wild-type OATP1B3 and these two mutants (Letschert et al., 2004). 
Clinical studies have shown that patients with S112A and M223I polymorphisms 
have higher serum concentrations of digoxin (Miura et al., 2007) and enhanced 
enterohepatic circulation of mycophenolic acid (Tsujimoto et al., 2008). However, 
the clearance of both unbound and total paclitaxel was not significantly associated 
with the S112A or M223I polymorphisms (Smith et al., 2007). 
 
(iv)  Chimeric proteins 
            Another strategy to study structure-function relationships is using chimeric 
proteins. This strategy works best when there are at least two or more orthologs or 
paralogs that share high amino acid sequence identities but different substrate 
spectra. In the case of OATP/Oatps, members in the same subfamily such as 
human paralogs OATP1B1 and OATP1B3, rat paralogs Oatp1a1 and Oatp1a4, or 
even human OATP1A2 and its rat ortholog Oatp1a1 are all very good candidate 
pairs for building chimeras.  The aim of constructing chimeric proteins is to 
isolate the essential structure or amino acid sequence that makes one OATP/Oatp 
different from the other. Although OATP/Oatps in the same subfamily share very 
similar primary, secondary and even tertiary structures, there is much evidence 
that they are able to transport distinct substrates (Hagenbuch and Meier, 2003; 
Konig et al., 2006; Hagenbuch and Gui, 2008). Gui and Hagenbuch (2008) 
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 constructed chimeric proteins between OATP1B1 and OATP1B3. They replaced 
single transmembrane domains of OATP1B3 with corresponding domains from 
OATP1B1 one at a time. Using this technique, they have shown that TM10 in 
OATP1B3 plays an essential role in recognition and/or translocation of CCK-8, an 
OATP1B3 specific substrate (Gui and Hagenbuch, 2008). In addition, the same 
strategy has been applied using OATP1B1 as the backbone, and TM8, TM9 
(Miyagawa et al., 2009), and TM10 (Gui and Hagenbuch, 2009) of OATP1B1 
have been shown to affect the transport of estrone-3-sulfate and/or estradiol-17β-
glucuronide.   
 
(v)  Site-directed mutagenesis 
           In order to identify the roles of individual amino acid residues involved in 
transport, site-directed mutagenesis has been a useful approach. By changing a 
target amino acid to another amino acid, a mutant protein is generated with 
identical or slightly different structure. When combined with functional assays, 
this method provides useful information about the role of a particular amino acid 
in the transport of a substrate. In principle, most point mutations do not 
dramatically alter function. However, transport function will be altered or 
destroyed when some critical amino acids are mutated. This may be due to either 
disrupting the interaction of the substrate to the transporter by the mutated amino 
acid, or due to altered conformational changes that are normally required for 
translocation of the substrates. In addition, loss of function may also occur due to 
misfolding of the protein or a lack of surface expression. A successful example 
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 using this technique is the structure-function relationship studies of lactose 
permease performed prior to the report of its crystal structure. Several key amino 
acids were identified using site-directed mutagenesis, and later, they were 
confirmed by crystal structure, to be critical in substrate binding and translocation 
(Frillingos et al., 1998; Kaback et al., 2001; Abramson et al., 2003). Mutagenesis 
is currently widely used in structure and function relationship studies of 
membrane transporters for which the crystal structure is not available. The most 
common strategy is to replace a residue with alanine. Alanine has a non-polar 
aliphatic side chain with relatively small steric effects. In site-directed 
mutagenesis, it has been widely used as a substitute for amino acids with charged, 
aromatic, or polar side chains. Using the alanine side chain to replace a functional 
group on other amino acids not only reduces the chance of introducing additional 
steric hindrance, but more importantly, reveals the potential effects of the replaced 
functional group on the structure and/or function of the transporter. Site-directed 
mutagenesis, especially alanine mutations, have been used in studying the 
structure-function relationship of many transporters e.g. hOAT1 (human organic 
anion transporter 1 SLC22A6). Using this technique, amino acids in TM1 (Hong et 
al., 2004), TM7 (Hong et al., 2007), the C-terminus (Xu et al., 2006) as well as 
several aromatic amino acids (Perry et al., 2006) have been shown to be important 
either for transport function and/or structural stability.   
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 (vi)  Cysteine scanning mutagenesis 
          Cysteine scanning mutagenesis is another widely used strategy in which 
consecutive residues are changed to cysteines. Chemical modifications of the 
introduced cysteine residues can provide information about the accessibility of a 
particular residue to the extracellular space. The purpose of the cysteine scanning 
is to locate the boundaries of the transmembrane domain and the interface of 
substrates and the transporter. This technique was first introduced by Arthur 
Karlin and Myles Akabas at Columbia University to identify channel-lining 
residues of the nicotinic acetylcholine receptor (nAChR) (Karlin and Akabas, 
1998). Shortly after its development, this method was widely used in many areas, 
including examination of channel domains, mapping of ligand-gated channel 
binding sites, mapping of receptor binding sites and transporter binding sites 
(Newell and Czajkowski, 2007). In principle, the backbone of the “wild-type” 
transporter should contain no reactive thiol (-SH) groups. Cysteine residues are 
then introduced into the wild-type protein by site-directed mutagenesis to replace 
the amino acid residues to be probed. Subsequently, -SH-specific reagents, such as 
derivatives of methanethiosulfonate (MTS) are applied to probe the physico-
chemical nature of the environment.  MTS reagents can react with cysteine 
residues and only label the free –SH groups that are exposed to the surrounding 
environment. Depending on different sizes, the smaller the MTS reagent is, the 
deeper inside the protein it can go.   More importantly, transport activities can be 
quantified to examine whether MTS reagents are able to physically block the 
binding site or translocation pathway of the substrate. Using this technique, 
 24
 several amino acids and transmembrane domains that are important in hASBT 
(human apical sodium-dependent bile acid transporter SLC10A2) mediated 
transport have been successfully mapped (Banerjee et al., 2005; Hussainzada et 
al., 2008; Khantwal and Swaan, 2008). However, one drawback of this technique 
is that sometimes, it is very difficult to obtain a cysteine free backbone which still 
retains the proper transport function.  
 
(vii)  Post-translational modification studies 
           In addition to interactions with key amino acids, transport function can also 
be affected by post-translational regulation, such as glycosylation and 
phosphorylation.  As mentioned previously, there are three N-glycosylation sites 
in Oatp1a1, asparagines 124, 135, and 492, located at the extracellular loops 2 and 
5. Single and multiple site-directed mutagenesis studies have shown that the 
extent of N-glycosylation controls mainly membrane targeting of Oatp1a1 and 
may also affect functional activity (Lee et al., 2003; Wang et al., 2008).  The 
effect of phosphorylation of Oatp1a1 on transport function has also been studied. 
Glavy et al. (2000) have shown that phosphorylated Oatp1a1, as compared to 
unphosphorylated Oatp1a1, remains on the plasma membrane but has reduced 
transport activity (Glavy et al., 2000). Guo and Klaassen using the oocyte system, 
demonstrated that protein kinase C but not protein kinase A supresses Oatp1a1 
and Oatp1a4 mediated transport (Guo and Klaassen, 2001). A recent study has 
shown that protein kinase C mediated phosphorylation causes rapid internalization 
of OATP2B1 (Kock et al., 2010).  These studies indicate that the phosphorylation 
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 state is an important consideration when assessing the altered transport activities 
of OATP/Oatps in physiological and pathological conditions.  
 
(2)    Characteristics of substrates in OATP/Oatp-mediated transport. 
            Part (1) summarizes the structural requirements of transporter protein for 
the proper function of OATP/Oatp-mediated transport. As we know, OATP/Oatps 
are able to transport a wide spectrum of substrates. Therefore, studying the 
structural features of the substrates and how the substrates, inhibitors, and 
stimulators interact with the transporter is another effective approach to study the 
transport mechanism. In this following part, I will review the studies of the 
transport mechanism based on the transported substrates.  
 
(i)     Structural features of OATP/Oatp substrates 
          In general, most substrates of OATP/Oatps are amphipathic organic anions 
with a molecular weight of more than 450. OATP/Oatp substrates usually are 
bound to albumin under normal physiological conditions.  These compounds are 
more likely to be secreted into bile as opposed to the smaller hydrophilic anionic 
compounds that are substrates of organic anion transporters (OATs) and are 
mostly secreted into urine (Hagenbuch and Meier, 2003).  In recent years, 
researchers have been attempted to determine the common characteristics of 
Oatp/OATP substrates. One of the approaches many researchers have used is the 
substrate-based in silico modeling. Substrate-based modeling methods do not 
require prior knowledge of the transporter structure. They correlate the biological 
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 activity of a series of substrates or inhibitors with their molecular or chemical 
properties. These models not only provide important information about the key 
structures of substrates, but also assist in the design or prediction of additional 
substrates. Two major methods used in this field are pharmacophore modeling and 
3D-QSAR (quantitative structure-activity relationship) modeling. A 
pharmacophore is a certain spatial arrangement of structural features that are 
required for a particular biological function. Identification of a pharmacophore 
was originally designed to assist in the development of alternative or more active 
substrates or inhibitors for pharmaceutical purposes.  This method has been 
widely used in the transporter field to study the binding of substrates. 
Pharmacophore models for Oatp1a1 and OATP1B1 have been studied and some 
molecular characteristics of OATP/Oatp substrates have been identified including 
hydrogen bond acceptors and hydrophobic features (Chang et al., 2005). Whereas 
a traditional pharmacophore model is able to distinguish an active structure versus 
an inactive structure, 3D-QSAR modeling method generates a mathematical 
equation quantitatively describing the bioactivity as a function of 3D spatial and 
chemical interactions to identify the important key structure features for substrate 
binding. Currently, the most widely used method of choice in 3D-QSAR studies is 
comparative molecular field analysis (CoMFA). It correlates both electrostatic and 
steric interactions with bioactivity (Chang and Swaan, 2006). A QSAR model for 
Oatp1a5 substrates has been generated and based on the derived model, new 
potential Oatp1a5 substrates have been identified and confirmed experimentally 
(Yarim et al., 2005). In addition, based on CoMFA analysis of nuclear receptor 
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 ligands as competitive inhibitors of OATP1B1-mediated estradiol-17β-
glucuronide transport, the substrate binding site of OATP1B1 has been predicted 
to consist of a large hydrophobic middle section with basic residues at both ends 
(Gui et al., 2009).   
 
(ii)    Driving force of OATP-mediated transport 
           In addition to studying the substrate structures, the interactions between 
substrates and other molecules can also reveal information about the transport 
mechanism. However, the exact mechanism of the driving force of OATP/Oatp 
mediated transport is still unknown. OATP/Oatp-mediated transport has been 
shown to be independent of a sodium gradient (Kullak-Ublick et al., 1995; Noe et 
al., 1997; Walters et al., 2000). Moreover, there is evidence that OATP/Oatps may 
function as an exchanger. Intracellular GSH (Li et al., 1998; Li et al., 2000) and 
biocarbonate (Shi et al., 1995; Satlin et al., 1997) may play a role in Oatp1a1 and 
Oatp1a4-mediated transport. OATP2B1 has been shown to be more active and 
transport more substrates at low pH (Kobayashi et al., 2003). Later, Leuthold et al. 
(2009) have shown that most OATP/Oatps transport better at low pH due to a 
highly conserved histidine at the outside of TM 3 (Leuthold et al., 2009). For 
OATP1B1 and OATP1B3, it is generally accepted that they function as 
bidirectional carriers, but the role of GSH in transport mediated by members in 
OATP1B subfamily is controversial (Briz et al., 2006; Mahagita et al., 2007).  
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 (iii)    Modulators of OATP-mediated transport 
          In addition to the interactions of the transporter with both substrates and the 
“counter ions” that drive the exchange, many other modulators such as inhibitors 
and stimulators also affect OATP/Oatp mediated transport. In many occasions, 
OATP/Oatp substrates are also inhibitors of other OATP/Oatp substrates. Thus 
identifying the inhibitors of model substrates is often used as the first step of 
searching for new substrates. In addition, there are compounds, such as 
clotrimazole, that are able to stimulate transport of certain OATPs in a substrate 
dependent way (Gui et al., 2008). Therefore, both inhibitors and stimulators are 
important modulators for OATP/Oatp mediated transport. Moreover, because 
OATP/Oatps play very important roles in the disposition of xenobiotics, such as 
drugs and toxins, interactions of different molecules at the transporter level serve 
as one of the important underlying mechanisms of drug-drug or drug-food 
interactions that may cause the increase of drug toxicity or decrease of drug 
efficacy as described previously. Moreover, modulators could also be used as a 
way to increase transporter mediated drug uptake into target sites, such as cancer 
cells. 
 
          In summary, using in silico modeling methods combined with wet lab 
approaches, several basic features of OATP/Oatp substrates have been described. 
In general, many OATP/Oatp substrates are relatively large organic compounds 
that have a hydrophobic center with at least one hydrophilic group. Both hydrogen 
bonds and ionic bonds seem to play important roles in substrate binding and/or 
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 translocations. However, the detailed mechanisms of OATP/Oatp-mediated 
transport still remain vague, and the general driving force of OATP/Oatps is still 
unknown. Compared to OATP/Oatps, the organic anion transporter (OAT) family 
has very similar structural and functional features, except the average molecular 
weight of substrates for OATs are smaller than for OATP (Hagenbuch, 2010). 
Similarly, numerous studies have investigated the structure-function relationships 
of OATs. Although the primary aim of this dissertation is to study the structure-
function relationship of the OATP/Oatp family, it is always important to compare 
and contrast the subject of interest with the knowledge in the extended field.   In 
the next section, I will briefly review some of the very basic features of the OAT 
family that serves as the background information of the primary research in 
chapter 5. 
 
IV.   BRIEF INTRODUCTION TO OAT 
          In the body, the liver and the kidney are the two major organs for the 
elimination of xenobiotics, including organic anions. Relatively small (molecular 
weight less than 400 to 500) and hydrophilic organic anions, also termed type-I 
organic anions, are primarily excreted via the kidney, whereas more hydrophobic, 
type-II organic anions, such as bile acids and glucuronide conjugates, are 
preferentially excreted by the liver (Sekine et al., 2006). It is not surprising that 
both liver and kidney have very complicated transporter systems facilitating the 
active transport of these compounds. Type-I organic anions are preferred 
substrates of the OAT family, whereas type-II organic anions are preferred 
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 substrates for the OATP/Oatps family. The OAT family members are structurally 
similar to organic cation transporters (OCTs), and both OCT and OAT families 
belong to the SLC22A gene family. Similar to OATP/Oatps, both OATs and OCTs 
have very broad substrate spectra and members of both families are predicted to 
have 12-transmembrane domains. Members in the OAT family have multiple 
glycosylation sites localized in the first extracellular loop between transmembrane 
domains 1 and 2, and multiple phosphorylation sites in the intracellular loop 
between transmembrane domains 6 and 7 as well as in the carboxyl terminus 
(You, 2004). To date, the following members of the OAT family have been 
identified and functionally characterized: hOAT1/rOat1 (SLC22A6), 
hOAT2/rOat2 (SLC22A7), hOAT3/rOat3 (SLC22A8), hOAT4 (SLC22A11), rOat5 
(SLC22A9), hURAT1 (SLC22A12) hOAT6/rOat6 (SCL22A20) and hOAT7 
(SLC22A9).  
 
 
          Human OAT1 is the best studied member of the OAT family. It functions as 
an organic anion/dicarboxylate exchanger and is expressed in multiple tissues, 
primarily on the basolateral side of kidney proximal tubule cells (Sekine et al., 
1997; Hosoyamada et al., 1999; Kojima et al., 2002). It can transport more than 
100 different compounds, and mediates the active secretion of both endogenous 
chemicals and xenobiotics in kidneys (Sekine et al., 2006).  The coding region of 
OAT1 has been shown to have low genetic diversity, and may not contribute 
substantially to inter-individual differences in renal elimination of xenobiotics 
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 (Fujita et al., 2005). Similar to OATP/Oatps, glycosylation plays an important role 
in the targeting of OAT1 to the plasma membrane (Tanaka et al., 2004). 
Furthermore, a theoretical three-dimensional model was generated for human 
OAT1 (hOAT1) based on fold recognition with the crystal structure of the 
glycerol 3-phosphate transporter (GlpT) from E. coli. In combination with site-
directed mutagenesis, two aromatic amino acids, Try230 in TM5 and Phe438 in 
TM10, have been identified to play important roles in substrate/transporter 
interactions (Perry et al., 2006).  In addition, the chloride dependency of hOAT1 
can be blunted by mutation of the conserved positively charged amino acid 
Arg466 in TM11 (Rizwan et al., 2007).  
 
          Among the OAT members in humans, OAT1, OAT3 and OAT4 are 
predominantly expressed in kidney, whereas OAT2 is abundantly expressed in 
liver (Hosoyamada et al., 1999; Cha et al., 2000; Sun et al., 2001). OAT2 has also 
been detected at the basolateral membrane of kidney proximal tubules (Enomoto 
et al., 2002b) whereas in rat, Oat2 is localized in the brush-border membrane 
(Kojima et al., 2002; Ljubojevic et al., 2007). Therefore, OAT2/Oat2 expression 
differs among species. Using the oocyte system, hOAT2 has been shown to be a 
sodium-independent multi-specific organic anion/dimethyldicarboxylate 
exchanger (Kobayashi et al., 2005). However, the detailed transport mechanism of 
OAT2/Oat2 is still unclear. 
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           OAT3 and OAT1 have many similarities. First, OAT3 is primarily located 
on the basolateral membrane of proximal tubules (Race et al., 1999; Motohashi et 
al., 2002). Second, it is also a dicarboxylate/organic anion exchanger which 
moves organic anionic substrates into the cell (Race et al., 1999). In addition, 
knockout mice models of both Oat1 (Eraly et al., 2006) and Oat3 (Sweet et al., 
2002) have been reported. Although both knockout mice showed no 
morphological abnormalities, the loss of renal organic anion transport was 
observed in both models.  Several important amino acids have been identified 
using site-directed mutagenesis, including Arg454 and Lys370, that are essential 
for the anion specificity of rat Oat3 (Feng et al., 2001) and an aromatic pocket 
composed mainly of residues in TM7 that are in the translocation pathway of rat 
Oat3. The aromatic residues in this pocket may interact directly with substrates of 
rat Oat3 via hydrogen bonds and π-π interactions (Feng et al., 2002). 
 
          OAT4 is a human specific transporter localized primarily on the apical side 
of the proximal tubules (Ekaratanawong et al., 2004). It is also found in placenta 
and adrenocortical cells (Cha et al., 2000; Asif et al., 2005). Similar to OAT1 and 
OAT3, OAT4 is an organic anion/dicarboxylate exchanger (Ekaratanawong et al., 
2004). Several histidines and glycines as well as N-glycosylation sites have been 
identified to be important for surface targeting of hOAT4 (Zhou et al., 2004a; 
Zhou et al., 2004b; Zhou et al., 2005). Very similar to Oatp1a1, it has been shown 
that surface expression and function of OAT4 is modulated through PDZ 
interaction with the network of PDZK1 and NHERF1 (Miyazaki et al., 2005). 
 33
 OAT4 and URAT1 are the only two OAT members that contain PDZ domains. 
Interestingly, both transporters together with Oatp1a1 are all located on the brush 
border membrane of proximal tubule cells, suggesting that PDZ scaffold may be a 
mechanism of regulating the handling of organic anions on the apical side of 
proximal tubule cells.  
 
          Oat5 has been identified as a rodent specific transporter from mice and rat 
kidneys (Youngblood and Sweet, 2004; Anzai et al., 2005; Kwak et al., 2005). It 
is expressed in both males and female rodents and female mice has higer 
expression of Oat5 than male mice (Cheng and Klaassen, 2009). It has been 
shown that Oat5 can mediate sodium independent transport of estrone-3-sulfate 
and a number of drugs but the detailed transport mechanism is still unclear (Zhou 
and You, 2007).   
 
          URAT1/Urat1, another OAT family member, is a urate/organic anion 
exchanger that is expressed in the apical membrane of proximal tubule cells 
(Enomoto et al., 2002a). It is thought to play an important role in urate transport 
from the tubule lumen back into the proximal tubule cells for further reabsorption. 
The rat Urat1 has not been functionally characterized.  
 
          Oat6 is expressed predominantly in mouse olfactory mucosa (Monte et al., 
2004; Kaler et al., 2006; Schnabolk et al., 2006). It is one of the few members of 
OATs/Oats which has no expression in kidney. Oat6 also acts as an organic 
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 anion/dicarboxylate exchanger when expressed in Xenopus oocyte and Chinese 
hamster ovary (CHO) cells (Schnabolk et al., 2006). Human OAT6 has not been 
functionally characterized.  
 
 The liver specific OAT7 is expressed at the basolateral membrane of 
hepatocytes and was recently characterized as a multispecific organic anion 
transporter (Shin et al., 2007). In Xenopus oocytes, OAT7 transported estron-3-
sulfate, dehydroepiandrosterone sulfate and the short chain fatty acid butyrate but 
none of the typical substrates of the organic anion or cation transporters. 
Furthermore, its transport was not affected by probenecid, the prototypical OAT 
inhibitor (Shin et al., 2007). 
 
          Among all members in the OAT family, the transport mechanisms of 
OAT1/Oat1 and OAT3/Oat3 have been mostly extensively studied. In general, 
they share a great amount of similarities with OATP/Oatp mediated transport. As 
mentioned previously, compared to OATP/Oatps, OATs/Oats preferentially 
transport smaller and more hydrophilic organic anions. However, sometimes, the 
substrate spectra for these two transporter families overlap. For example, 
perfluorooctanoate (C8), a compound widely used in industry, has been shown to 
be a substrate for hOAT1/rOat1 (Nakagawa et al., 2008), hOAT3/rOat3 
(Nakagawa et al., 2008), hOAT4 (Nakagawa et al., 2009) as well as rOatp1a1 
(Katakura et al., 2007; Yang et al., 2009). Kinetic analyses have shown that the 
Km of rOat1 and rOat3 (51.0 µM for Oat1 and 80.2 µM for Oat3) (Nakagawa et 
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 al., 2008) are much lower than the Km of rat Oatp1a1 (162.2 µM) (Yang et al., 
2009) mediated C8 transport. Although both rat Oat and Oatp transporters are able 
to transport C8, Oat1 and Oat3 have higher affinity for C8 than Oatp1a1. We have 
known that the general substrates for OATP/Oatps have larger molecular weights 
than OAT/Oat substrates. If C8 fits better into the “binding pocket” of Oats, are 
Oatps better at transporting larger molecules that have similar structures?   In 
addition to weight, what is the size preference of OATP/Oatp substrate? In the 
next section, I will introduce a series of compounds that have almost identical 
structures to C8, but with different chain length. These compounds will be used in 
the primary research in this dissertation described in chapter 5 to probe the spatial 
size of the “substrate binding pocket” of OATs/Oats and OATP/Oatps.  
 
V.   BRIEF INTRODUCTION TO PERFLUORINATED CARBOXYLATES  
          Perfluorinated carboxylates (PFCAs) are the fully fluorinated analogues of 
fatty acids. They share the same carbon backbones with regular fatty acids. 
However, instead of carbon-hydrogen bonds (C-H), PFCAs only have carbon-
fluorine bonds (C-F). In general, the carbon chain lengths of the most commonly 
used PFCAs are from two carbons to eighteen carbons. Because of the 
electronegativity difference between carbon and fluorine (2.5 vs 4.0), C-F bonds 
are highly polar, and thus very strong.  The strength of the C-F bonds makes 
PFCAs ideal chemicals to be used in industrial processes, especially in high 
temperature and corrosive environments.  
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           Many studies have investigated the toxicological effects and environmental 
dispositions of PFCAs, especially C8 which is among the most widely used 
perfluorinated compound since the 1960s. Due to its extraordinary stability, C8 is 
persistent and bioaccumulates in the environment. Tests in rodents have 
demonstrated that C8 can activate peroxisome proliferator activated receptor α 
(PPARα) and cause several negative effects, including increased β-oxidation of 
fatty acids, increased cytochrome P-450 (CYP450)-mediated reactions, and 
inhibition of the secretion of very low-density lipoproteins and cholesterol from 
liver (Kennedy et al., 2004). However, human exposure to perfluorinated 
compounds has not shown to produce significant clinical effects. Significant 
association of increased total cholesterol and uric acid serum levels with C8 serum 
levels has been reported recently (Costa et al., 2009). However, because most 
perfluorinated compounds used in industry, including C8, are highly resistant to 
degradation, it is important to understand their absorption, distribution, 
metabolism, and excretion, as well as potential health and target organ effects of 
these compounds.                   
                                                                                                                                                                   
          Interestingly, all PFCAs have highly similar structural characteristics with 
many of the OATP/Oatp substrates, such as a hydrophobic center and negative 
potential at the hydrophilic head. The only difference between different PFCAs is 
the carbon chain length, and as a result, the size of the molecule. As a 
consequence, the hydrophobicity and lipophobicity will change with increased 
chain length.  Table 1-3 summarizes the molecular weight and calculated chain 
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 length of each PFCA. Based on the molecular weight, PFCAs with 9 carbons and 
above are more likely to be substrates for OATPs, whereas PFCAs with 8 carbons 
or less should be preferred substrates for OATs. Moreover, as the molecules get 
larger, the distance between the hydrophobic center and the hydrophilic head 
increases. If PFCAs with different chain lengths are indeed substrates for OATs, 
the predicted chain lengths may provide information with regard to the size of the 
“binding pocket” in OATs/Oats and OATP/Oatps. However, except for C8, there 
is no experimental evidence that other PFCAs are substrates of any OATs/Oats or 
OATP/Oatps before the studies presented in chapter 5 were reported.  
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 Table 1-3: Summary of PFCAs with different chain lengths. 
 
Carbon 
# 
Name Acronym  Molecular 
Formula 
M.W Calculated 
Length 
(Å) 
      
C2 Trifluoroacetic acid   CF3COOH 114.0 1.9 
C3 Pentafluoropropionic acid  CF3CF2COOH 164.0 2.9 
C4 Perfluorobutyric acid PFBA CF3CF2CF2COOH 214.0 4.3 
C5 Perfluoropentanoic acid PFPA CF3(CF2)3COOH 264.1 5.4 
C6 Perfluorohexanoic acid PFHxA CF3(CF2)4COOH 314.1 6.8 
C7 Perfluoroheptanoic acid PFHpA CF3(CF2)5CO2H 364.1 7.3 
C8 Perfluorooctanoic acid PFOA CF3(CF2)6COOH 414.1 8.8 
C9 Perfluorononanoic acid PFNA CF3(CF2)7COOH 464.1 9.6 
C10 Perfluorodecanoic acid PFDA CF3(CF2)8COOH 514.1 11.1 
C11 Perfluoroundecanoic acid PFUDA CF3(CF2)9COOH 564.1 11.9 
C12 Perfluorododecanoic acid PFDDA CF3(CF2)10COOH 614.1 13.4 
C13 Perfluorotridecanoic acid PFTrDA CF3(CF2)11COOH 664.1 14.3 
C14 Perfluorotetradecanoic acid PFTtDA CF3(CF2)12COOH 714.1 15.8 
C15 Perfluoropetadecanoic acid PFPDA CF3(CF2)13COOH 764.1 16.8 
C16 Perfluorohexadecanoic acid PFHxDA CF3(CF2)14COOH 814.1 18.2 
C17 Perfluoroheptadecanoic acid PFHpDA CF3(CF2)15COOH 864.1 18.8 
C18 Perfluorooctadecanoic acid PFODA CF3(CF2)16COOH 914.1 20.3 
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  VI.   CONCLUDING REMARKS FOR THE INTRODUCTION 
            In the past 15 years, since the discovery of the first Oatp, the field of 
OATP/Oatp-mediated transport has been developing rapidly. OATP/Oatps have 
the ability of transporting many structurally unrelated xenobiotics, including 
numerous drugs and toxins, and thus great attention has been drawn to the drug-
drug or drug-food interactions that occur at the transporter level, as well as to the 
impact of OATPs on inter-individual variability of drug disposition. However, the 
studies of the more fundamental aspects, such as transport mechanism of 
OATP/Oatps, are still few in number and many principle questions remain:  1) 
How do OATP/Oatps transport substrates across the membrane; 2) Why can 
one single OATP/Oatp transport different substrates with unrelated 
structures; 3) What is the driving force of the transport; 4) What is the 3-
dimensional structure of OATP/Oatps; and 5) Do OATP/Oatps function as 
multimers.  Although limited knowledge is available to answer these questions, 
the emerging research of many laboratories has begun to reveal some answers to 
these questions.   
 
VII.   SPECIFIC AIMS OF THIS DISSERTATION  
          To uncover the mechanisms of OATP/Oatp-mediated transport requires 
answers to very basic questions on how OATP/Oatps work at the molecular level, 
and what sub-domain(s) in the OATP/Oatp protein play key roles in initiating and 
completing the transport process, as well as what are the structural requirements 
of the active domain(s). Of course, much time and effort from many researchers 
 40
 will be necessary to answer all of these questions. Thus, the overall goal of my 
research has been built upon previous findings, and has focused largely on 
identifying the key amino acids that play an important role in OATP/Oatp-
mediated transport, and investigating the spatial size of the substrate binding 
pocket. In presenting this dissertation, I will defend three specific aims.   
 Specific aim 1 evaluates the hypothesis that conserved positively charged 
amino acids play important roles in OATP1B1 transport function. Based on a 
3-dimensional structural model, several conserved positively charged amino acids 
have been suggested to be important for the function of OATP1B family 
members. To address this aim, site-directed mutagenesis was performed on 
selected amino acids and the resulting constructs were transiently expressed in 
HEK293 cells for functional analysis. Surface biotinylation and western blot were 
used to quantify total protein and surface expression of wild-type and mutated 
transporters. The purpose of this study was to determine whether these conserved 
positively charged amino acids are involved in substrate binding and /or substrate 
translocation.  
 Specific aim 2 evaluates the hypothesis that quantifying transport 
activities of different substrates of chimeras between rat Oatp1a1 and 
Oatp1a4 in combination with site-directed mutagenesis should allow us to 
identify regions and/or individual amino acids that are important for 
Oatp1a4-mediated substrate recognition and/or transport. To address this 
aim, chimeric proteins were made between Oatp1a1 and Oatp1a4 and transport of 
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 digoxin, which is an Oatp1a4 but not an Oatp1a1 substrate, was used as a tool to 
investigate and identify the amino acids that are important in Oatp1a4 mediated 
transport function. In addition, the effects of mutations on transport of other 
common Oatp substrates such as taurocholate, DPDPE and estradiol-17β-
glucuronide were evaluated as well. The purpose of this study was to determine 
the critical region and/or residues that are important in Oatp1a4-mediated 
transport, and to further characterize the roles of these amino acids in the transport 
processes.  
 
 Specific aim 3 evaluates the hypothesis that different rat renal organic 
anion transporters of the Oat and Oatp families selectively transport PFCAs, 
depending on chain lengths.  To address this aim, cDNA constructs of Oats or 
Oatp1a1 were transiently or stably transfected into HEK293 and CHO cells and 
the inhibitory effects of PFCAs with carbon chain lengths, from C2-C18, on 
transport of model substrates were evaluated. In addition, direct transport of the 
strongest inhibitors was quantified. The purpose of this study was to determine the 
size selectivity of Oats and Oatp1a1 in PFCA transport. Instead of altering the 
transporter structure, this is an approach using substrates of different sizes as 
rulers to probe the “substrate binding pocket” of intact transporters.  Furthermore, 
these findings are also important in explaining the in vivo disposition patterns of 
PFCAs observed in rats.  
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 CHAPTER 2 
 
EXPERIMENTAL MATERIALS AND METHODS 
 
 
I. CELL CULTURE  
          Human embryonic kidney (HEK293) cells were grown at 37°C in a 
humidified 5% CO2 atmosphere in Dulbecco’s Modified Eagle Medium High 
Glucose (Invitrogen, Carlsbad, CA), supplemented with 10% FBS (Hyclone, 
Logan, UT), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen, 
Carlsbad, CA). 
 
          Chinese Hamster Ovary (CHO) cells (CHO-wild-type and CHO-Oatp1a1) 
were grown at 37 °C in a humidified 5% CO2 atmosphere in Dulbecco's Modified 
Eagle Medium, containing 1 g/L D-glucose, 2 mM L-glutamine, 25 mM Hepes 
buffer, and 110 mg/l sodium pyruvate, supplemented with 10% FBS, 50 μg/mL L-
proline, 100 U/mL penicillin, and 100 μg/mL streptomycin. 
 
          FlpIn™-HEK293 wild-type cells (Invitrogen, Carlsbad, CA) were 
maintained at 37 °C in a humidified 5% CO2 atmosphere in Ham's F12/DMEM 
(1/1) medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 100 μg/mL zeocin. 
 
           FlpIn™-HEK293 cells stably expressing rat Oat2 or stably transfected with 
pcDNA5/FRT empty vector were maintained at 37 °C in a humidified 5% CO2 
 43
 atmosphere in Ham's F12/DMEM (1/1) medium supplemented with 10% FBS, 
100 U/mL penicillin, 100 μg/mL streptomycin, and 400 μg/mL hygromycin B. 
 
 
II.  CONSTRUCTION OF AN OAT2 STABLE CELL LINE  
          Oat2 was cloned from kidney RNA of Sprague–Dawley rats. Briefly, total 
RNA was isolated from the frozen rat kidney using Trizol, following the 
manufacturer's instructions (Invitrogen Inc., Carlsbad, CA).  Subsequently, RNA 
was reverse transcribed into single strand cDNA using Reverse Transcription 
System from Promega (Promega, Madison, WI). The open reading frame of rat 
Oat2 was amplified by PCR, using gene specific primers (Table 2-1) and a 
Phusion High-Fidelity PCR kit (Finnzyme, Espoo, Finland). The amplicon was 
then gel purified and subcloned into the pcDNA5/FRT vector for stable 
transfection into mammalian cells using NheI and KpnI restriction enzyme sites. 
The cDNA sequence was verified by sequencing both strands individually. 
FlpIn™-HEK293 cells were plated in 6-well plates without antibiotics, and then 
transfected as described in the manufacturer's instructions (Invitrogen, Carlsbad, 
CA). Twenty-four hrs after transfection, cells were re-plated onto 10 cm plates in 
medium supplemented with 400 μg/mL hygromycin B, for selection for two 
weeks with one subsequent 1:3 passage after one week. The pooled cells were 
tested for uptake of the model substrate [3H]-p-aminohippurate and used in PFCA 
transport studies. FlpIn™-HEK293 cells stably transfected with pcDNA5/FRT 
empty vector were used as a negative control.  
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 Table 2-1: Primers used for cloning Oat2 from rat kidney 
 
 Primer Restriction site 
Features 
FWD 5' ACCGGCTAGCGCCACCATGGGCTTCGAAGA
CCTGCT 
NheI Kozak seq 
RVS 3' AGAGGGTACCCTAATGGTGATGGTGATGAT
GCACATCTTCCTCCTGGGTA 
KpnI His tag 
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III. SITE-DIRECTED MUTAGENESIS OF OATP1B1 
           Human OATP1B1*1b was subcloned into the pcDNA5/FRT vector 
(Invitrogen, Carlsbad, CA) and was considered wild-type compared to the 
introduced mutations. Single amino acid mutations were introduced by site-
directed mutagenesis using the QuickChange® system (Stratagene, La Jolla, CA), 
following the manufacturer’s instructions. Briefly, a high fidelity DNA 
polymerase was used to replicate both strands of DNA plasmid using a set of 
primers with point mutations. Primers used in the mutagenesis reactions are listed 
in Table 2-2. After PCR cycles, the parental template DNA plasmids were 
digested by DpnI. The product of PCR was transformed into XL-1 Blue 
supercompetent cells, and ampicilin resistant colonies were subjected to 
sequencing to select for mutations.    Plasmid DNA was prepared using HiSpeed 
Plasmid Midi or Maxi Kits (Qiagen, Germantown, MD), and both strands of all 
constructs were sequenced to confirm the presence of the designed mutations and 
the absence of additional spontaneous mutations. 
 
IV. CONSTRUCTION OF CHIMERAS AND MUTANTS OF Oatp1a4  
            In order to avoid problems with different RNA stabilities due to different 
3’ untranslated regions, all constructs were cloned into the Oatp1a1 backbone. 
This Oatp1a1 backbone was constructed as follows: The Oatp1a1 cDNA 
(GenBank accession number NM_017111) in the pSPORT1 vector was cut with 
restriction enzymes NcoI and BsmI. The resulting overhangs were filled  
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 Table 2-2: Primers used for site-directed mutagenesis of OATP1B1 
 
 
Mutation   Primers (5'-3') 
R181A forward: GTGTTCATGGGTAATATGCTTGCTGGAATAGGGGAGACTCCC 
 reverse: GGGAGTCTCCCCTATTCCAGCAAGCATATTACCCATGAACAC 
R181K forward: GTGTTCATGGGTAATATGCTTAAAGGAATAGGGGAGACTCCCATAG 
 reverse: CTATGGGAGTCTCCCCTATTCCTTTAAGCATATTACCCATGAACAC 
R181H forward: CATGGGTAATATGCTTCATGGAATAGGGGAGACTCCC 
 reverse: GGGAGTCTCCCCTATTCCATGAAGCATATTACCCATG 
R580A forward: CCACTCAATGGTTATAGCAGCACTAGGAGGAATTCTAGC 
 reverse: GCTAGAATTCCTCCTAGTGCTGCTATAACCATTGAGTGG 
R580K forward: CCACTCAATGGTTATAAAAGCACTAGGAGGAATTCTAGCTCC 
 reverse: GGAGCTAGAATTCCTCCTAGTGCTTTTATAACCATTGAGTGG 
R580H forward: CCACTCAATGGTTATACATGCACTAGGAGGAATTCTAGCTCC  
 reverse: GGAGCTAGAATTCCTCCTAGTGCATGTATAACCATTGAGTGG 
R57A forward: GTTCCATCATTCATATAGAAGCGAGATTTGAGATATCCTCTTCTCTTG 
 reverse: CAAGAGAAGAGGATATCTCAAATCTCGCTTCTATATGAATGATGGAAC 
R57K forward: GAAAAGAGATTTGAGATATCCTCTTCTC 
 reverse: AAATCTCTTTTCTATATGAATGATGGAAC 
K361A forward: GGTGCTTTTACTTATGTCTTCGCATACGTAGAGCAACAGTATGG 
 reverse: CCATACTGTTGCTCTACGTATGCGAAGACATAAGTAAAAGCACC 
K361R forward: TTCAGATACGTAGAGCAACAGTATGG 
 reverse: GTATCTGAAGACATAAGTAAAAGCACC 
K90A forward: GTGAGTTACTTTGGATCCGCACTACATAGACCAAAGTTAATTGG 
 reverse: CCAATTAACTTTGGTCTATGTAGTGCGGATCCAAAGTAACTCAC 
K90R forward: GTGAGTTACTTTGGATCCCGACTACATAGACCAAAGTTAATTGG 
 reverse: CCAATTAACTTTGGTCTATGTAGTCGGGATCCAAAGTAACTCAC 
H92A forward: GTTACTTTGGATCCAAACTAGCTAGACCAAAGTTAATTGGAATCGG 
 reverse: CCGATTCCAATTAACTTTGGTCTAGCTAGTTTGGATCCAAAGTAAC 
H92K forward: GAGTTACTTTGGATCCAAACTAAAGAGACCAAAGTTAATTGGAATCGG 
 reverse: CCGATTCCAATTAACTTTGGTCTCTTTAGTTTGGATCCAAAGTAACTC 
H92R forward: CTTTGGATCCAAACTACGTAGACCAAAGTTAATTGGAATCGG 
 reverse: CCGATTCCAATTAACTTTGGTCTACGTAGTTTGGATCCAAAG 
R93A forward: CTTTGGATCCAAACTACATGCACCAAAGTTAATTGGAATCGGTTG 
 reverse: CAACCGATTCCAATTAACTTTGGTGCATGTAGTTTGGATCCAAAG 
R93K forward: CTTTGGATCCAAACTACATAAACCAAAGTTAATTGGAATCGGTTG 
  reverse: CAACCGATTCCAATTAACTTTGGTTTATGTAGTTTGGATCCAAAG 
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 in with Klenow enzyme (Amersham Biosciences, Buckinghamshire HP7 9NA, 
England) and after dephosphorylation with calf intestinal alkaline phosphatase 
(Promega, Madison, WI, U.S.A.), the Oatp1a1 backbone was gel purified. This 
vector allowed cloning of blunt ended cDNAs between bases 89 and 2142 of the 
original Oatp1a1 construct resulting in identical 3’ and 5’ untranslated sequences.  
 
          To be able to detect all constructs with the same antibody, a 6-His tag was 
attached to the Oatp1a1 and Oatp1a4 open reading frame (ORF) by PCR 
amplification, with the primers Oatp1a1f90 and Oatp1a1rHis for Oatp1a1 and 
Oatp1a4f122 and Oatp1a4rHis for Oatp1a4 (Table 2-3). To reduce PCR related 
mutations, all amplifications were performed with the proofreading enzyme Pfu 
Turbo DNA Polymerase (Stratagene, La Jolla, CA). After amplification of the 
His-tagged Oatp1a1 and Oatp1a4 ORFs, they were cloned into the Oatp1a1 
backbone. The correct orientation and sequence were confirmed by sequencing 
both strands on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, 
Foster City, CA).  
 
          For the construction of the chimeras, an overlap PCR approach was used. In 
the first round of PCR, two overlapping fragments (chimf and chimr primers are at 
the same position on the two cDNA strands and thus overlap) were produced with 
templates and primers according to Tables 2-3 and 2-4. After gel-purification of 
the amplification products, they were used as templates for a second round of 
PCR, using the flanking primers (reverse and universal, Tables 2-3 and 2-4). 
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 These final amplicons contained the multiple cloning site of the original 
pSPORT1 vector, and therefore were cut with the restriction enzyme SalI and 
NotI. After gel-purification of the digested fragments, they were directionally 
cloned into a SalI-NotI cut pSPORT1 vector and their correct sequence was 
verified by sequencing both strands. 
 
          To introduce single amino acid mutations, a similar overlap PCR approach 
was used. The middle primers (Table 2-3) contained the desired mutation and 
together with the flanking “reverse” and “universal” primers, the mutation was 
introduced after two rounds of PCR. All constructs were verified by sequencing 
both strands. 
 
           For transient transfection in HEK293 cells, all cDNA constructs containing 
His tags, including Oatp1a1, Oatp1a4, chimeric proteins and single point mutants 
of Oatp1a4 in the pSPORT1 vectors, were cut with the restriction enzymes SalI. 
The resulting overhangs were filled in with Klenow enzyme (New England 
Biolabs, Ipswich, MA). The cDNA inserts of Oatp1a1, Oatp1a4 and the mutants 
were then cut again with NotI and after dephosphorylation with calf intestinal 
alkaline phosphatase (New England Biolabs, Ipswich, MA), the inserts were gel 
purified and subcloned into pExpress-1 vector cut with NotI and SmaI. 
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 Table 2-3: Primers used to prepare the different chimeras and mutants 
Primer Sequence (5’ to 3’)  
 Primers to introduce the His tag  
Oatp1a1f90 GAAGAAACAGAGAAAAAGATTGCA  
Oatp1a1rHis TTAATGGTGATGGTGATGATGCAGCTTCGTTTTCAGT  
Oatp1a4f122 GGAAAATCTGAGAAAAGGGTTGCA  
Oatp1a4rHis TCAATGGTGATGGTGATGATGGTCCTCCGTCACTTTC  
 Primers for chimeras Chimera 
Reverse CAGGAAACAGCTATGAC All 
Universal TGTAAAACGACGGCCAGT All 
Chim1f ATTTACATGCTTTTCATCCTTA 1/2 
Chim1r TAAGGATGAAAAGCATGTAAAT 1/2 
Chim1af TTACTGTCAAGAAAGCTGCA 3 
Chim1ar TGCAGCTTTCTTGACAGTAA 3 
 Primers for mutations Mutation 
Mut1for AGTGTTCTCCAGGTGAATGCATTTATC F328V 
Mut1rev GATAAATGCATTCACCTGGAGAACACT F328V 
Mut2for CTCCAGTTCAATGGCTTTATCAATTCA A330G 
Mut2rev TGAATTGATAAAGCCATTGAACTGGAG A330G 
Mut3for GCATTTATCAATAAATTTACCTTCATG S334K 
Mut3rev CATGAAGGTAAATTTATTGATAAATGC S334K 
Mut4for TCCACTGCTGAGGCAGTCTTCCTTATG V353A 
Mut4rev CATAAGGAAGACTGCCTCAGCAGTGGA V353A 
Mut5for ACTGCTGAGGTAATATTCCTTATGGGT V354I 
Mut5rev ACCCATAAGGAATATTACCTCAGCAGT V354I 
Mut6for ATGGGTCTTTATAGCTTACCTCCAATA M361S 
Mut6rev TATTGGAGGTAAGCTATAAAGACCCAT M361S 
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Table 2-4: Templates and primers used to construct the different chimeras 
 
Chimera Template Forward 
primer    
1st PCR 
Reverse 
primer  
1st PCR 
Template    
2nd PCR 
Forward 
primer 
2nd PCR 
Reverse 
primer  
2nd PCR 
1 Oatp1a1 
Oatp1a4 
Reverse 
Chim1f 
Chim1r 
Universal
Amplification 
product of 1st 
PCR 
Reverse Universal
2 Oatp1a4 
Oatp1a1 
Reverse 
Chim1f 
Chim1r 
Universal
Amplification 
product of 1st 
PCR 
Reverse Universal
3 Oatp1a1 
Oatp1a4 
Reverse 
Chim1af 
Chim1ar 
Universal
Amplification 
product of 1st 
PCR 
Reverse Universal
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V. TRANSIENT TRANSFECTION OF HEK293 CELLS 
           Twenty-four hrs before transfection, HEK293 cells were harvested by 
trypsinization and re-plated at 250,000 cells/well in 24-well plates (coated with 0.1 
mg/ml poly-D-lysine). The transfection mixture consisted of 0.8 µg of plasmid DNA 
and 2µL LipofectamineTM 2000 (Invitrogen, Carlsbad, CA). The transfection was 
performed according to the manufacture’s protocol and the transfected cells were 
incubated at 37°C for 48 hrs before use.  
 
VI. PROTEIN EXPRESSION IN STABLE CELL LINES 
          For Oatp1a1 and Oat2 stable cell lines, cells were plated at 40,000 cells per 
well on 24-well plates and 48 h later medium was replaced with medium containing 5 
mM sodium butyrate to induce nonspecific gene expression (Palermo et al., 1991). 
After another 24 h in culture, the cells were used for uptake experiments or surface 
biotinylation.  
 
VII. PROTEIN EXPRESSION IN X. LAEVIS OOCYTES:  
          For in vitro synthesis of cRNA, the cDNA clones in pSPORT-1 vector were 
linearized with NotI and capped cRNA was synthesized using the mMESSAGE 
mMACHINE T7 kit (Ambion, Austin, TX) according to the manufacture’s protocol. 
X. laevis oocytes were prepared and handled as described previously (Hagenbuch et 
al., 1991; Hagenbuch et al., 1996). Briefly, frogs were anaesthetized by immersion for 
15 min in a 0.17% solution of ethyl m-aminobenzoate (MS-222). Oocytes were 
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 removed and incubated at room temperature for 3 hrs in Ca2+ -free OR-2 solution, 
supplemented with 2 mg/ml collagenase (Sigma type I). They were then washed in 
modified Barth’s solution, consisting of 88mM NaCl, 1mM KCl, 2.4mM NaHCO3, 
15mM HEPES-NaOH, pH 7.6, 0.3mM Ca(NO)2·(4H2O), 0.41mM CaC12·(6H2O), 
0.82mM MgSO4·(7H2O), 10 units/ml penicillin and 10 µg/ml streptomycin. Stage V 
and VI oocytes were selected for further experiements. After an overnight incubation 
at 18 °C, healthy oocytes were injected with 50 nl water or 5 ng of the respective 
cRNA.  
 
VIII. TRANSPORT ASSAY ( X. LAEVIS OOCYTES):  
          After 3 days in culture at 18 °C, transport of radiolabeled substrate [3H]-
digoxin (PerkinElmer Life Sciences, Boston, MA) was quantified at 25 °C in an 
oocyte uptake buffer containing 100 mM choline chloride, 2 mM KCl, 1 mM CaCl2, 
1 mM MgCl2, and 10 mM Hepes/Tris, pH 7.5. Oocytes were washed once in oocyte 
uptake buffer. Between 5 and 10 oocytes were then incubated at 25 ºC in uptake 
buffer containing radiolabeled substrates. After the indicated time interval, the uptake 
was terminated by the addition of 1 ml of ice-cold uptake buffer. Furthermore, 
oocytes were additionally washed 3 times in 10 ml of cold buffer. Single oocytes 
were then dissolved in 1 ml of 10% (w/w) sodium dodecyl sulfate. After addition of 5 
ml of scintillation fluid (Opti-FluorTM Packard Instrument International, S.A., Zurich, 
Switzerland) the oocyte-associated radioactivity was quantified in a Packard Tri-
CarbTM 2200 CA liquid scintillation analyzer. 
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            Kinetic analysis of digoxin was determined at 15 min which was within the 
initial linear range. The obtained values, corrected for the values of the water injected 
oocytes, were fitted to the Michaelis-Menten equation using non-linear regression 
analysis. 
 
IX. TRANSPORT ASSAY (MAMMALIAN CELLS) 
            After washing the cells three times with prewarmed (37°C) uptake buffer (142 
mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM 
glucose, and 12.5 mM HEPES, pH 7.4), 200µL uptake buffer containing radiolabeled 
substrates with sufficient unlabeled compound to achieve the indicated 
concentrations, were added to initiate transport. After incubating for the indicated 
time periods, transport was terminated by four washes with ice-cold uptake buffer.  
Cells were lysed with 300µL 1% Triton X-100 at room temperature for 30 min. Two 
hundred microliters of cell lysate were transferred to 24-well scintillation plates 
(Perkin Elmer, Shelton, CT) and radioactivity was quantified after adding Optiphase 
Supermix scintillation cocktail (Perkin Elmer) in a MicroBeta liquid scintillation 
counter. For unlabeled PFCA substrates, final concentrations in cell lysates were 
analyzed using LC-MS/MS. The remaining 100 µL cell lysate were used to determine 
the protein concentration using the BCATM Protein Assay (Pierce). All transport 
activities were corrected for total protein concentration. 
 
 54
           Kinetic analyses were all determined within the initial linear time range. 
Transport of radiolabeled estradiol-17β-glucuronide was quantified from 1µM to 50 
µM; transport of radiolabeled estrone-3-sulfate was quantified from 0.05µM to 2µM; 
transport of radiolabeled sulfobromophthalein was quantified from 0.05µM to 3µM; 
transport of radiolabeled taurocholate was quantified from 5µM to 200µM; transport 
of radiolableled digoxin was quantified from 0.1µM to 5µM and transport of PFCAs 
was quantified from 10µM to 300µM. Transporter-specific uptake was obtained by 
subtracting the uptake into empty vector-transfected cells or wild-type cells from the 
uptake into transporter expressing cells. Michaelis-Menten type nonlinear curve 
fitting was carried out to obtain estimates of the maximal uptake rate (Vmax) and the 
apparent affinity constant (Km) (Graphpad Prism, GraphPad Software Inc., La Jolla, 
CA).  
 
X. SURFACE BIOTINYLATION IN HEK293 CELLS:  
            Forty eight hrs after transfection,  HEK293 cells were washed with ice-cold 
phosphate-buffered saline Ca2+/Mg2+ (PBS-CM; 138mM NaCl, 2.7mM KCl, 1.5mM 
KH2PO4, 9.6mM Na2HPO4, 1mM MgCl2, 0.1mM CaCl2, pH7.4) and then treated with 
1mg/ml membrane-impermeable biotinylating agent sulfosuccinimidyl 2-
(biotinamido)-ethyl-1,3-dithiopropionate (sulfo-NHS-SS-biotin; Pierce, Rockford, IL) 
at 4°C for 1 hr with shaking. Subsequently, cells were washed three times with ice 
cold PBS-CM containing 100mM glycine to remove the remaining labeling reagent. 
The cells were then lysed in 300µL lysis buffer (150mM NaCl, 10mM Tris·HCl, 
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 1mM EDTA, 1% Triton X-100 and 0.1% SDS, pH7.5) containing protease inhibitors 
(Complete, Roche Applied Science, Indianapolis, IN) at 4°C with constant agitation 
for 1 hr. Following centrifugation at 10,000 x g (4°C) for 2 min, 50µL of NeutrAvidin 
(Pierce) beads were added to 250µL of cell lysate supernatant and incubated at room 
temperature for 1 hr with constant agitation. Beads were then washed 4 times with 
lysis buffer, and the biotinylated proteins were recovered from the beads by 
incubating with 2xLaemmli buffer with 50mM DTT for 30 min at room temperature.  
 
 
XI. SDS-PAGE AND WESTERN BLOT 
            Forty micro liters of surface proteins were separated on 8% SDS-PAGE 
minigels at 150V for 1 hr and then transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA) for 1 hr at 100V. The membrane was blocked for 1 hr with 5% non-fat 
dry milk in PBS at room temperature, followed by overnight incubation of anti-
OATP1B1 antibody (1:2500 dilution) at 4°C. After washing with 0.1% PBS/Tween-
20 3 times for 10 min each, the membrane was incubated with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Pierce) for 1 hr at room temperature in 
2.5% milk in PBS (1:10,000 dilution). Following extensive washing with 0.1% 
PBS/Tween-20, the secondary antibody was detected using the ECL kit 
(AmershamTM, Buckinghamshire, UK). Protein loading was normalized using an 
antibody against the plasma membrane marker Na+/K+ ATPase α subunit (Abcam, 
Cambridge, MA) (1: 5000 dilution). Horseradish peroxidase-conjugated goat anti-
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 mouse IgG (Pierce) was used as secondary antibody (1:10,000 dilution). Immunoblots 
were developed using the ECL plus kit (AmershamTM). The intensity of protein bands 
was quantified using ImageJ (http://rsbweb.nih.gov/ij/). Band intensities at 5-6 
different exposure times were quantified to ensure that the signal was within the 
linear range of the film.  
 
XII. LC-MS/MS ANALYSIS FOR PFCAS 
          For single concentration uptake and time dependency studies, Waters 
ACQUITY ultra performance LC system with a Waters Quattro Premier XE triple 
quadrupole mass spectrometer with an ESI source (Waters, Milford, MA) were used. 
The entire LC–MS system was controlled by MassLynx 4.1 software. 
Chromatographic separations were performed with an ACQUITY UPLC C18 column 
(1.7 μm, 50 mm × 2.1 mm ID) (Waters, Milford, MA). The mobile phase consisted of 
35% H2O  and 65% acetonitrile, at a total flow rate of 0.3 mL/min. MRM transitions 
363 -> 319 amu, 413 -> 369 amu, 463 -> 419 amu,  513 -> 469 amu were chosen for 
C7,  C8,  C9 and C10 quantification. C7 was used as internal standard for C8, C9 and 
C10 quantification, whereas C8 was used as an internal standard for C7 
quantification. Samples were prepared by adding 60 µL cell lysate into 120µL 
acetonitrile containing internal standard. The tubes were then vortexed vigorously for 
5 sec followed by centrifugation at 25,000 x g for 20 min. One hundred and fifty 
microliters of supernatant were then transferred to a new clean polypropylene tube 
and stored at -20ºC until analyzed.  
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           For transporter kinetic studies, the instrument used was the Sciex API 5000 
mass spectrometer (Applied Biosystems / MDS-Sciex, Foster City, CA).  The Turbo 
Ion Spray (pneumatically assisted electrospray ionization) in negative ion mode was 
used.  Separation of the compounds were completed on a Mac-Mod ACE ® C-18, 5 
µm, 100 x 2.1 mm i.d. HPLC column with a gradient flow rate of 0.250 mL/min.  
Mobile phase was acetonitrile and 2 mM ammonium acetate solution in reagent grade 
water.  The initial mobile phase was 25% acetonitrile and 75% ammonium acetate 
solution. The concentration was held for 1.0 min. Between 1.0 min and 4.0 min the 
composition was changed to 10% 2 mM ammonium acetate solution and 90% 
acetonitrile.   The 90% acetonitrile composition was held until 7.00 min into the run. 
Between 7 min and 7.80 min the acetonitrile concentration was decreased to 25% and 
held until 10.5 min until re-equilibration of the HPLC columns was completed.  
Transition ions were monitored as follows:  C7: 363 -> 319 amu; C8: 413 -> 369 
amu; C9: 463 -> 419 amu ; C10: 513 -> 469 amu; Internal Standard: dual 13C-labeled 
C8: 415 -> 370 amu. Samples were prepared by the addition of 25 µL of cell lysate to 
the polypropylene 1.8 mL conical tip tube containing the internal standard matrix 
matched blank buffer. Standards were introduced to similar tubes and matrix matched 
blank buffer (25uL) of either CHO lysate or HEK293 lysate were pipetted as 
appropriate.  To the tube containing the 25 µL of cell lysate, 175 µL of a solution 
containing 5% of 2 mM ammonium acetate and 95% acetonitrile was added (total 
volume 200 µL).  The tube was vortexed vigorously for 5 sec followed by 
centrifugation at 2500 x g.  An 80 µL aliquot of supernatant was transferred to a new 
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 clean 100 µL polypropylene vial; the vial was capped with a polypropylene cap and 
placed in the auto sampler for injection into the LC-MS/MS system.   A 4 µL 
injection was used for the analysis.   
 
 
XIII. STATISTICAL ANALYSIS 
          Statistical significance was analyzed using a two-tailed, unpaired Student’s t 
test (GraphPad Prism, GraphPad Software Inc., La Jolla, CA). Data were considered 
statistically significant at p<0.05. 
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 CHAPTER 3 
 
SEVERAL CONSERVED POSITIVELY CHARGED AMINO ACIDS ARE 
IMPORTANT FOR OATP1B1 FUNCTION 
 
 
SPECIFIC AIM AND HYPOTHESIS 
          Chapter 3 will address specific aim 1 and will evaluate the hypothesis that 
conserved positively charged amino acids play important roles in OATP1B1 
transport function. Based on a 3-dimensional structural model, several conserved 
positively charged amino acids have been suggested to be important for the function 
of OATP1B family members. The purpose of this study is to determine whether 
these conserved positively charged amino acids are involved in substrate binding 
and /or substrate translocation using site-directed mutagenesis.  
         
I. INTRODUCTION 
 
          OATP1B1 is a transport protein expressed at the basolateral membrane of 
human hepatocytes (Abe et al., 1999; Hsiang et al., 1999; Konig et al., 2000). It 
belongs to the organic anion transporting polypeptide superfamily (OATP, gene 
symbol SLCO) (Hagenbuch and Meier, 2004), and mediates the sodium-independent 
transport of a wide range of structurally unrelated amphipathic organic compounds 
(Konig et al., 2006; Hagenbuch and Gui, 2008). Due to its broad substrate spectrum, 
OATP1B1 is important for hepatic clearance of many drugs and other xenobiotics. 
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 Therefore, understanding the transport mechanisms of OATP1B1 is essential to 
explain and prevent potential adverse drug interactions occurring at the transporter 
level.  
 
          Naturally occurring polymorphisms have provided some insight into the 
structure-function relationship for OATP1B1. OATP1B1*1b (388A>G, N130D) and 
OATP1B1*5 (521T>C, V174A) are the two most frequently observed 
polymorphisms (Tirona et al., 2001; Nozawa et al., 2002; Konig et al., 2006). N130D 
does not affect transport of most substrates or surface expression of the protein 
(Tirona et al., 2001; Iwai et al., 2004; Kameyama et al., 2005), whereas V174A alone 
or together with N130D (OATP1B1*15) decreases clearance and increases plasma 
concentration of pravastain, simvastatin, ezetimibe, SN-38 and bilirubin (Nishizato et 
al., 2003; Ieiri et al., 2004; Niemi et al., 2004; Nozawa et al., 2005; Zhang et al., 
2007; Han et al., 2008; Neuvonen et al., 2008; Oswald et al., 2008; Pasanen et al., 
2008; van der Deure et al., 2008). In vitro studies using transiently transfected cell 
lines suggest that the decreased transport activity of OATP1B1*15 may be due to 
decreased protein expression on the cell surface (Kameyama et al., 2005) or due to 
decreased turnover number of the mutated transporter (Iwai et al., 2004). Structurally, 
OATP1B1 shares 80% amino acid sequence identity with OATP1B3, another 
transporter in the same subfamily. Functionally, OATP1B1 and OATP1B3 exhibit 
overlapping substrate spectra in addition to their own specific substrates (Konig et al., 
2006; Hagenbuch and Gui, 2008). Therefore, construction of chimeric proteins 
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 between OATP1B1 and OATP1B3 is another strategy to study structure-function 
relationship for both transporters. Using this technique, it has been shown that three 
amino acid residues within transmembrane domain 10 in OATP1B3 are important for 
recognition and/or translocation of CCK-8, an OATP1B3 specific substrate (Gui and 
Hagenbuch, 2008). In addition, using the same strategy, the eighth, ninth (Miyagawa 
et al., 2009) and  tenth (Gui and Hagenbuch, 2009) transmembrane domain of 
OATP1B1 have been shown to affect the transport of estrone-3-sulfate and/or 
estradiol-17β-glucuronide.   
 
          Due to the lack of crystal structure information, comparative modeling has been 
used to predict the structure of OATPs. Because OATPs are predicted to have 12-
transmembrane domains, which is common to members of the major facilitator 
superfamily (MFS), the known crystal structures of two membrane transporters in the 
MFS were used as templates to generate a 3D structural model for OATP1B3 (Meier-
Abt et al., 2005). Based on this model, a putative binding pocket within an aqueous 
pore that contains several positively charged amino acid residues that are conserved 
throughout the OATP1 family was proposed (Meier-Abt et al., 2005). A recent study 
has confirmed in OATP1B3 that K41 and R580 in transmembrane domains are 
important for BSP transport (Glaeser et al., 2010). However, the roles of these 
positively charged amino acids in OATP1B1 mediated transport are still unknown.  
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           Therefore in this study, we performed site-directed mutagenesis and 
characterized the mutant proteins with respect to surface expression and transport 
function to determine the significance of these conserved positively charged amino 
acids for OATP1B1. 
 
II. RESULTS AND DISCUSSION 
2.1  Expression and function of alanine mutants 
          To determine the functional effects of the individual conserved positively 
charged amino acids facing the putative binding pocket (Meier-Abt et al., 2005), we 
performed site-directed mutagenesis and changed amino acid residues at the positions 
indicated in Figure 3-1; R181 and R580 in predicted transmembrane domains 4 and 
11, R57 and K361 at the predicted extracellular side, and K90, H92 and K93 at the 
predicted intracellular side of OATP1B1. Initially, we individually replaced all seven 
amino acids with alanines and transiently expressed these mutants in HEK293 cells. 
We purified membrane proteins using surface biotinylation and performed western 
blot analysis using an anti-OATP1B1 antibody. As demonstrated in Figure 3-2, all 
OATP1B1 constructs were detected at the cell surface at different expression levels. 
Na+/K+ ATPase, a membrane protein naturally expressed in all HEK293 cells, was 
used as loading control. Most alanine mutants were able to express normally on the 
cell surface, except for R580A which was only expressed at about 30% of the control. 
We observed this low expression level also in total cell lysates (data not shown), 
indicating that this mutation may alter protein synthesis, folding or stability.  
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Figure 3-1    Predicted topological model of human OATP1B1 with mutation 
sites 
Topological structure of OATP1B1 was predicted by TMPred 
(http://www.ch.embnet.org/software/TMPRED_form.html). Amino acids mutated in 
this study are indicated in black and the positions are listed in the boxes pointing to 
these residues.   
 
 64
  
 
 
Figure 3-2     Surface expressions of alanine mutants in HEK293 cells 
Representative western blots of surface-biotinylated proteins detected with a 
polyclonal anti-OATP1B1 antibody (75kDa). HEK293 cells transfected by empty 
vector were used as negative controls. The same blot was also probed with an 
antibody against the plasma membrane marker Na+/K+-ATPase α subunit (103 kDa) 
as a protein loading control.  
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           Given that OATP1B1 is a multispecific transporter (Hagenbuch and Gui, 2008) 
and that for certain substrates multiple substrate binding sites have been suggested 
(Tamai et al., 2001; Noe et al., 2007; Hagenbuch and Gui, 2008), we determined the 
transport activity of each mutant by quantifying uptake of the model substrates [3H]-
estradiol-17β-glucuronide, [3H]-estrone-3-sulfate, and [3H]-sulfobromophthalein 
(BSP). Quantified values were normalized to whole cell protein as well as to surface 
expressed OATP. First, we quantified uptake of 1µM estradiol-17β-glucuronide. 
HEK293 cells transfected with wild-type OATP1B1 transported 63±8 pmol/mg total 
protein/min estradiol-17β-glucuronide which was 70 fold higher than empty vector 
transfected HEK293 cells (0.9±0.2 pmol/mg total protein/min). Net uptake was 
considered as wild-type OATP1B1-mediated transport and set to 100%. This high 
signal to background ratio allowed us to compare transport activities of mutants to 
wild-type OATP1B1. Figure 3-3 shows that transport of estradiol-17β-glucuronide 
(black bars) by the two mutants at the extracellular side, R57A and K361A, was 
reduced to about 30% of wild-type OATP1B1. Transport by the transmembrane 
domain mutant R181A was not different from wild-type OATP1B1, whereas 
transport by R580A was slightly increased. Of the three intracellular mutants, K90A 
and H92A showed slightly decreased transport whereas transport by R93A was 
normal (Figure 3-3). For estrone-3-sulfate at a concentration of 0.1µM, HEK293 cells 
transfected with wild-type OATP1B1 transported 8.3±0.8 pmol/mg total protein/30s, 
whereas empty vector transfected HEK293 cells transported only 0.14±0.02 pmol/mg 
total protein/30s. This resulted in a net uptake of 8.2±0.9 pmol/mg total protein/30s 
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 which after correction for surface expression was set to 100 %. Compared to 
estradiol-17β-glucuronide, we observed similar results for the transport of estrone-3-
sulfate by the alanine mutants (Figure 3-3, grey bars). The results with BSP, another 
high-affinity substrate for OATP1B1 (Cui et al. 2001, Kullak-Ublick et al. 2001), are 
shown in Figure 3-3 with white bars. Uptake of 0.1µM BSP by wild-type OATP1B1 
amounted to 13.1±2.0 pmol/mg total protein/min, whereas empty vector transfected 
HEK293 cells transported 1.2±0.4 pmol/mg total protein/min. This resulted in a net 
uptake of 11.9±2.0 pmol/mg total protein/min, which was set to 100%. Compared to 
the previous two substrates, BSP transport was not as strongly affected by alanine 
mutations at the two extracellular sites R57 and K361. Uptake by the transmembrane 
R181A was comparable to estradiol-17β-glucuronide and estrone-3-sulfate, whereas 
uptake by R580A was markedly increased. Mutations of the intracellular residues 
K90 and H92 to alanine resulted in BSP uptake similar as for estradiol-17β-
glucuronide and estrone-3-sulfate, whereas an alanine at position R93 affected BSP 
transport more than the other two substrates. These results were a first hint for 
substrate specific effects of the different amino acid replacements.    
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 Figure 3-3    Uptake of estradiol-17β-glucuronide estrone-3-sulfate and 
sulfobromophthalein mediated by OATP1B1 and alanine mutants after 
normalization for surface expression. 
Uptake of 1µM [3H]-estradiol-17β-glucuronide (black bar) and 0.1µM [3H]-
sulfobromophthalein (BSP, white bar) was quantified at 37ºC for 1min (initial linear 
rate condition); uptake of 0.1µM [3H]-estrone-3-sulfate (gray bar) was quantified at 
37ºC for 30 sec (initial linear rate condition) with HEK293 cells expressing empty 
vector, OATP1B1, or alanine mutants. The net uptakes were obtained by subtracting 
the uptake of empty vector transfected cells from the uptake of OATP1B1 or mutant 
transfected cells. The results were normalized for surface protein expression and 
presented as percentage of wild-type OATP1B1 (WT).   Each bar is the mean ± 
standard error (SE) of five independent experiments. Asterisks (*) indicate significant 
difference from wild-type OATP1B1. *, p<0.05.  
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 2.2  Expression and function of mutants on the extracellular side 
          In order to test whether re-introduction of a positively charged amino acid 
residue at positions 57 and 361 would rescue transport function, we constructed 
mutants that contained a lysine at 57 (R57K) or an arginine at 361 (K361R). Both 
mutants were expressed at the surface normally (Figure 3-4A). Re-introduction of the 
positively charged lysine at position 57 (R57K) increased transport of estradiol-17β-
glucuronide (Fig. 3-4B) and BSP (Fig. 3-4D) as compared to the alanine mutant. 
Estrone-3-sulfate transport was slightly increased, but the increase did not reach 
statistical significance (Fig. 3-4C). Compared to the alanine mutant, re-introduction 
of a positive arginine at position 361 (K361R) did not affect transport of any of the 
three tested substrates (Fig. 3-4B, C, D). These results suggest that at least for 
estradiol-17β-glucuronide and BSP, a positively charged residue at position 57 is 
important, whereas at position 361, the lysine is required and cannot be replaced by 
the positively charged arginine.  
 
          It is important to emphasize that all these experiments were performed at a 
single time point and a single concentration within the initial linear range. Although 
such experiments can yield important information about changes in the transport 
activities of the involved proteins, kinetic analyses are needed to make conclusions 
about potential changes in the apparent affinities or Vmax values. Therefore, we 
determined the kinetic parameters for wild-type OATP1B1 and the extracellular 
mutants for estradiol-17β-glucuronide, estrone-3-sulfate, and BSP. Although two 
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 Figure 3-4    Surface expression and transport function of extracellular R57 and 
K361 mutants.  
(A) Quantification of surface expression of R57 and K361 mutants normalized to 
loading control Na+/K+-ATPase presented as a percentage of wild-type OATP1B1 
(WT). Each bar is the mean ± standard error (SE) of five independent experiments. 
Uptake of 1µM [3H]-estradiol-17β-glucuronide (B), 0.1µM [3H]-estrone-3-sulfate (C) 
or 0.1µM [3H]-sulfobromophthalein (BSP) (D) mediated by R57 and K361 mutants 
was quantified at 37ºC under initial linear rate conditions and presented as % of wild-
type after correction for surface expression. Each bar is the mean ± standard error 
(SE) of five independent experiments. *, p<0.05; ns, no significant difference.  
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 binding sites were identified for OATP1B1 mediated estrone-3-sulfate transport 
(Tamai et al., 2001; Noe et al., 2007), we only studied the high-affinity component 
because transport at low concentrations was affected by the mutations. The data in 
Table 3-1 summarizes the kinetic experiments. Apparent Km values obtained for wild-
type OATP1B1 were within the published values for estradiol-17β-glucuronide 
(Konig et al., 2000; Cui et al., 2001; Tamai et al., 2001; Hirano et al., 2004; Gui et al., 
2008), estrone-3-sulfate (high-affinity, low-capacity binding site)  (Hirano et al., 
2004; Noe et al., 2007) and BSP (Cui et al., 2001; Kullak-Ublick et al., 2001). With 
respect to estradiol-17β-glucuronide, both alanine mutants, R57A and K361A, had 
lower affinities as compared to wild-type OATP1B1. The apparent Km values 
increased almost 5 fold for R57A from 5.7 to 27.1 μM and moderately for K361A to 
14.5 μM. Restoring the positive charges resulted in a reversal of the effects for 
position 57. The apparent Km value for R57K (8.6 μM) was close to the Km value for 
wild-type OATP1B1 (5.7 μM), whereas the apparent Km value of K361R remained 
elevated like the Km value obtained for K361A. These data suggest that a positively 
charged amino acid at position 57 is important for a normal estradiol-17β-glucuronide 
transport, whereas at position 361 the lysine is required. The corresponding Vmax 
values did not change as much as the apparent Km values (Table 3-1), and thus the 
transport efficiencies (Vmax/Km) for all four mutants were mainly affected by the Km 
values and clearly decreased to less than 50 % of wild-type OATP1B1 (Table 3-1). 
However, reintroducing a positively charged residue at position 57 increased 
transport efficiency from 27 to 50 % of wild-type, whereas both mutants at position  
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 Table 3-1: Kinetic parameters of wild-type OATP1B1 and extracelluar mutants 
 
 
 
Kinetic parameters of wild-type and mutated OATP1B1-mediated estradiol-17β-
glucuronide, BSP, and estrone-3-sulfate uptake were quantified under initial linear 
rate conditions and presented as mean ± SE of 3-8 independent experiments. All Vmax 
values are corrected for surface expression. Uptake of estradiol-17β-glucuronide 
(1µM to 50 µM) and BSP (0.05µM to 3µM) was quantified at 37ºC for 1 min; uptake 
of estrone-3-sulfate (0.05µM to 2µM) was quantified at 37ºC for 30 sec. Asterisks (*) 
indicate significant difference based on unpaired, two-tailed Student t test.  *, p<0.05.  
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 361 remained at about 30 to 40 %. The findings for BSP transport were very similar. 
Alanine replacement at both positions increased the apparent Km values about two 
fold, whereas reintroduction of a positive charge only had an effect at position 57 
(Table 3-1). The Vmax values of the mutants did not differ significantly from wild-
type, except for K361R for which the Vmax value was reduced. When transport 
efficiencies were calculated, it became apparent that at position 57, alanine reduced 
the transport efficiency to 41 % of wild-type OATP1B1. Re-introduction of a positive 
charge at position 57 with a lysine increased the transport efficiency to the same as 
wild-type OATP1B1. In constrast, at position 361 the lysine is specifically required 
for proper transport because the alanine and the arginine mutants had Vmax/Km values 
of only 38 and 27 % of wild-type OATP1B1, respectively (Table 3-1), and re-
introducing a positive charge did not improve transport efficiency. The alanine 
mutant R57A had a slightly decreased affinity for estrone-3-sulfate transport. The 
apparent Km for R57A (0.8µM) was twice as high as for wild-type OATP1B1 
(0.4µM). However, in contrast to estradiol-17β-glucuronide and BSP, re-introduction 
of a positive charge with a lysine did not return the Km value (0.7µM) significantly 
towards the value of wild-type OATP1B1. Because the Vmax values only slightly 
decreased, the overall transport efficiencies were decreased for both mutants, mainly 
due to increased Km values. The alanine mutation at position K361 did not affected 
the affinity for estrone-3-sulfate transport, but resulted in a 2.5 fold lower Vmax value 
(Table 3-1). The mutation to an arginine decreased the affinity 4.5 fold from 0.4 μM 
to 1.8 μM with no significant change in Vmax (Table 3-1). Thus the decreased 
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 transport efficiencies were due to a decrease in the Vmax for K361A, and due to 
increase in the Km for K361R. Taken together, these results strongly suggest that a 
positive charge at position 57 is important for estradiol-17β-glucuronide and BSP 
transport, whereas a lysine at position 361 is absolutely required for transport of all 
three substrate tested. These conclusions are further supported by the fact that in all 
nine so far functionally characterized human OATPs a lysine is conserved at the 
position corresponding to 361 in OATP1B1, whereas a positive charge is conserved 
at the position corresponding to 57 in OATP1B1 (arginine at 57: OATP1A2, 
OATP1B1, OATP1B3, OATP1C1, OATP3A1, OATP4A1, and OATP5A1; lysine at 
57: OATP2A1, OATP2B1, OATP4C1, and OATP6A1).          
 
2.3  Expression and function of mutants in transmembrane domains. 
          To further study the roles of transmembrane R181 and R580 in transporting the 
different substrates we generated in addition to the alanine mutants also positively 
charged mutants R181K, R181H, R580K and R580H. As shown in Figure 3-5A, 
R181K was not expressed at the cell surface at all and therefore its function could not 
be determined whereas surface expression of R181H was reduced to about 60% of 
wild-type. Surface expression of R580A was reduced but surface expressions of 
R580K and R580H were normal. These data suggest that a positively charged amino 
acid at position 580 is essential for proper surface expression of the protein. Transport 
activities of all mutants for the three substrates, estradiol-17β-glucuronide, estrone-3-
sulfate, and BSP are compared in Figure 3-5B. Among the different transmembrane  
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 Figure 3-5   Surface expression and transport function of transmembrane 
mutants R181 and R580. 
(A) Representative western blots of surface-biotinylated proteins detected with a 
polyclonal anti-OATP1B1 antibody (75kDa). The same blot was also probed with an 
antibody against the plasma membrane marker Na+/K+-ATPase α subunit (103 kDa) 
as a protein loading control.  
 (B) Uptake of 1µM [3H]-estradiol-17β-glucuronide (black bar), 0.1µM [3H]-estrone-
3-sulfate (gray bar) and 0.1µM [3H]-BSP (white bar) was quantified individually in 
HEK293 cells expressing R181 or R580 mutant at 37ºC under initial linear rate 
conditions and presented as % of wild-type after corrected for surface expression. 
R181K is not detectable on the cell surface, and thus the transport activity was too 
low to be quantified. Each bar is the mean ± standard error (SE) of five independent 
experiments. Asterisk (*) indicate significantly different activities between wild-type 
and mutated transporters. *, p<0.05.   
  
 
 77
  
 
 
 78
 mutants, R181A and R580H had almost normal transport activities for all of the 
tested substrates, whereas the R580K mutant had reduced transport activities. 
Interestingly, both R181H and R580A exhibited differences in transport of the three 
substrates. Mutant R181H had decreased estradiol-17β-glucuronide transport, normal 
to slightly decreased estrone-3-sulfate transport, but increased BSP transport. Mutant 
R580A demonstrated moderately increased estradiol-17β-glucuronide and estrone-3-
sulfate (both to 140% of wild-type OATP1B1) uptake but strongly increased BSP (to 
250% of wild-type OATP1B1) uptake. To investigate whether these differences in 
substrate handling of the transmembrane mutants were due to changes in apparent Km 
or Vmax, we performed kinetics analysis (Table 3-2). R181A showed no significant 
differences from wild-type for all three substrates tested.  R181H had a slightly 
increased Km for estradiol-17β-glucuronide, whereas no significant changes in Km 
were observed for estrone-3-sulfate and BSP. Vmax values of R181H were not 
different from wild-type OATP1B1. Therefore, we conclude that a histidine at 
position 181 may affect substrate recognition for estradiol-17β-glucuronide. 
However, we also conclude that the positive charge at this position is not directly 
involved in transport of the three substrates investigated, because it can be replaced 
by the neutral alanine without significant changes in transport activity. This 
conclusion is further supported by the fact that the R181 is only conserved within the 
OATP1 family.  
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 Table 3-2: Kinetic parameters of transmembrane mutants 
 
 
 
Kinetics experiments were done under the same conditions as described in Table 3-1. 
*, p<0.05. 
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         At the other transmembrane position, mutant R580A showed increased transport 
efficiency for estradiol-17β-glucuronide (145%), estrone-3-sulfate (167%), and BSP 
(189%) (Table 3-2). For estradiol-17β-glucuronide  and BSP , these effects were 
mainly due to a doubling of the Vmax values with a slight or no change in apparent 
Km. However, for estrone-3-sulfate, the increase was mainly due to a decrease of the 
apparent Km (from 0.4 to 0.2µM), whereas the Vmax remained the same. When we re-
introduced a positive charge by a lysine at position 580, both Km and Vmax values for 
all substrates were affected. For estradiol-17β-glucuronide and estrone-3-sulfate, 
R580K had significantly decreased Vmax (estradiol-17β-glucuronide from 243 to 18 
pmol/mg per min; estrone-3-sulfate from 65 to 10 pmol/mg per min), and Km values  
(estradiol-17β-glucuronide from 4.9  to 0.6 µM; estrone-3-sulfate from 0.4 to 0.2 
µM). For BSP, the Vmax value was slightly decreased (from 47 to 31 pmol/mg per 
min), whereas the Km value was increased two fold (from 0.5 to 1.2 µM) (Table 3-2). 
However, when we re-introduced a positive charge with a histidine at position 580, 
Vmax values for estradiol-17β-glucuronide and estrone-3-sulfate increased as 
compared to the lysine mutation, but were still significantly lower than the wild-type. 
However, the Vmax value for BSP transport (26 pmol/mg/min) was about the same as 
for the lysine mutant R580K and slightly lower than wild-type OATP1B1, but the Km 
value (0.3 µM) was significantly lower (1.2 µM). Compared to wild-type, the overall 
transport efficiencies of R580H for all three substrates were not altered due to 
simultaneous changes in Vmax and Km values. The fact that both lysine and histidine 
mutations at 580 significantly decreased Vmax, suggests that arginine at this position is 
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 important for the translocation process. Furthermore, because both R580K and 
R580H mutations affected the turnover numbers for estradiol-17β-glucuronide and 
estrone-3-sulfate more than that for BSP suggests that the different substrates may be 
handled differently by the transporter. Alternatively it is possible that interactions 
between other amino acid side chains and the different substrates are affected by the 
mutations.  These results together with cell surface expression data suggest that R580 
is involved in both maintaining the correct conformation of OATP1B1 at the cell 
surface and proper transport function.  Such an important role for this amino acid 
position is also supported by an absolute conservation of the arginine residue at this 
position within all eleven human OATPs.     
 
2.4  Expression and function of mutants on the intracellular side 
          Finally, we investigated the effects of mutations at the intracellular conserved 
positively charged residues. We constructed K90A, K90R, H92A, H92K, H92R, 
R93A, and R93K and determined their surface expression (Figure 3-6A), as well as 
uptake of estradiol-17β-glucuronide (Figure 3-6B), estrone-3-sulfate (Figure 3-6C), 
and BSP (Figure 3-6D) mediated by these mutants. Except for the H92 mutants that 
had about 60% to 70% of wild-type surface expression (Figure 3-6A), all the other  
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 Figure 3-6    Surface expression and transport function of intracellular K90, H92 
and R93 mutants.  
(A) Quantification of surface expression of intracelluar mutants normalized to loading 
control Na+/K+-ATPase presented as a percentage of wild-type OATP1B1 (WT). 
Each bar is the mean ± standard error (SE) of 3-5 independent experiments. Uptake of 
1µM [3H]-estradiol-17β-glucuronide (black bar), 0.1µM [3H]-estrone-3-sulfate (gray 
bar), and 0.1µM [3H]-BSP (white bar) was quantified individually in HEK293 cells 
expressing intracellular mutants K90 (B), H92 (C) and R93 (D)  at 37ºC under initial 
linear rate conditions, and is presented as % of wild-type after correction for surface 
expression. Each bar is mean ± standard error (SE) of 5 independent experiments. *, 
p<0.05.  
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 mutants expressed normally on the cell surface. With respect to transport, K90A 
showed slightly decreased uptake for all three substrates (about 70% of wild-type), 
whereas K90R-mediated uptake was normal (Figure 3-6B). All three H92 mutants 
had slightly decreased estradiol-17β-glucuronide and BSP uptake (65% to 80% of 
wild-type), but normal estrone-3-sulfate uptake (Figure 3-6C). R93 mutants showed 
decreased BSP uptake (about 65% of wild-type) but no significant effects on 
estradiol-17β-glucuronide or estrone-3-sulfate transport (Figure 3-6D). These results 
suggest that a positively charged amino acid is required at position 90 for normal 
transport of all three substrates. However at positions 92 and 93, reintroducing 
positively charged amino acid residues did not restore normal transport activity of any 
of the substrates tested. Subsequently, we characterized the transport kinetics of the 
different mutants, and the results are summarized in Table 3-3. Apparent Km values 
for all three substrates did not change for both K90A and K90R mutants, whereas 
K90A had slightly decreased Vmax values. Therefore K90R had slightly higher overall 
transport efficiency values than K90A. All H92 and R93 mutants had only decreased 
Vmax values for estradiol-17β-glucuronide transport resulting in decreased overall 
transport efficiency. However, for estrone-3-sulfate and BSP transport, the overall 
Vmax/Km values for H92 and R93 mutants remained very close to the values for wild-
type, due to simultaneously decreased Km and Vmax values.  
 
          In summary, a positively charged residue at position 90 seems to be preferred 
for normal translocation of all three substrates. At positions 92 and 93, the histidine  
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 Table 3-3: Kinetic parameters of intracelluar mutants 
 
 
 
 
Kinetics experiments were done under the same conditions as described in Table 2. *, 
p<0.05.  
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 and arginine, rather than just the positive charge, seem to affect transport activity. 
These findings are also consistent with the fact that H92 is conserved throughout the 
human OATP1 to OATP4 subfamily, and R93 is conserved throughout the OATP1 to 
OATP3 subfamily, whereas K90 is only conserved in the OATP1 family and an 
arginine can be found at this position for almost all the other OATPs.  However, all 
three intracellular residues (K90, H92 and R93) are not as important for transport 
function compared to the two extracellular residues (R57 and K361) and one 
transmembrane domain residue (R580).   
 
          In conclusion, for proteins with unknown structure and transport mechanisms, 
comparative modeling combined with the analysis of conserved amino acid residues 
is a powerful tool to identify candidate residues that may play important roles in 
structure and/or function of a transporter. Site-directed mutagenesis has provided 
useful structural and mechanistic information for the bacterial transporters in the 
major facilitator superfamily, lactose permease (Abramson et al., 2003), glycerol-3-
phosphate transporter (Huang et al., 2003) and multidrug transporter EmrD (Yin et 
al., 2006) prior to their crystallization. Because of the mainly anionic nature of 
OATP1B1 substrates, we used site-directed mutagenesis to investigate the roles of 
several conserved positively charged amino acids facing the putative binding pocket 
of OATP1B1. We have shown the important role of the positive charge at R57 for 
substrate recognition/binding and at R580 for surface expression. We also 
demonstrated that two conserved amino acids are essential, K361 for substrate 
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 binding/translocation, and R580 for substrate translocation. These findings are 
important steps towards elucidating the structure-function relationship of OATP1B1.    
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 CHAPTER 4 
 
IDENTIFICATION OF AMINO ACID RESIDUES ESSENTIAL FOR 
EFFICIENT TRANSPORT MEDIATED BY RAT Oatp1a4 
 
 
SPECIFIC AIM AND HYPOTHESIS 
          Chapter 4 will address specific aim 2 and will evaluate the hypothesis that 
quantifying transport activities of different substrates mediated by chimeras 
between rat Oatp1a1 and Oatp1a4 in combination with site-directed 
mutagenesis should allow us to identify regions and/or individual amino acids 
that are important for Oatp1a4-mediated substrate recognition and/or 
transport.  The purpose of this study is to determine the critical region and/or 
residues that are important in Oatp1a4-mediated transport and to further 
characterize the roles of these amino acids in the transport processes.  
     
I.          INTRODUCTION 
          Organic anion transporting polypeptides (rodents: Oatps; human: OATPs) form 
a superfamily of membrane transport proteins that are subdivided into 6 mammalian 
families (≥ 40 % amino acid sequence identities, OATP1-6) and 13 subfamilies (≥ 60 
% amino acid sequence identities) (Hagenbuch and Meier, 2004). The OATP1 family 
is the best characterized family and contains the rodent Oatp1a1 (gene symbol 
Slco1a1), Oatp1a3 (Slco1a3), Oatp1a4 (Slco1a4), Oatp1a5, (Slco1a5), Oatp1a6 
(Slco1a6), Oatp1b2 (Slco1b2), Oatp1c1 (Slco1c1) as well as the human OATP1A2 
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 (SLCO1A2), OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3) and OATP1C1 
(SLCO1C1). Most of these OATP/Oatps are multispecific carriers that transport a 
variety of amphipathic organic compounds, including bile acids, organic anionic 
dyes, steroid conjugates, thyroid hormones, prostaglandins, anionic oligopeptides, 
numerous drugs, and other xenobiotics (Hagenbuch and Meier, 2003). All OATPs 
have been predicted to have 12-transmembrane  domains (TM) and the 12-TM 
topology of Oatp1a1 has been confirmed experimentally using epitope-specific 
antibodies and immunofluorescence (Wang et al., 2008). 
 
          A few studies have been reported investigating the molecular basis of the 
substrate specificity of members of the OATP-gene superfamily and several structural 
elements involved in substrate binding and/or translocation have been identified. 
Experiments with the OATP2A1/Oatp2a1 from human, rat, and mouse, as well as 
some of their chimeras suggest that the C-terminal half of the protein is important for 
the apparent affinity of prostaglandin E2 (Pucci et al., 1999). Using cysteine-scanning 
mutagenesis, the same group mapped the substrate-binding site of the rat Oatp2a1 to 
TM 10 (Chan et al., 1999) and identified conserved cationic amino acids important 
for prostaglandin transport (Chan et al., 2002). Furthermore, using chimeric proteins 
between OATP1B1 and OATP1B3 in combination with site-directed mutagenesis, 
several amino acids in TM10 of OATP1B3 have been identified to be important for 
CCK-8 transport (Gui and Hagenbuch, 2008).  Similar strategies have been employed 
for OATP1B1, in which TM9 and TM8 (Miyagawa et al., 2009) or TM10 (Gui and 
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 Hagenbuch, 2009) have been identified to affect the transport of estrone-3-sulfate 
and/or estradiol-17β-glucuronide.   However, no such studies have been performed 
for transporters in the OATP1A/Oatp1a subfamily. 
 
          Among the five rat transporters in the Oatp1a subfamily, only Oatp1a1 
(Jacquemin et al., 1994) and Oatp1a4 (Noe et al., 1997) have been shown to be 
expressed in the liver. Besides common substrates like the bile acid taurocholate (Noe 
et al., 1997; Eckhardt et al., 1999), the steroid–conjugate estradiol-17β-glucuronide 
(Kanai et al., 1996; Noe et al., 1997; Eckhardt et al., 1999) and the opioid peptide D-
penicillamine2,5 enkephalin (DPDPE) (Noe et al., 1997; Kakyo et al., 1999; Reichel et 
al., 1999; Gao et al., 2000), there are compounds that are specific substrates for either 
Oatp1a1 or Otap1a4. For example, digoxin is a good substrate for Oatp1a4 but is not 
transported by Oatp1a1 (Cattori et al., 2001). Bromosulfophthalein (BSP) in 
constrast, has been shown to be transported by Oatp1a1 but not by Oatp1a4 (Gao et 
al., 2000).  
 
          Based on these substrate specificities and the overall high amino acid sequence 
identity of 77%, we hypothesized that constructing chimeric proteins between 
Oatp1a1 and Oatp1a4 in combination with site-directed mutagenesis, and quantifying 
transport uptake of the Oatp1a4-specific digoxin would allow us to identify regions 
that are important for Oatp1a4-mediated substrate transport. 
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 II.     RESULTS AND DISCUSSION 
 2.1   Digoxin transport with chimeras between Oatp1a1 and Oatp1a4. 
          In order to examine the structural requirements for Oatp1a4-mediated transport, 
we constructed chimeras between Oatp1a1, which does not transport digoxin, and 
Oatp1a4, which represents a high-affinity digoxin transporter, and quantified uptake 
of digoxin. Using digoxin transport as a functional tool should allow us to identify 
regions that are important for Oatp1a4-mediated digoxin transport.  
 
           Chimeras were constructed using an overlap PCR approach with primers that 
were identical for Oatp1a1 and Oatp1a4. Because the nucleotide sequence identity 
between Oatp1a1 and Oatp1a4 determined the location of the primers (Tables 2-3 and 
2-4), chimeras did not necessarily begin or end at the beginning or end of a certain 
TM (Figure 4-1A). Chimera 1 contained TM 1-7 of Oatp1a1 followed by the C-
terminal TM 8-12 of Oatp1a4, and chimera 2 was constructed as the mirror image of 
chimera 1 containing TM 1-7 of Oatp1a4 followed by TM 8-12 of Oatp1a1. In order 
to be able to detect all chimeras as well as Oatp1a1 and Oatp1a4 with the same 
antibody, all constructs were made with a C-terminal His-tag. Together with His-
tagged wild-type Oatp1a1 and Oatp1a4, chimeras 1 and 2 were expressed in X. laevis 
oocytes.  As published previously (Noe et al., 1997), Oatp1a4 mediated digoxin 
transport had a more than 10-fold signal to background ratio in this expression 
system. Furthermore, preliminary experiments revealed that the His-tagged Oatps 
transported typical substrates at the same rates as the wild-type Oatps (data not  
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 Figure 4-1: Digoxin transport by wild-type and chimeric Oatp1a1 and Oatp1a4 
constructs in oocytes (A) and HEK293 cells (B).  
(A) X. laevis oocytes were injected with 50 nl water or 5 ng cRNA of the respective 
His-tagged constructs and after three days in culture, transport of 0.5 μM [3H]-
digoxin was determined at 25 °C with 9-12 oocytes per condition. Black boxes and 
thick lines represent Oatp1a1, whereas white boxes and thin lines represent Oatp1a4. 
Values are given as percent of the initial transport rates obtained for wild-type 
Oatp1a4-injected oocytes and correspond to the mean of three (one for chimera 3) 
independent experiments. (B) Uptake of 0.5µM [3H]-digoxin was quantified at 37ºC 
for 30 sec (initial linear rate condition) with empty vector pExpress-1, Oatp1a4, 
Oatp1a1 or three chimeric transporter expressing HEK293 cells 48 hrs after 
transfection. Each bar is mean ± standard deviation of triplicates.  
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 shown). Initial uptake rates for digoxin were determined and expressed in percent of 
the uptake obtained for wild-type Oatp1a4-expressing oocytes. Compared to Oatp1a4, 
only chimera 1 was able to mediate significant transport of digoxin, whereas chimera 
2 and Oatp1a1 did not transport digoxin (Figure 4-1A). Because this construct 
contained the C-terminal TM 8-12 of Oatp1a4 and the reciprocal chimera 2 did not 
mediate digoxin transport, we concluded that TM 8-12 are important for Oatp1a4-
mediated digoxin transport. To further investigate how much of this C-terminal 
portion of Oatp1a4 is needed for digoxin transport, an additional chimera was 
produced (chimera 3) and functionally tested in oocytes. The intracellular loop 4 has 
the same amino acid sequence in both Oatps. Therefore chimera 3 differs from 
chimera 1 only with respect to TM8 and extracellular loop (EL) 4. Because chimera 3 
did not transport digoxin (Figure 4-1A), we concluded that the amino acid residues in 
TM8 and EL4, and/or their interactions with the rest of the C-terminal half of 
Oatp1a4 are important for Oatp1a4 mediated digoxin transport.  
 
          In order to test whether these results were expression system dependent, we 
transiently expressed these His-tagged chimeric proteins along with wild-type 
Oatp1a4 and Oatp1a1 in HEK293 cells and quantified digoxin transport uptake. 
Figure 4-1B shows the transport activities of the three chimeric transporters observed 
in HEK293 cells.  Chimera 1 was able to transport digoxin but chimeras 2 and 3 were 
not. Thus, in both expression systems, amino acid residues in TM8 and EL4 or their 
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 interactions with the rest of the C-terminal half of Oatp1a4 are important for digoxin 
transport. 
 
2.2    Surface expression of chimeras between Oatp1a1 and Oatp1a4 in HEK293 
cells. 
          In order to test whether the reduced digoxin transport activity of chimeras 2 and 
3 was due to reduced surface expression levels, we examined surface expression of 
Oatp1a4, Oatp1a1, and the three chimeric proteins in HEK 293 cells using surface 
biotinylation experiments. As shown in Figure 4-2A, all three chimeric transporters 
were detected on the cell surface. However, the surface expression level of chimera 3 
was about 50% of chimeras 1 and 2.  Thus, the amino acids that differ between 
chimera 1 and 3 seem to be important for proper surface expression and transport. 
Two major bands, one at about 60 kDa and the other at about 85 kDa, were detected 
for chimera 1 and Oatp1a1. For Oatp1a4 and chimera 2 only one band close to the 
higher molecular weight, and for chimera 3  only one major band close to the lower 
molecular weight were seen (Figure 4-2A). This surface expression pattern was 
consistent throughout various experiments.  Na+/K+ ATPase, a membrane protein 
naturally expressed in HEK293 cells was used as a loading control (Figure 4-2B).  
 
          After PNGase F treatment of purified surface proteins, only one major band 
with a decreased apparent molecular weight was detected for all constructs (Figure 4-
2C), indicating that the multiple bands of chimera 1, chimera 3 and Oatp1a1 are due 
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 to different N-glycosylation states. It has been shown in HeLa cells that of the four N-
glycosylation sites,  the three at positions N124, N135 and N492 are used in Oatp1a1 
(Wang et al., 2008). The first two sites N124 and N135 are located in the N-terminal 
half of Oatp1a1, and the third one (N493) in the C-terminal half. Therefore, for 
Oatp1a1 and chimera 1, the lower band probably corresponds to a partially 
glycosylated form, and the upper band was the fully glycosylated form. Chimera 3, in 
which TM8 and EL4 were replaced with Oatp1a1 sequences, is probably only 
partially glycosylated. This could be due to a conformation change of the chimeric 
protein compared to the wild-type protein that decreases the accessibility of the N-
glycosylation sites to the glycosylation enzymes and/or substrates. For Oatp1a4, 
although not confirmed experimentally, it has been predicted that in the N-terminal 
half, in addition to N123 and N134, which are equivalent to N124 and N135 in 
Oatp1a1, there is another N-glycosylation site N140. This additional site in Oatp1a4 
might increase the chance for full N-glycosylation, because all three sites (N124, 
N135 and N140) are very close to each other.  Therefore, only one major glycosylated 
band was observed for Oatp1a4 and Chimera 2, which shares the N-terminal half of 
wild-type Oatp1a4.  
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Figure 4-2: Surface expression of chimeric Oatp1a1 and Oatp1a4 constructs in 
HEK293 cells.  
(A) Representative Western blots of surface-biotinylated proteins detected with a 
monoclonal anti-tetra-His antibody. HEK293 cells transfected with empty vector 
pExpress-1 were used as negative controls. (B) The same blot was also probed with 
an antibody against the plasma membrane marker Na+/K+-ATPase α subunit as a 
loading control. (C) Surface-biotinylated proteins were incubated with N-Glycosidase 
F (PNGase F) for 1 hr at 37ºC for deglycosylation and detected with anti-tetra-His 
antibody. 
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 2.3   Taurocholate, estradiol-17β-glucuronide, DPDPE and BSP transport by 
chimeras between Oatp1a1 and Oatp1a4 in HEK293 cells.  
          Given the substrate multi-specificity of Oatps, we extended the studies beyond 
digoxin transport and tested the four general Oatp substrates taurocholate, estradiol-
17β-glucuronide, DPDPE, and BSP.   In HEK293 cells expressing Oatp1a1 and 
Oatp1a4, taurocholate and estradiol-17β-glucuronide are good substrates for both 
Oatp1s (Figure 4-3A and B). Similar to digoxin, chimera 1 was able to transport 
taurocholate (Figure 4-3A) and estradiol-17β-glucuronide (Figure 4-3B) better than 
Chimera 2 and Chimera 3, suggesting that these three substrates may be handled 
similarly. However, although DPDPE was transported well in both Oatp1a4 and 
Oatp1a1 expressing cells as compared to the vector control cells, chimera 1 and 
chimera 3 did not mediate any transport, and the uptake mediated by chimera 2 was 
only 10% of Oatp1a4 and 14% of Oatp1a1 (Figure 4-3C). It has been shown 
previously in the X. laevis system that BSP is a substrate for Oatp1a1 but not for 
Oatp1a4 (Reichel et al., 1999). However, when we expressed Oatp1a4 in HEK293 
cells we could measure BSP transport that was about twice the value obtained with 
the empty vector (Figure 4-3D). Oatp1a1-mediated BSP transport was only 6 times 
the value of the empty vector control (Figure 4-3D). Therefore, we conclude that BSP 
is a substrate of Oatp1a4 when expressed in HEK293 cells. These results can be 
explained by the fact that the experiments in oocytes were performed at a BSP 
concentration of 4µM as compared to 0.5µM in the HEK293 cell system. 
Furthermore, the signal obtained for Oatp1a1 in oocytes was 25 times above  
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 Figure 4-3: Transport of taurocholate (A), estradiol-17β-glucuronide (B), 
DPDPE (C) and BSP (D) mediated by wild-type and chimeric Oatp1a1 and 
Oatp1a4 constructs in HEK293 cells.  
 
Uptake of 20µM [3H]-taurocholate (A), 0.5 µM estradiol-17β-glucuronide (B), 1 µM 
DPDPE (C) and 0.5 µM BSP (D) was quantified at 37ºC for 30 sec (initial linear rate 
condition) with HEK293 cells expressing empty vector pExpress-1 (pE-1), Oatp1a4, 
Oatp1a1 or the three chimeric transporters 48 hrs after transfection. Each bar 
represents the mean ± standard deviation of triplicate determinations.  
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 background whereas in HEK293 cells it was only 6 times above empty vector cells. 
Thus, a twofold signal with overlapping standard deviations in oocytes compared to 
the 25-fold signal for Oatp1a1 probably led the authors to conclude that Oatp1a4 does 
not transport BSP.  Both Chimera 1 and Chimera 2 were able to transport BSP 
whereas chimera 3 did not transport BSP (Figure 4-3D).  
 
          The same chimeric protein transported different substrates differently. Chimera 
1 was able to transport taurocholate, estradiol-17β-glucuronide, and BSP, but not 
DPDPE, which indicates that Oatp1a4 is similar to other OATP/Oatps (Tamai et al., 
2001; Noe et al., 2007) in that it has multiple binding sites for various substrates. 
Unlike for most of the Oatp1a4 substrates tested, the presence of only the C-terminal 
half of Oatp1a4 was not adequate for  DPDPE transport, neither was the presence of 
only the N-terminal half. It is therefore likely that the transport pathway for DPDPE 
requires interactions between the two halves, whereas for other Oatp1a4 substrates, 
critical interactions are primarily in the C-terminal region. Alternatively, interactions 
with amino acids of the Oatp1a1 part may result in a functional protein for substrates 
other than DPDPE. The concept of multiple binding sites is also consistent with the 
kinetic and inhibition studies reported earlier (Sugiyama et al., 2002). Those data 
suggested that estradiol-17-β-glucuronide could interact at a different recognition site 
than taurocholate and digoxin. In the current study, the C-terminal half of Oatp1a4 
seems to be important for the transport of digoxin, estradiol-17-β-glucuronide, and 
taurocholate.  
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          Whereas chimera 1, which has the N-terminal half of Oatp1a1 and the C-
terminal half of Oatp1a4, was able to transport the two common substrates 
taurocholate and estradiol-17β-glucuronide, its reciprocal chimera 2, which has the C-
terminal half of Oatp1a1, did not transport the two substrates. However, both chimera 
1 and chimera 2 were able to transport BSP. These results suggest that BSP may be 
transported using a similar pathway in both Oatp1a1 and Oatp1a4, whereas for other 
common substrates, the translocation pathway requires different amino acids that 
cannot be complemented by the other Oatp.  
 
          Finally, chimera 3 was not able to transport any of the 5 substrates tested. 
However, chimera 1 with TM8 and EL4 added to the rest of the C-terminal part of 
Oatp1a4, was able to transport all substrates except for DPDPE. Therefore, it is 
possible that TM8 and EL4 are required for maintaining the correct conformation of 
the binding/translocation pathway. This result is consistent with a recent study that 
reported that when replacing TM8 of OATP1B1 with OATP1B3, transport rates for 
estadiol-17β-glucuronide and estrone-3-sulfate were markedly decreased (Miyagawa 
et al., 2009). Because a reduced surface expression with only partial glycosylation of 
chimera 3 was observed on western blots, the lack of full glycosylation and (as a 
consequence the lack of) surface expression could also contribute to the decreased 
transport rates. However, to understand whether the N-glycosylation will affect 
transport function, more studies are needed. 
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 Given that digoxin, taurocholate, and estradiol-17β-glucuronide were handled 
in a very similar way, we decided to continue with digoxin as a functional tool and 
compare the amino acid sequence of the region that differs between chimera 1 and 3. 
  
2.4    Comparison of amino acids 324 to 387 of Oatp1a4 with Oatp1a1 and 
Oatp1a5. 
          In order to identify the role of single amino acids in Oatp1a4-mediated digoxin 
transport, the 64 amino acids of Oatp1a4 that differ between chimera 1 and chimera 3 
were aligned to the corresponding amino acids of Oatp1a1 and Oatp1a5 (Figure 4-
4A). The multiple alignments of both Oatp1a4 and Oatp1a5 with Oatp1a1 revealed 
that there are only 6 amino acid residues that differ in the digoxin transporters, 
Oatp1a4 and Oatp1a5, compared with Oatp1a1, the non-digoxin transporter (Figure 
4-4A, boxed). F328 of Oatp1a4 corresponds to a valine in Oatp1a1, A330 to a 
glycine, S334 to a positively charged lysine, V353 to an alanine, V354 to an 
isoleucine and M361 to a serine. As shown in Figure 4-4B, these six amino acid 
residues are all located close to the extracellular border of TM 7 and 8 or within TM7 
and TM8 of the predicted membrane topology of Oatp1a4.  
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Figure 4-4: Partial amino acid sequence alignment and location of mutations in 
rat Oatp1a4 around TM 7 and 8.  
(A) The 64 amino acids that were replaced from chimera 1 to chimera 3 (Figure 4-1) 
are shown and the amino acid residues that differ between Oatp1a1 and both Oatp1a4 
and Oatp1a5 are boxed and labeled. (B) Location of the six amino acid residues is 
shown in the predicted membrane topology of Oatp1a4. 
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 2.5    Site-directed mutagenesis of Oatp1a4 and functional characterization of 
the mutants in X. laevis oocytes. 
           Because any of the identified amino acid residues could be important for 
Oatp1a4-mediated digoxin transport, each of the six residues was changed 
individually in His-tagged Oatp1a4 to its counterpart amino acid residue in Oatp1a1. 
Because X. laevis oocyte system provides a very sensitive signal to background ratio, 
the resulting mutant Oatp1a4 proteins were first expressed in oocytes and digoxin 
transport rate was compared to wild-type Oatp1a4. As shown in Figure 4-5, digoxin 
transport rates of mutants A330G, V353A, and V354I were comparable to wild-type 
Oatp1a4. In contrast, digoxin transport rates obtained with mutant F328V was about 
60% of wild-type Oatp1a4 with high variations and S334K as well as M361S were 
less than 40%. These results suggest that in the X. laevis oocyte system, the two 
individual Oatp1a4 mutants S334 and M361 are important for Oatp1a4 mediated 
digoxin transport and F328 might be important for Oatp1a4 mediated digoxin 
transport. 
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Digoxin 
 
Figure 4-5: Digoxin transport by wild-type and mutated Oatp1a4 in oocytes.  
X. laevis oocytes were injected with 50 nl water or 5 ng cRNA of the respective 
constructs and after three days in culture transport of 0.5 μM [3H]-digoxin was 
determined at 25 °C with 9-12 oocytes per condition. Values represent the means ± 
S.E. of three independent experiments and are given as percent of the initial transport 
rates obtained for wild-type Oatp1a4-injected oocytes. * p < 0.05 compared to 
Oatp1a4. 
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 2.6    Expression and functional analysis of Oatp1a4 mutants F328V, S334K, and 
M361S in HEK293 cells 
          In order to confirm the results in oocytes and measure the surface expression of 
the mutants, we transiently expressed Oatp1a4 and mutants F328V, S334K, and 
M361S in HEK293 cells. Membrane proteins were purified using surface 
biotinylation, and western blot analysis was performed using the anti-His antibody. 
As demonstrated in Figure 4-6A, all Oatp1a4 constructs could be detected on the cell 
surface at different expression levels. Compared to wild-type Oatp1a4, F328V had 
the same surface expression level whereas the cell surface expression level of S334K 
and M361S was decreased. Na+/K+ ATPase was used as a loading control (Figure 4-
6B). Quantification of several blots from different experiments have shown that on 
average, the surface expression level of S334K was about 50% and the surface 
expression level of M361S was less than 20% of wild-type Oatp1a4.  The reason for 
the decreased surface expression level of these two mutants could be that either the 
original amino acids are critical for maintaining a stable structure, or the introduction 
of a new amino acid destabilizes the structure of the transporter.  
 
          Digoxin transport was also quantified in HEK293 cells transiently transfected 
with Oatp1a4 and the three mutants (Figure 4-6C). Digoxin transport mediated by 
F328V was the same as that by wild-type Oatp1a4, whereas S334K and M361S 
mediated digoxin transport was less than 20% of wild-type.   The results for S334K  
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 Figure 4-6: Surface expression and digoxin transport of wild-type and mutated 
Oatp1a4 constructs in HEK293 cells.  
(A) Representative Western blots of surface-biotinylated proteins detected with a 
polyclonal anti-6-His antibody. HEK293 cells transfected with empty vector 
pExpress-1 were used as negative controls. (B) The same blot was also probed with 
an antibody against the plasma membrane marker Na+/K+-ATPase α subunit as a 
loading control. (C) Uptake of 0.5µM [3H]-digoxin was quantified at 37ºC for 30 sec 
(initial linear rate condition) with HEK293 cells expressing empty vector pExpress-1, 
Oatp1a4 or a mutated transporter. The net uptakes were obtained by subtracting the 
uptake of empty vector transfected cells from the uptake of Oatp1a4 or mutant 
transfected cells. The results were normalized for total protein expression and 
presented as percentage of wild-type Oatp1a4. Each bar represents the mean ± 
standard deviation of three independent experiments with triplicates. (D) Uptake of 
increasing concentrations of digoxin was quantified under initial linear rate conditions 
(30 sec) at 37ºC with HEK293 cells expressing empty vector, wild-type Oatp1a4 or 
F328V. After subtracting the values obtained with the empty vector transfected 
HEK293 cells and corrected for total protein concentration, net uptake was fitted to 
the Michaelis-Menten equation. Each point represents the mean ± standard deviation 
of triplicate determinations.  
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 and M361S were consistent with the observations in the X. laevis oocyte system. 
Because M361S was minimally expressed on the cell surface, the reduced transport 
rate is probably mainly due to the lack of surface expression. For S334K however, 
where the surface expression level on average is about half of wild-type Oatp1a4 but 
the observed transport rate is less than 20% of wild-type Oatp1a4, it means that this 
mutation probably affects both surface expression and transport activity. Although in 
the X. laevis oocyte system, F328V had a slightly decreased transport rate, this 
mutation did not affect the digoxin transport rate in HEK293 cells under initial linear 
rate conditions. The concentration dependent uptake is shown in Figure 4-6D and 
further demonstrates that at low concentrations, F328V had the same transport 
kinetics as wild-type Oatp1a4. Therefore, in HEK293 cells, the F328V mutation does 
not affect either surface expression or transport of digoxin, whereas the S334K 
mutation may affect both surface expression and transport rate. M361S mainly 
affected surface expression.   
 
2.7  Taurocholate, estradiol-17β-glucuronide, DPDPE, and BSP transport by  
wild-type and mutated Oatp1a4 in HEK293 cells.  
           The transport rates of the four substrates mediated by the three mutants F328V, 
S334K, and M361S were also quantified in HEK293 cells. As shown in Figure 4-7, 
uptake of taurocholate, estradiol-17β-glucuronide, and DPDPE mediated by F328V  
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Figure 4-7: Transport of taurocholate, estradiol-17β-glucuronide, DPDPE, and 
BSP mediated by wild-type and mutated Oatp1a4 in HEK293 cells.  
Uptake of 20µM [3H]-taurocholate (black), 0.5 µM estradiol-17β-glucuronide (gray), 
1 µM DPDPE (white) and 0.5 µM BSP (hatched) was quantified at 37ºC for 30 sec 
(initial linear rate condition) with HEK293 cells expressing empty vector pExpress-1, 
Oatp1a4, or the mutated transporter. The net uptakes were obtained by subtracting the 
uptake of empty vector transfected cells from the uptake of Oatp1a4 or mutant 
transfected cells. The results were normalized for total protein expression and 
presented as percentage of wild-type Oatp1a4.   Each bar is mean ± standard 
deviation of three independent experiments with triplicate determinations. 
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 was decreased to 40% - 50% of the wild-type Oatp1a4 whereas BSP uptake, similar 
to digoxin, remained the same. For S334K, uptake of taurocholate and estradiol-17β-
glucuronide was less than 20% of the wild-type, whereas DPDPE and BSP uptake 
was about 50% - 60% of the wild-type. The transport rates of all four common 
substrates mediated by M361S were less than 20% of the wild-type Oatp1a4.  
 
          The mutation F328V had different effects on different substrates. It did not 
affect transport rates of digoxin or BSP, but the transport rates of taurocholate, 
estradiol-17β-glucuronide and DPDPE were decreased. This can be explained in 
different ways. 1) Valine interacts with some of the substrates and thus slows their 
transport process; or 2) The mutation caused a general conformation change that only 
affected some of the substrates, because the affected substrates have different binding 
sites/translocation pathways. The effect of mutation S334K was also substrate 
dependent. For DPDPE and BSP, the decreased transport activity (50% - 60% of 
wild-type Oatp1a4) was consistent with the extent of decreased surface expression 
(about 50% of wild-type Oatp1a4). For taurocholate and estradiol-17β-glucuronide, 
similarly as for digoxin, the transport activity was almost abolished. Therefore, in 
addition to surface expression, S334K also affected the transport rate of digoxin, 
taurocholate, and estradiol-17β-glucuronide, but not of DPDPE or BSP. And finally, 
consistent with the very low surface expression level of M361S, none of the 
substrates were transported by this mutant.  
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           Our data do not address whether these amino acid residues are directly involved 
in substrate recognition or translocation. However, the bulkiness of the side chains, 
e.g. in the amino acid residues methionine at position 361 (M361) and phenylalanine 
at position 328 (F328) could be important to maintain the protein in a conformation 
optimal for stability and substrate transport. Its loss would then lead to altered 
transport functions as suggested in an earlier chimeric analysis of the glucose 
transporters (Hxt1 and Hxt2) in yeast (Kasahara et al., 2004). A previous study 
aiming to generatr a theoretical structural model representative of OATP/SLCO 
superfamily members (Meier-Abt et al., 2005), provides some insights concerning the 
location of the individual amino acids examined in the present study. The three sites 
(F328, S334 and M361) were all facing the putative binding pore in the theoretical 
models, and may thus be expected to affect the transport pathway directly. However, 
kinetic analysis for the mutants with measurable transport is needed to determine 
whether these amino acids affect the apparent affinity (Km) constant and/or the 
maximal transport rate (Vmax). 
 
III.    OVERALL CONCLUSION 
          Because OATP/Oatps are multi-specific transporters, identifying the domains 
that are important for Oatp1a4 mediated transport using different substrates will 
provide valuable information to further understand how the transporter members in 
this superfamily translocate these structurally unrelated compounds across the plasma 
membrane. Using chimeric and mutant Oatp1a4 protein, we evaluated the Oatp1a4-
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 mediated transport of five different substrates. Our study indicates that (1) the C-
terminal half of Oatp1a4 is important for the transport of four substrates including 
digoxin, taurocholate, estradiol-17β-glucuronide, and BSP; (2) EL4 and TM8 may be 
important in constructing the binding/ translocation interface of the transporter with 
substrates, and (3) Oatp1a4 might have different binding/translocation pathways for 
different substrates. These data, combined with previous findings by other groups 
provide further understanding of OATP/Oatp mediated transport of a broad spectrum 
of substrates. However, to characterize and explain the underlying molecular 
mechanisms, additional experiments including crystallization of the substrate-
transporter complexes, in combination with functional characterization of point 
mutations of critical residues, are required. 
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 CHAPTER 5 
 
CHARATERIZATION OF RAT RENAL ORGANIC ANION 
TRANSPORTERS IN TRANSPORTING PERFLUORINATED 
CARBOXYLATES WITH DIFFERENT CHAIN LENGTHS 
 
 
SPECIFIC AIM AND HYPOTHESIS 
          Chapter 5 will address specific aim 3 and will evaluate the hypothesis that 
different rat renal organic anion transporters of the Oat and Oatp families 
selectively transport PFCAs depending on the chain lengths. The purpose of this 
study is to determine the size selectivity of Oats and Oatp1a1 in PFCA transport. 
Furthermore, with the previous in vivo observation of PFCA disposition patterns and 
the gender specific expression of Oats and Oatps in kidney, the findings of this study 
also highlight the important role of transporters in renal excretion of PFCAs. The 
roles of Oats and Oatps in the gender-dependent renal elimination pattern of PFCAs 
with different chain length are thoroughly discussed in this chapter. Additional 
discussion in Chapter 6 will address the size selectivity of the “binding pocket” in 
OATs/Oats and OATP/Oatps. 
        
I. INTRODUCTION 
           Perfluorinated carboxylates (PFCAs) are fatty acid analogues with fully 
fluorinated carbon back-bones. A representative structure of perfluorooctanoate (C8) 
is shown in Figure 5-1. The chain lengths for most commercially available PFCAs 
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 range from 2 to 18 carbons (C2 – C18).  PFCAs are generally stable to metabolic and 
environmental degradation and are found at low concentrations in samples of 
environmental and biological media. Although trifluoroacetate (C2) can occur 
naturally, C2 and most other perfluorinated carboxylates are present in the 
environment as a result of various commercial uses. PFCAs can also arise from 
degradation of other polyfluorinated chemicals (D'Eon et al., 2006; Fasano et al., 
2006; Wallington et al., 2006; D'Eon and Mabury, 2007) and are more resistant to 
natural degradation than hydrocarbon carboxylates, due to the presence of multiple 
carbon-fluorine bonds (Lemal, 2004). Both PFOA (C8) and PFDA (C10) have been 
shown to be potent PPARα activators and their toxicological effects observed in 
rodents and the potential concerns for humans have been well summarized in several 
reviews (Vanden Heuvel, 1996; Kudo and Kawashima, 2003; Kennedy et al., 2004). 
Renal clearance of PFCAs is influenced by chain length, isomeric structure (branched 
vs. linear), species, and, in some cases, gender within a species (Vanden Heuvel et al., 
1991; Kudo and Kawashima, 2003; Butenhoff et al., 2004; Kennedy et al., 2004; 
Chang et al., 2008; Chengelis et al., 2009; De Silva et al., 2009).  
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Figure 5-1. Structure of PFOA (C8) 
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            As an example of the differences that can occur in elimination kinetics, in 
humans, the geometric mean half-life of perfluorooctanoate (C8) serum elimination in 
a group of retired production workers was 3.5 years (95% CI, 3.0–4.1) with no 
obvious gender differences (Olsen et al., 2007). This compares to cynomolgus 
monkeys, for which the serum C8 elimination half-life is estimated to be several 
weeks (Butenhoff et al., 2004). However, in male rats, the serum elimination half-life 
of C8 is several days, as compared to hours for female rats (Kudo and Kawashima, 
2003; Kennedy et al., 2004). In contrast, the estimated elimination half-life of 
perfluorobutyrate (C4) is approximately 3 to 4 days for humans and 1.5 days for 
cynomolgus monkeys (Chang et al., 2008), again with no obvious gender differences 
in either species. Unpublished preliminary data have shown that in male and female 
rats exposed to C4, serum elimination half-lives are approximately 6 to 9 and 2 to 4 
hrs, respectively.  
 
            Because PFCAs are not known to undergo metabolic conversion (Lau et al., 
2007), differences in elimination kinetics are hypothesized to be due to differences in 
renal elimination as a result of differences in renal transport processes (Kudo et al., 
2001; Katakura et al., 2007; Nakagawa et al., 2008; Tan et al., 2008; Nakagawa et al., 
2009). Since the rat is one of the most commonly used species in toxicological 
studies, it is important to identify the transport systems involved in the renal 
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 elimination of PFCAs to further understand potential toxicological effects and 
extrapolate the findings to humans. 
 
            The renal organic anion transport system is a very important system in 
facilitating the daily elimination of toxic compounds and reabsorption of useful 
anionic metabolites. There are several major transporter families that are involved in 
the transport of organic anions in kidneys: the organic anion transporter (Oat) family, 
the organic anion transporting polypeptide (Oatp) superfamily, the multidrug 
resistance protein (Mdr), and the multidrug resistance-associated protein (Mrp) 
superfamilies (Sekine et al., 2006). In the rat proximal tubule, these transporters are 
expressed in a polarized manner with specific transporters being differentially 
localized in the basolateral membrane and apical membrane. Transporters localized at 
the basolateral membrane include Oat1, Oat3 (Tojo et al., 1999; Kojima et al., 2002), 
and Oatp4c1 (Mikkaichi et al., 2004). Transporters localized at the brush-border 
membrane include Oat2 (Kojima et al., 2002), Urat1 (Rizwan and Burckhardt, 2007), 
Oat5 (Anzai et al., 2005), Oatp1a1 (Bergwerk et al., 1996), Mdr1a/b (Sekine et al., 
2006), Mrp2 (Schaub et al., 1997), and Mrp4 (van Aubel et al., 2002). Gender-
dependent expression patterns occur with several of these transporters, including 
Oat1, Oat2, Oat3 (Buist et al., 2002; Cerrutti et al., 2002; Ljubojevic et al., 2004; 
Ljubojevic et al., 2007), Oatp1a1 (Lu et al., 1996; Kato et al., 2002), and Mdr1b (Lu 
and Klaassen, 2008).  Among these transporters, Oat1, Oat3, and Oatp1a1 have been 
 120
 shown to transport C8 (Katakura et al., 2007; Nakagawa et al., 2008; Yang et al., 
2009). 
 
        Given the in vivo evidence that there are gender dependent renal elimination 
patterns for PFCAs with chain lengths from 7 to 10 (Kudo et al., 2001), we 
hypothesized that PFCAs with different chain lengths are substrates of different 
organic anion transporters, and that the location and gender specific expression of 
those transporters contribute to the renal elimination pattern.  In this study, we 
investigated the roles of the five rat renal organic anion transporters (Oat1, Oat2, 
Oat3, Urat1, and Oatp1a1) in transporting PFCAs of various chain lengths (C2 – 
C18).  Initial experiments studied the potential of C2 – C18 PFCAs to inhibit known 
substrates of the transporters.  Based on those results, PFCA uptake and transport 
kinetic studies were performed, focusing on four PFCAs (C7 – C10). 
 
II.    RESULTS  
2.1      Oat1- and Oat3-mediated transport of PFCAs.  
          In HEK293 cells transiently transfected with rat Oat1, transport of the model 
substrate [3H]-p-aminohippurate (PAH) was strongly inhibited by 10μM of C7, 
followed by C6 and C8 (Figure 5-2A), whereas other homologs did not show 
significant inhibition at this concentration.  In HEK293 cells expressing Oat3, transport 
of the model substrate [3H]-estrone-3-sulfate (E-3-S) was strongly inhibited by 10 μM  
C8  
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Figure 5-2.  Inhibitory effect of PFCAs on Oat1 and Oat3 mediated transport.   
Oat1-mediated 88nM [3H]-p-aminohippurate (PAH) (A) or Oat3-mediated 7nM [3H]-
estrone-3-sulfate (E-3-S), (B) uptake was quantified at 37 °C for 1 min in the absence 
or presence of 10µM PFCAs with chain lengths from two (C2) to eighteen (C18) 
carbon atoms in Oat expressing or empty vector pExpress-1 (pE) transfected HEK293 
cells. The results were corrected for total protein concentration in each well. Each bar 
is the mean ± standard deviation of triplicates. *, p<0.05 compared to Oat-mediated 
uptake in the absence of PFCAs. 
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 and C9, followed by C7 and C10 (Figure 5-2B), whereas other homologs did not show 
significant inhibition at this concentration.  In both cases, uptake of model substrates 
into empty vector transfected HEK293 cells was not affected by the presence of PFCAs 
(data not shown).   
 
          Based on the results of inhibition studies, Oat1- and Oat3-mediated uptake of C7, 
C8, C9, and C10 into Oat1- and Oat3-expressing HEK293 cells was quantified using 
LC-MS/MS.  These results were obtained at a single time point (1 min) and at a single 
concentration (10 μM).  As shown in Figure 5-3A, uptake by Oat1 was highest for C7 
and C8, followed by C9, whereas uptake of C10 was the lowest.  Uptake into Oat3 
expressing cells was highest for C9, followed by C8, C7, and C10 (Figure 5-3B).   
 
          In order to further understand how well these compounds are transported by Oat1 
and Oat3, as well as whether these two transporters are important in the renal 
elimination of C8 and C9, Oat1 mediated C7 and C8 as well as Oat3 mediated C8 and 
C9 transport was further characterized.  First, time-dependent uptake at low and high 
substrate concentrations was determined.  At a low concentration (10µM), uptake 
mediated by Oat1 appeared linear up to 1.5 min for both C7 and C8 (Figure 5-4A and 
B), whereas uptake of C8 and C9 mediated by Oat3 appeared linear up to 2 min (Figure 
5-4C and D).  At a high concentration (300 µM), uptake of C7 and C8 by Oat1 as well 
as C8 and C9 by Oat3 appeared linear up to 1 min (data not shown).  Therefore, for 
kinetic analysis, all concentration-dependent uptakes were quantified at the 1 min time  
 123
  
 
Figure 5-3.  Oat1 (A) and Oat3 (B) mediated uptake of C7, C8, C9 and C10.  
Uptake of 10µM C7 to C10 was quantified at 37 °C for 1 min with empty vector 
transfected (white) or Oat expressing (grey) HEK293 cells. Black bars indicate net 
uptake after subtracting the values of empty vector transfected cells from Oat-
expressing cells. Uptake values were corrected for total protein concentration in each 
well. Each bar represents the mean ± standard deviation of triplicates. *, p<0.05 
compared to vector control.  
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Figure 5-4.  Oat1 (A, B) and Oat3 (C, D) mediated time dependent transport of 
PFCAs. 
 Uptake of 10µM PFCAs was quantified at 37 °C at the indicated time points with 
empty vector transfected (♦) or Oat expressing (■) HEK293 cells. Net uptake values 
(▲) were obtained by subtracting the uptake values of empty vector transfected cells 
from Oat expressing cells. Each point represents the mean ± standard deviation of 
triplicates. 
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 point.  Concentration-dependent transport of PFCAs by Oat1 and Oat3 is shown in 
Figure 5-5.  Kinetic parameters were calculated based on the Michaelis–Menten 
equation, and the Km and Vmax values are summarized in Table 5-1. The apparent Km 
values for Oat1-mediated transport of C7 (50.5 μM) and C8 (43.2 μM) were very 
similar. The Km value for Oat3-mediated C8 uptake (65.7 μM) was lower than for C9 
(175 μM), but the Vmax value of C9 uptake (8.7 nmol/mg x min-1) was higher than that 
of C8 (3.8 nmol/mg x min-1).  Therefore, although there were some differences in the 
affinities, both transporters had similar efficiencies (Vmax/Km) for both substrates that 
were quantified. 
 
2.2       Oatp1a1-mediated transport of PFCAs.  
           In the CHO cell line stably expressing rat Oatp1a1, transport of the model 
substrate [3H]-estradiol-17β-glucuronide (E-17β-G) was inhibited by 10μM of C9, C10, 
and C11 by 20 to 40% (Figure 5-6A), whereas uptake of model substrate into CHO-
wild-type cells was not affected by the presence of PFCAs (data not shown).  Next, 
uptake of 10µM C7, C8, C9, and C10 into CHO-Oatp1a1 expressing cells was 
compared. Uptake of C9 and C10 was highest followed by C8, with minimal uptake of 
C7 (Figure 5-6B). Therefore, saturation kinetics for Oatp1a1-mediated transport were 
determined for C8, C9, and C10.  Figure 5-7 A to C shows that transport of C8, C9, and 
C10 mediated by Oatp1a1 appeared linear up to 2 min at the 10µM concentration, 
whereas at the high concentration (300 µM), uptake was only linear up to 1 min (data  
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Figure 5-5. Kinetics of Oat1 (A, B) and Oat3 (C, D) mediated transport of PFCAs.   
Uptake of increasing concentrations of PFCAs was quantified under initial linear rate 
conditions at 37ºC with Oat-expressing and empty vector transfected HEK293 cells. 
After subtracting the values obtained with the empty vector transfected HEK293, and 
corrected for total protein concentration, net Oat-mediated uptake was fitted to the 
Michaelis-Menten equation to obtain Km and Vmax values. Each point represents the 
mean ± standard error from a pool of two independent experiments with triplicates.  
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 Table 5-1: Kinetic parameters of Oat1 and Oat3 mediated PFCA transport 
 
Transporter PFCA 
Km
(µM) 
Vmax 
(nmol/mg protein x min-1)
Vmax/Km 
(mL/mg protein x min-1)
Oat1 C7 50.5 ± 13.9 2.2 ± 0.2 0.04 ± 0.01 
 C8 43.2 ± 15.5 2.6 ± 0.3 0.06 ± 0.02 
Oat3 C8 65.7 ± 12.1 3.8 ± 0.5 0.06 ± 0.01 
 C9 174.5 ± 32.4 8.7 ± 0.8 0.05 ± 0.01 
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 Figure 5-6. Inhibition of Oatp1a1 mediated transport and uptake of selected 
PFCAs by Oatp1a1. 
(A) Uptake of 10nM estradiol-17β-glucuronide (E-17β-G) was quantified at 37 °C for 1 
min with Oatp1a1 expressing or wild-type CHO cells (WT) in the absence or presence 
of 10µM PFCAs with chain lengths from two (C2) to eighteen (C18) carbon atoms. 
Each bar represents the mean ± standard deviation of triplicate samples *, p<0.05 
compared to Oatp1a1-mediated uptake in the absence of PFCAs. (B) Uptake of 10µM 
C7 to C10 was quantified at 37 °C for 1 min with wild-type (open bars) or Oatp1a1 
expressing (grey bars) CHO cells. Black bars indicate net uptake after subtracting the 
uptake values of wild-type from Oatp1a1 expressing cells. Each bar represents the 
mean ± standard deviation of triplicates. *, p<0.05 compared to vector control.  
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 Figure 5-7. Oatp1a1 mediated time and concentration dependent transport of 
PFCAs.  
Uptake of 10µM  C8 (A), C9 (B) and C10 (C) was quantified at 37 °C at the indicated 
time points with wild-type (♦) or Oap1a1 expressing (■) CHO cells. Net uptake values 
(▲) were obtained by subtracting the uptake values of wild-type from Oatp1a1 
expressing cells. Each point represents the mean ± standard deviation of triplicates. 
Uptake of increasing concentrations of C8 (D), C9 (E) and C10 (F) was quantified 
under initial linear rate conditions at 37ºC. Net Oatp1a1-mediated uptake was fit to the 
Michaelis-Menten equation to obtain Km and Vmax values. Each point represents the 
mean ± standard error from a pool of two independent experiments with triplicates.  
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 not shown).  As a result, all concentration-dependent uptakes for Oatp1a1 were 
quantified at 1 min. Figure 5-7 D to F show saturation kinetics for the three substrates, 
and the calculated parameters are summarized in Table 5-2. The Km value of 126.4 µM 
for Oatp1a1-mediated C8 transport was about six-fold higher than the value for C9 
(20.5 µM) and four fold higher than the value for C10 (28.5 µM).  Taking the Vmax 
values into account, the overall transport efficiency for C8 uptake was about one half 
that for C9 and C10 transport. 
 
2.3       Oat2- and Urat1-mediated PFCA transport.  
          In Flp-In CHO cells stably transfected with Oat2, transport of the model substrate 
[3H]-PAH (Figure 5-8A) was inhibited 40% to 60% by most of the PFCAs at 10μM. 
However, the chain-length-dependent inhibition pattern observed for Oat1-, Oat3-, and 
Oatp1a1-mediated transport was not seen for Oat2.  Very similar results were obtained 
when the concentrations of the PFCAs were increased to 100µM (data not shown).  In 
HEK293 cells transiently transfected with rat Urat1, [14C]-uric acid transport was not 
inhibited strongly by any of the tested PFCAs at 10 μM (Figure 5-8B). After increasing 
the inhibitor concentration to 100 μM, C8 showed about 30% inhibition, whereas there 
was no difference for C7, C9, and C10 (data not shown). Direct uptake of 100µM C7, 
C8, C9, and C10 was determined in Oat2-expressing CHO cells, and compared to wild-
type CHO cells.  No significant net Oat2-mediated uptake could be seen (Figure 5-9A). 
Similarly, direct uptake of 100 µM C7, C9, and C10 into Urat1- expressing HEK293 
cells (Figure 5-9B) was very similar to empty vector transfected HEK293 cells, 
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 Table 5-2: Kinetic parameters of Oatp1a1 mediated PFCA transport  
 
Transporter PFCA 
Km
(µM) 
Vmax 
(nmol/mg protein x min-1)
Vmax/Km 
(mL/mg protein x min-1)
Oatp1a1 C8 126.4 ± 23.9 9.3 ± 1.4 0.07 ± 0.02 
 C9 20.5 ± 6.8 3.6 ± 0.5 0.18 ± 0.06 
 C10 28.5 ± 5.6 3.8 ± 0.3 0.13 ± 0.03 
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Figure 5-8. Effect of PFCAs on Oat2 and Urat1 mediated transport. 
Uptake of Oat2-mediated 88nM [3H] – PAH (A) or Urat1-mediated 10µM [14C]- uric 
acid (B) uptake was quantified at 37 °C for 1 min in the absence or presence of 10µM 
PFCAs with chain lengths from two (C2) to eighteen (C18) carbon atoms. Each bar 
represents the mean ± standard deviation of triplicates. *, p<0.05, compared to Oat2 or 
Urat1-mediated uptake in the absence of PFCAs. 
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Figure 5-9.  Oat2 (A) and Urat1 (B) mediated uptake of C7, C8, C9 and C10. 
Uptake of 100µM C7 to C10 was measured at 37 °C for 1 min with empty vector 
transfected (white bars) or transporter-expressing (grey bars) HEK293 cells. 
Concentrations of PFCAs were corrected for total protein concentration in each well. 
Each bar represents the mean ± standard deviation of triplicates. *, p<0.05, compared to 
vector control.  
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 whereas uptake of C8 was approximately a third higher for Urat1-expressing cells, 
consistent with the inhibition in [14C]-uric acid observed at 100 µM C8. 
 
III.      DISCUSSION:  
          A gender-dependent elimination pattern of PFCAs with different chain lengths 
has been reported in rats in vivo (Kudo et al., 2001).  In the present study, we have 
demonstrated that, depending on the chain length, PFCAs from C7 to C10 are 
substrates of three renal organic anion transporters: Oat1, Oat3, and Oatp1a1. C8 is a 
substrate of Oat2 and Urat1 (Figure 5-10).  We have also demonstrated that C7 and C8 
have the highest affinities for Oat1 and Oat3, whereas C9 and C10 have the highest 
affinities for Oatp1a1. 
 
          Both Oat1 and Oat3 have been reported to be expressed at the basolateral 
membrane (Kojima et al., 2002); (Tojo et al., 1999) and function as organic 
anion/dicarboxylate exchangers (Sekine et al., 1997; Sweet et al., 1997; Wolff et al., 
1997; Bakhiya et al., 2003; Sweet et al., 2003).  Based on the estimation that greater 
than 90% of PFOA is bound to serum albumin (Han et al., 2003), Oat1 and Oat3 
mediated excretion may play an important role in renal elimination of PFCAs (Figure 
5-10). This is further supported by a study that showed that pre-treatment with 
probenecid, which inhibits Oat1 and Oat3, reduces renal clearance of PFOA (Kudo et 
al., 2002).  Katakura et al. (Katakura et al., 2007)  showed that Oat3-transfected 
Xenopus laevis oocytes  
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Figure 5-10.  Diagram of PFCA transport in kidney. M>F: the expression level of 
the indicated transporter is higher in male rats; F>M: the expression level of the 
indicated transporter is higher in female rats. C7, C8, C9 and C10 in parentheses: 
substrates of the indicated transporter.   
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 transport C8.  The apparent Km values of Oat1 and Oat3-mediated C8 transport in our 
study are very close to previously published apparent Km values (51 μM for Oat1 and  
80 μM for Oat3, respectively) (Nakagawa et al., 2008). We also found that Oat1 has 
very similar transport efficiencies for C7 and C8. Oat3 has similar overall transport 
efficiency for C8 and C9. Moreover, our results indicate that compared to Oat1, Oat3 is 
better at transporting PFCAs with longer carbon chains (C9 and C10). Although 
gender-dependent expression has been reported for both Oat1 and Oat3 (Cerrutti et al., 
2002; Ljubojevic et al., 2004), the rats used in the PFOA renal elimination study done 
by Kudo et al. did not show marked differences at the mRNA level for either Oat1 or 
Oat3 (Kudo et al., 2002). This could due to the rats used in study by Kudo et al. was 
much younger than the rats used in the study by Lerrutti et al. and Kjubojevic et al.. 
Thus, available data suggest that Oat1 and Oat3 may play an important role in the 
secretion of PFCAs from plasma into proximal tubule cells, and that additional 
transporters must be involved in the observed gender-dependent renal excretion pattern.   
 
          Oatp1a1 is an important transporter expressed on the apical membrane of 
proximal tubule cells with a male dominant expression pattern (Bergwerk et al., 1996; 
Kato et al., 2002; Kudo et al., 2002). It mediates reabsorption of organic anions in 
exchange for intracellular reduced glutathione (Li et al., 1998).  Katakura et al. 
demonstrated that Oatp1a1-expressing Xenopus laevis oocytes transported C8 
(Katakura et al., 2007) and Yang et al. (Yang et al., 2009) extended these studies and 
determined that the apparent Km value for Oatp1a1-mediated C8 transport is 162 µM. 
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 Furthermore, they calculated apparent inhibition constants for estrone-3-sulfate uptake 
by C6, C7, C8, C9 and C10. Based on these inhibition constants, and assuming that in 
addition to C8, other PFCAs are also substrates of Oatp1a1, they predicted that PFCAs 
with longer chain lengths would have higher affinities (apparent Ki values for C6: 1858 
μM; C7: 399 μM; C8: 84 μM; C9: 45 μM; C10: 27 μM). In this present study, we 
determined directly the apparent Km values for C8 (126 µM), C9 (20µM) and C10 (28 
µM). The apparent Km value for C8 of 126 μM determined in this study is comparable 
to the apparent Km value of 162 μM described by Yang et al. (Yang et al., 2009). 
Furthermore, the apparent Km value of 28 μM for C10 determined in this study is 
similar to the apparent Ki value of 28 μM (Yang et al., 2009). However, the predicted 
affinities by Yang et al  for C8 (84 μM) is much lower  than the values quantified by 
Yang et al. (162 μM) (Yang et al., 2009) and by us (126 μM), and the predicted 
affinities for C9 (45 μM) is higher than the values quantified by us (21µM)  .  
 
          The significant differences in the Km values that we quantified in this study for 
Oatp1a1-mediated C8, C9 and C10 uptake suggest that Oatp1a1 transports C10 and C9 
with higher efficiency (Vmax/Km) than C8. Because Oatp substrates are mainly anionic 
amphipathic molecules with high molecular weight (>450) that under normal 
physiological conditions are bound to albumin (Hagenbuch and Meier, 2003), it is not 
surprising that PFDA (MW 514) and PFNA (MW 464) are better substrates for 
Oatp1a1 than PFOA (MW 414). Furthermore, the strong reabsorption mediated by 
Oatp1a1 for PFCAs with greater chain length may also explain the fact that the longer 
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 the carbon chain, the less PFCA is excreted into the urine (Kudo et al., 2001). Because 
male rats have more Oatp1a1 present at the apical membrane, it is reasonable that in 
male rats less C8 and C9 are excreted into the urine than in female rats as was shown 
previously (Kudo et al., 2001).   
 
          In this study, we also investigated the role of two other apical organic anion 
transporters, Oat2 and Urat1. Oat2 has a female dominant expression pattern in the rat 
at the apical membrane of proximal tubule cells. However, in humans, this transporter 
is localized to the basolateral membrane (Enomoto et al., 2002b; Kojima et al., 2002; 
Ljubojevic et al., 2007). Although most PFCA tested in this study inhibited Oat2-
mediated PAH uptake by 40% to 60%,  the chain length dependent inhibition pattern as 
shown for Oat1, Oat3 and Oatp1a1 mediated transport was not seen. The general 
inhibition of PFCAs observed could be due to the low signal to noise ratio because the 
amount of PAH transported into Oat2-expressing cells is only about twice as much as 
that of wild-type cells.   
 
          Furthermore, direct transport of C7 to C10 into Oat2-expressing CHO cells did 
not show any difference from wild-type CHO cells. The same result was obtained when 
we tested the direct transport of C7 to C10 in HEK cells transiently transfected with rat 
Oat2 (data not shown). Thus, we conclude that in our experimental systems, Oat2 does 
not transport C7, C8, C9 or C10, which for C8 is consistent with the previous finding 
by Nakagawa et al. (Nakagawa et al., 2008) that Oat2 does not transport C8 in 
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 transiently transfected HEK cells. Similar to Oat2, Urat1 did not show any chain length 
dependent inhibition pattern. Although C8 transport into Urat1 expressing HEK293 
cells was slightly higher than empty vector transfected cells, the signal to noise ratio 
was not large enough for further characterization. Among the three transporters 
expressed at the apical membrane, Oatp1a1 is the major player in the reabsorption of 
PFCAs.   
 
          There are also efflux transporters expressed at the apical membrane, including 
Mdr1a/1b and Mrps which may play a role in active secretion of PFCAs into urine. 
Mdr1b is much higher expressed in female rats at the mRNA level (Lu and Klaassen, 
2008) and could therefore potentially affect secretion of PFCAs across the apical 
membrane in female rats. Given the complexity of transporter systems expressed in the 
kidney, further studies are needed to elucidate PFCA excretion from proximal tubule 
cells into the tubular lumen.  
 
          The roles of several human transporters in renal clearance of C8 have been 
studied by other groups.  It has been shown that human Oat1 and Oat3 have similar C8 
transport capacity compared to the rodent homologues (Nakagawa et al., 2008). The 
same group also showed that a human specific transporter hOAT4 also transports C8 
(Nakagawa et al., 2009). The functional studies of rat transporters by us and others 
combined with previously published in vivo toxicokinetics experiments will allow us to 
generate additional human transporter candidates that may play important roles in 
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 PFCA disposition. For example, Oatp1a1 has been shown in current and previous 
studies to be important in reabsorption of C8, C9 and C10 in rats. It would be very 
interesting to look at the role of human OATP1A2, which is the orthologue of rat 
Oatp1a1, in transporting PFCAs with different chain lengths. Such studies will also 
provide valuable experimental kinetic parameters for toxicokinetic modelling of PFCAs 
in humans.  
   
          In conclusion, our studies reveal that PFCAs with different chain lengths are 
substrates of the two basolateral transporters, Oat1 and Oat3, as well as of the apical 
transporter, Oatp1a1, in rat proximal tubule cells.  The male dominant expression level 
of Oatp1a1 in kidney as well as differences in transport efficiencies for PFCAs with 
different chain lengths suggests a role of Oatp1a1 in the gender-specific renal 
elimination pattern in rats.  Further research is required to understand the basis of 
potential species differences in organic-anion transporter-mediated transport of PFCAs 
and how these may relate to species differences in elimination kinetics that have been 
observed.   
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CHAPTER 6 
 
SUMMARY AND DISCUSSION OF DISSERTATION 
 
          Organic anionic transporting polypeptides are important membrane transporters 
that mediate sodium-independent transport of amphipathic organic compounds in 
mammalian cells. Contrary to most SLC family members that have very specific 
substrate selectivity, OATP/Oatps are able to recognize and transport many 
structurally unrelated substrates. Together with the organic anion transporters 
(OATs), the organic cation transporters (OCTs), the multi-drug resistance protein 
(MDR), and the multi-drug resistance-associated proteins (MRPs), OATP/Oatps play 
an essential role in absorption, disposition, excretion and homeostasis of many 
physiological metabolites and foreign compounds. Malfunction of OATPs, due to 
genetic polymorphisms can lead to decreased drug efficacy, and more importantly, 
increased toxicity. Abnormal expression patterns of OATPs have also been reported 
in several cancers.  Therefore, for better human health it is important to understand how 
these transporters function and how they are regulated.  
 
          Prior to this dissertation work, very little was known about structure-function 
relationship of OATP/Oatps. It was suggested that the C-terminal half of human 
OATP2A1 may determine the transport affinity for prostaglandin E2 by using chimeras 
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 between human and mouse proteins (Pucci et al., 1999).  Cysteine scanning was used 
to map the substrate binding site of OATP2A1 and TM10 has been shown to be 
involved at least partially in substrate binding (Chan et al., 1999). The same group 
also studied the roles of conserved transmembrane cationic amino acids in OATP2A1 
mediated transport, and R560 in TM11 was identified to be important in substrate 
translocation (Chan et al., 2002).  In 2005, theoretical 3-D structural models for the 
OATP superfamily members OATP1B3 and OATP2B1 were published, in which a 
positively charged binding pocket was predicted by quantifying the electrostatic 
potential on the surface (Meier-Abt et al., 2005). The overall goal of this dissertation 
has been to extend those previous findings. My research has focused on the structure-
function relationship of OATP/Oatps. Concurrently with my research, a few more studies 
with similar research interests have been published.  The critical role of transmembrane 
domain (TM) 10 for OATP1B3-mediated transport was characterized. (Gui and 
Hagenbuch, 2008). Miyagawa et al. later demonstrated that TM8 and TM9 in OATP1B1 
affects transport kinetics of estrone-3-sulfate and estradiol-17β-glucuronide (Miyagawa et 
al., 2009). The importance of TM10 in OATP1B1 protein structure and transport function 
was further studied by Gui and Hagenbuch (2008). Although the roles of several 
transmembrane domains and individual amino acids for the transport function of 
OATP1B subfamily members have been studied in detail, very little is known about the 
binding/translocation sites for different substrates.  
 
          As mentioned in the introduction, I will defend three specific aims in this 
dissertation. In the first specific aim, I evaluated the hypothesis that conserved 
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 positively charged amino acids play important roles in OATP1B1 transport function. 
OATP1B1 and 1B3 are closely related transport proteins that mediate translocation of 
a wide range of compounds across the sinusoidal membrane of hepatocytes. Using 
comparative modeling, based on crystal structures of major facilitator superfamily 
members, a putative structural model of OATP1B3 with a “Positive Binding Pocket” 
has been predicted (Meier-Abt et al., 2005). Based on this model, we tested the 
hypothesis that positive amino acids, conserved in the OATP1B family and predicted 
to be facing this binding pocket, are important for OATP1B1 function. We performed 
site-directed mutagenesis and expressed the resulting constructs in HEK293 cells for 
functional analysis. Surface expression of wild-type and mutated transporters were 
quantified using surface biotinylation, followed by Western blot. Alanine 
substitutions of R57 (R57A) and K361 (K361A), which are located at the 
extracellular entrance of the putative binding pocket, greatly reduced transport 
activity for all three model substrates (estradiol-17β-glucuronide, estrone-3-sulfate 
and bromosulfophthalein) of OATP1B1. R57 positive charge substitution (R57K) 
rescued transport function, but K361 positive charge substitution (K361R) did not. 
Substitution of the transmembrane domain R580 with alanine resulted in less than 
30% surface expression compared to wild-type OATP1B1. At the intracellular side of 
OATP1B1, K90A moderately reduced transport activity of all three substrates and 
K90R successfully rescued the function. Mutations of H92 and R93 affected BSP 
transport more than estradiol-17β -glucuronide or estrone-3-sulfate transport.  In 
conclusion, conserved positively charged amino acid residues facing the putative 
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 binding pocket of OATP1B1 are important in transport function and/or surface 
expression of the transporter. 
           
          Cationic amino acids, such as arginine, are not often seen within 
transmembrane domains. R580 as a predicted transmembrane arginine is highly 
conserved in all OATP/Oatp families. Chan et al. demonstrated that replacing R560, 
the arginine at the corresponding position in TM11 of OATP2A1 with the neutral 
asparagine abolished transport. However, substitution with the positively charged 
lysine resulted in a comparable Km but a greatly decreased Vmax value (Chan et al., 
2002), indicating that this arginine is important in substrate translocation. Moreover, 
R454 in TM11 of rOAT3 is well conserved among OAT family members, whereas at 
the same position of OCTs, there is a conserved negatively charged aspartic acid. 
When mutating R454 to D, rOAT3 lost transport activity for most model substrates 
except cimetidine (Feng et al., 2001). The observations in both studies are consistent 
with the results in specific aim 1 that the Vmax values of R580 mutants mediated 
estradiol-17β-glucuronide and estrone-3-sulfate transport were greatly decreased. 
More interestingly, the Vmax values of R580 mutants mediated BSP transport did not 
change, suggesting similar to rOAT3 mediated cimetidine transport, BSP might use 
an alternative translocation pathway that does not require the transmembrane 
arginine. The presence of multiple binding/translocation sites could, to a certain 
extent, explain the broad substrate specificity of OATP/Oatps and OATs.  
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          At the extracellular and intracellular side, positively charged amino acids can 
function to attract anions in some transporters. One example is the CFTR (cystic 
fibrosis conductance regulator) chloride channel. On both sides of the channel, are 
multiple positively charged amino acid clusters including arginines and lysines, to 
attract Cl- (Aubin and Linsdell, 2006; Zhou et al., 2008).  We observed an increased 
Km value by the mutation of R57A in OATP1B1. Although we do not know whether 
the substrates can directly bind to R57, this conserved R57 at the extracellular side of 
OATP1B1 might function to form a positively charged cluster with other amino 
acids, and attract organic anions to the extracellular mouth of the translocation 
pathway.  
 
          In the second specific aim, I evaluated the hypothesis that quantifying transport 
activities of different substrates mediated by chimeras between rat Oatp1a1 and 
Oatp1a4 in combination with site-directed mutagenesis should allow us to identify 
regions and/or individual amino acids that are important for Oatp1a4-mediated 
substrate recognition and/or transport. Most functionally characterized organic anion 
transporting polypeptides (Oatps) have overlapping substrate specificities and 
transport a wide variety of structurally unrelated compounds. Oatp1a4 is a high-
affinity digoxin transporter whereas Oatp1a1 does not transport digoxin. To identify 
the regions that are important for Oatp1a4-mediated transport, we expressed chimeras 
between Oatp1a4 and Oatp1a1 in X. laevis oocytes and HEK293 cells and used 
digoxin transport as a functional tool. Based on the results with these chimeras, we 
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 identified a region near transmembrane domain 8 as essential for digoxin transport. 
We then quantified uptake of the general Oatp substrates taurocholate, estradiol-17β-
glucuronide, DPDPE, and BSP in HEK293 cells expressing the chimeric  proteins. In 
addition to digoxin, chimera 1 with the C-terminal half of Oatp1a4 also transported 
taurocholate, estradiol-17β-glucuronide and BSP but not DPDPE. Consistent with 
findings for digoxin, replacing TM8 and EL4 of Oatp1a4 in chimera 1 with TM8 and 
EL4 of Oatp1a1 abolished transport activities of all substrates tested. Using site-
directed mutagenesis based on sequence alignments followed by digoxin uptake we 
identified three amino acids (F328, S334 and M361) that when mutated to their 
Oatp1a1 counterparts showed reduced function. Mutant F328V did not affect 
transport of BSP or digoxin but showed reduced transport of taurocholate, estradiol-
17β-glucuronide, and DPDPE. Transport rates of mutant S334K for taurocholate and 
estradiol-17β-glucuronide were less than 20% of the wild-type whereas BSP and 
DPDPE transport rates were about 50%, which is consistent with the surface 
expression level of this mutant. Mutant M361S mainly had decreased surface 
expression. In conclusion, the C-terminal half of Oatp1a4 is essential for Oatp1a4 
mediated transport in a substrate dependent way, and the amino acids in TM8 and 
EL4 might be important for maintaining the binding/transport pathway of Oatp1a4. 
 
          Previously, the contribution of the C-terminal half to the transport function of 
three OATP transporters, OATP1B1 (Gui and Hagenbuch, 2009; Miyagawa et al., 
2009), OATP1B3 (Gui and Hagenbuch, 2008) and OATP2A1 (Pucci et al., 1999) has 
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 been studied. For the OATP1B subfamily, in general, the finding was that the more 
C-terminal transmembrane domains were retained in the chimera,  the better were the 
specific transport activities (Gui and Hagenbuch, 2008; Gui and Hagenbuch, 2009; 
Miyagawa et al., 2009). For OATP2A1, the uptake and inhibition profiles of the 
chimeric protein with the C-terminal half of the human transporter and the N-terminal 
half of the mouse transporter were identical to human OATP2A1. Similarly, in our 
study, chimera 1, which contains the C-terminal half of Oatp1a4, was able to 
transport most of the Oatp1a4 substrates tested, except for DPDPE. However, 
chimera 2, which contains the C-terminal half of Oatp1a1 was only able to transport 
BSP but none of the other Oatp1a1 substrates tested. This suggests that Oatp1a1 
requires some additional N-terminal portion to transport digoxin, taurocholate, and 
estradiol-17β-glucuronide, whereas Oatp1a4 does not.  It has been shown in the X. 
laevis oocyte system that rifampicin strongly inhibits taurocholate and estradiol-17β-
glucuronide transport mediated by Oatp1a4, but does not inhibit Oatp1a1 (Fattinger et 
al., 2000). This suggests that in Oatp1a1, different amino acid residues comprise the 
binding sites, or translocation pathways of some of the common Oatp substrates. This 
could explain why rifampicin only inhibited Oatp1a4 but not Oatp1a1. Thus, in order 
to map the domain of Oatp1a1, which is important for most of the common 
substrates, construction of more chimeric proteins containing additional N-terminal 
transmembrane domains are needed in future studies.  
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            Chimeric proteins are powerful tools to study transport mechanism of different 
transporters with high amino acid sequence identity. Using a substrate specific for 
one transporter as a functional tool, combined with sequence comparisons to identify 
unique amino acid sequences, often leads to the discovery of key residues that are 
involved in the transport of the substrate. Usually, the two transporter pairs tested, 
such as OATP1B1 and OATP1B3, Oatp1a1 and Oatp1a4, or human and rodent 
NTCP/Ntcp, also have an overlap in their substrate spectra. Due to the high sequence 
identity, it is easy to hypothesize that those common substrates are probably handled 
through a very similar mechanism. Thus these residues that are important for the 
transport mechanism should be conserved and the mirror image or reciprocal 
chimeras should have similar effects on transport activity for common substrates. In 
my research I found exactly this for BSP and DPDPE transport mediated by chimera 
1 and chimera 2. However, for other common substrates, such as taurocholate and 
estradiol-17β-glucuronide, chimera 1 and chimera 2 behaved very differently. A 
conformational change of the transporter caused by the construction of chimeras 
might be one explanation for the different behaviors of the reciprocal constructs. 
However, taking into account that some modulators, such as the inhibitor rifampicin 
also have different effects on intact Oatp1a1 and Oatp1a4, it is possible that even for 
common substrates these two transporters may use different combinations of amino 
acid residues to form the transport pathway.  
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              In the third specific aim, I evaluated the hypothesis that different rat renal 
organic anion transporters in the Oat and Oatp families selectively transport PFCAs 
of different chain lengths. PFCAs are generally stable to metabolic and environmental 
degradation and are found at low concentrations in environmental and biological 
samples. Renal clearance of PFCAs depends on chain length, species, and, in some 
cases, gender within species. Whereas perfluoroheptanoate (C7) is almost completely 
eliminated renally in both male and female rats, renal clearance of perfluorooctanoate 
(C8) and perfluorononanoate (C9) is much higher in female rats. Perfluorodecanoate 
(C10) mainly accumulates in the liver for both genders. Therefore, we tested whether 
PFCAs with different chain lengths are substrates of rat renal transporters with gender 
specific expression patterns. Inhibition of uptake of model substrates was quantified 
for the basolateral Oat1 and Oat3, and the apical Oat2, Oatp1a1, and Urat1 with 
10μM PFCAs with chain lengths from 2-18 (C2 – C18) carbons. Perfluorohexanoate 
(C6), C7, and C8 inhibited Oat1-mediated p-aminohippurate transport, with C7 being 
the strongest inhibitor. C8 and C9 were the strongest inhibitors for Oat3-mediated 
estrone-3-sulfate transport, whereas Oatp1a1-mediated estradiol-17β-glucuronide 
uptake was inhibited by C9, C10, and perflourounidecanoate (C11), with C10 giving 
the strongest inhibition. No strong inhibitors were found for Oat2 or Urat1. Kinetic 
analysis was performed for the strongest inhibitors. Oat1 transported C7 and C8 with 
Km values of 51 μM and 43μM, respectively. Oat3 transported C8 and C9 with Km 
values of 66 μM and 175 μM, respectively. Oatp1a1-mediated transport yielded Km 
values of 126 μM (C8), 20 μM (C9), and 28 μM (C10). These results suggest that 
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 Oat1 and Oat3 are involved in the renal secretion of C7 to C9, whereas Oatp1a1 may 
contribute to the reabsorption of C8 through C10, with highest affinities for C9 and 
C10. 
 
         When using molecular weight as a standard, C10 (MW 514) and C9 (MW 464) 
are better substrates for Oatp1a1 than C8 (MW 414). However, the chain lengths of 
the linear form of PFCAs can also be used as a “ruler” to measure the actual size of 
the binding pocket.  It is very interesting that the calculated chain length of C9 (9.6 
Å) and C10 (11.6 Å) are also comparable to the calculated length of some of the 
Oatp1a1 substrates, such as estradiol-17β-glucuronide (~10 Å) whereas the chain 
length of C8 (8.8 Å), which is a less optimal substrate, is smaller. In contrast, Oat1 
and Oat3 are able to transport smaller PFCAs compared to Oatp1a1. C7 (7.3 Å) and 
C8 (8.8 Å) are the best sizes for Oat1 whereas C8 (8.8 Å) is a better size for Oat3 
than C9 (9.6 Å).  Therefore, similar to the molecular weight selectivity, Oats and 
Oatps also have spatial size selectivity for their substrates.  
 
          Usually, the larger the molecular weight of a molecule, the bigger is its 
molecular size. In this specific aim, we demonstrated that Oatp1a1 has a binding 
pocket that can accommodate molecules from 9 to 12 Å, whereas Oat1 and Oat3 
prefer substrates around 7 to 8 Å.  
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           There are also situations where the molecular weight of a molecule does not 
necessarily correlate with the size, for example, the molecules with rigid ring 
structures. Both uric acid and perfluoroheptanoates (C7) are substrates of Oat1. The 
molecular weight of uric acid is 168 whereas the molecular weight of C7 is 364. In 
the PFCA compound series, pentafluoropropionic acid (C3) (MW 164) has a 
molecular weight close to uric acid, but C3 is not a substrate of Oat1.  However, due 
to the presence of ring structures in uric acid, the longest distance in uric acid is 
around 6.2 Å (Sours and Swift, 2004) which is much closer to the predicted lengths of 
C7 (7.3 Å) than C3 (2.9 Å). Although direct transport was not quantified in this study, 
C6 (6.8 Å), which is even closer in size to uric acid, inhibited Oat1-mediated uptake 
by 40%, and thus may also be a substrate of Oat1. Therefore, in this case, the actual 
size of the molecule rather than the molecular weight would be a more accurate tool 
for substrate prediction.    
 
          Based on inhibition constants, Yong et al. (2009) predicted that PFCAs with 
longer chain lengths would have higher affinities for Oatp1a1 mediated transport 
(apparent Ki values for C6: 1857 μM; C7: 399 μM; C8: 84 μM; C9: 45 μM; C10: 27 
μM) (Yang et al., 2009). In our study, by quantifying the direct transport kinetics, we 
demonstrated that the apparent affinities of PFCA transport mediated by Oatp1a1 do 
not correspond linearly to the size of the molecules. For Oatp1a1, C9 and C10 have 
very similar Km values (20.5µM for C9 and 28.5 µM for C10). This is also true for 
Oat1 mediated C7 and C8 (50.5µM for C7 and 43.2 µM for C8). Therefore, it seems 
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 that the binding affinity of substrate is not affected as long as the substrate is within 
the size limit of “binding pocket”. However, when the size of the compound is at the 
upper limit of the substrate size range for a transporter, the actual size of the molecule 
will greatly affect the transport affinity. For example, because Oat3 has less affinity 
for C9 (Km=175 µM) than for C8 (Km=66µM), it may indicate that the size of C9 (9.6 
Å) is approaching the upper limit of the substrate size range for Oat3. Thus, linear 
PFCAs with different chain lengths are great tools to study the substrate size 
selectivity of Oats and Oatps.  
 
          Overall, in this dissertation, I examined the transport mechanism of organic 
anion transporting polypeptides from three perspectives. First, I investigated the roles 
of conserved positively charged amino acid residues. I found that some highly 
conserved amino acids are critical for transport function. Second, I focused on the 
differences between two highly similar transporters. Again, several amino acids that 
are important for transport function were identified. More importantly, in both 
studies, different results were obtained when using different substrates for functional 
measurements. This is consistent with previous studies, and further supports the 
hypothesis that OATP/Oatps have multiple binding sites/translocation pathways for 
their different substrates.  Finally, from the perspective of substrates, I predicted the 
size of the binding pockets in Oat1, Oat3 and Oatp1a1 using PFCAs with different 
chain lengths. This work has provided valuable information for further understanding 
the transport mechanism of OATP/Oatps. The experimental results, including the 
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 mutagenesis studies and the measurement of the binding pocket size, are also very 
helpful in testing the accuracy of future computational models. However, to fully 
understand the molecular mechanism of transporter functions, there is still a long way 
to go. With more advanced computational, molecular biological and crystallography 
techniques, further work is necessary to explore the more detailed structure-function 
relationship of membrane transporters.  
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CHAPTER 7 
 
FUTURE DIRECTIONS 
 
          The studies in specific aim 1 have shown that the positively charged amino 
acids R57 and K361 at the extracellular side of OATP1B1 are important in substrate 
binding. However, we do not know whether they can directly bind the substrates or 
whether other adjacent amino acids are also important in facilitating substrate 
binding. To further investigate these two potential substrate binding domains, a 
cysteine scanning mutagenesis study should be employed to probe the substrate 
accessibility of the amino acids close to R57 and K361. Because we know that 
OATP1B1 does not react with water soluble MTS reagents, the amino acids adjacent 
to R57 and K361 should be mutated to cysteine residues sequentially one at a time.  
MTS reagents will be used to probe the solvent accessibility of each mutated amino 
acid, and transport activity will be quantified in the absence and presence of MTS 
reagent to investigate substrate accessibility to the mutated amino acid. Cysteine 
scanning will allow us to identify important amino acids for substrate binding and /or 
translocation.  
 
          The results in specific aim1 suggest that OATP1B1 may have multiple sites for 
substrate binding. It is also possible that once the substrate is attracted to the 
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 transporter, there are multiple domains along the translocation pathway to facilitate 
different substrates across the membrane. The primary study in specific aim 1 
suggests that positive charge could be important in substrate binding, however, 
simply providing another positive charged amino acid at certain positions in 
transmembrane domains does not rescue the impaired translocation process. Given 
the amphipathic nature of OATP/Oatp substrates, aromatic amino acids such as 
tyrosine, tryptophan, and phenylalanine could form aromatic domains inside the 
binding pocket to translocate the substrates across the membrane through interactions 
within these aromatic groups. Therefore, to investigate the roles of conserved 
aromatic residues, especially those within the transmembrane domains, is another 
approach to study the mechanism of OATP/Oatp mediated transport. Aromatic 
residues will be mutated to size matched non-aromatic residues. Surface expression 
and transport function of the mutants will be tested.  
 
          OATP1B1 and OATP1B3 are two closely related transporters. They share only 
one rodent homologue Oatp1b2. Whether OATP1B1 and OATP1B3 can function as 
either homo-dimer or hetero-dimer is still unknown. One straight forward way to 
study dimerization is to establish the evidences of co-localization. DNA constructs 
containing either His-tagged or HA tagged OATP1B1 will be co-transfected into 
HEK293 cells. Cross-linking reagents with different chemistry and different chain 
lengths will be used to cross-link the nearest two transporters. Then, immuno-
precipitation will be carried out using one epitope tag and western blot will be used to 
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 detect the other epitope tag. If there is a positive band on the western blot, further 
analysis such as masspectrometry can be used to identify the reactive group of cross-
linking and possibly the distance between the two proteins.    
 
           Multiple binding sites for different substrates on Oatp1a4 have also been 
suggested in specific aim 2. Therefore, mapping the domains that are critical for the 
different substrates is also important in understanding the structure-function 
relationship of OATP/Oatp.  Thus, additional chimeras between Oatp1a1 and 
Oatp1a4 chimeras will be made. Each transmembrane domain will be reciprocally 
and sequentially exchanged. For example, the first set of chimeras has the first 
transmembrane domain swapped between Oatp1a1 and Oatp1a4, and the second set 
of mutants has the first two transmembrane domains swapped between the two 
transporters etc. Transport of different substrates will be quantified and the minimum 
structural requirements for transport function will be evaluated. Combined with 
computer modeling to compare the 3D structure differences between different 
chimeras, it is possible to identify critical domains for the transport of different 
substrates.  
 
          In specific aim 2, EL4 and TM8 have been identified to be important for the 
transport of several Oatp1a4 substrates. A similar strategy can be used to study the 
human orthologue OATP1A2. Substrate specificity will be determined among 
OATP1A2, Oatp1a1 and Oatp1a4 and the amino acid sequence of the three 
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 transporters will be compared at the same time. If a compound is found to be a good 
substrate for two out of three transporters, then the amino acid differences between 
the transporters could be used to determine the substrate specificity. Site-directed 
mutagenesis then will be used to investigate the roles of these amino acids in 
substrate selectivity of OATP1A2 mediated transport.  
 
          An interesting observation was made in the surface expression experiment of 
chimeric proteins in specific aim 2. Chimera 3 was only partially glycosylated on the 
cell surface, and chimera 3 did not have transport function for any of the substrates 
tested. Therefore, whether glycosylation plays a role in OATP/Oatp mediated 
transport activity is another question to be answered. Previous research has shown 
that when the N-glycosylation sites in Oatp1a1 were mutated, transport activity was 
abolished because the transporter was not expressed at the cell membrane  (Wang et 
al., 2008). Therefore, glycosylation is important for surface expression of Oatp1a1. 
To test whether glycosylation status is directly involved in transport processes, uptake 
of model substrates will be quantified in empty vector transfected cells and 
OATP/Oatp expressing cells before or after deglycosylation. In this way, the 
transporter is present on the surface. If there is any decreased transport activity due to 
deglycosylation treatment, the glycosylation state might be important for transport 
function.  
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           All above mentioned strategies will lead to a better understanding of the 
substrate recognition and transport mechanism of the OATP/Oatp family of 
multispecific transporters.  
 
             
 
 
 161
 REFERENCE LIST 
 
 
Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, 
Suzuki M, Naitoh T, Matsuno S and Yawo H (1999) Identification of a novel 
gene family encoding human liver-specific organic anion transporter LST-1. J 
Biol Chem 274:17159-17163. 
Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara 
K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, 
Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki 
M, Ohtani H, Shimosegawa T, Iinuma, Nagura H, Ito S and Matsuno S (2001) 
LST-2, a human liver-specific organic anion transporter, determines 
methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 
120:1689-1699. 
Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR and Iwata S (2003) 
Structure and mechanism of the lactose permease of Escherichia coli. Science 
301:610-615. 
Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ and Manautou JE 
(2008) Renal xenobiotic transporters are differentially expressed in mice 
following cisplatin treatment. Toxicology 250:82-88. 
Anzai N, Jutabha P, Enomoto A, Yokoyama H, Nonoguchi H, Hirata T, Shiraya K, 
He X, Cha SH, Takeda M, Miyazaki H, Sakata T, Tomita K, Igarashi T, Kanai 
Y and Endou H (2005) Functional characterization of rat organic anion 
 162
 transporter 5 (Slc22a19) at the apical membrane of renal proximal tubules. J 
Pharmacol Exp Ther 315:534-544. 
Asif AR, Steffgen J, Metten M, Grunewald RW, Muller GA, Bahn A, Burckhardt G 
and Hagos Y (2005) Presence of organic anion transporters 3 (OAT3) and 4 
(OAT4) in human adrenocortical cells. Pflugers Arch 450:88-95. 
Aubin CN and Linsdell P (2006) Positive charges at the intracellular mouth of the 
pore regulate anion conduction in the CFTR chloride channel. J Gen Physiol 
128:535-545. 
Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, 
Johns SJ, Ferrin TE, Carlson EJ, Burchard EG and Giacomini KM (2006) 
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 
and its genetic variants. J Pharmacol Exp Ther 318:521-529. 
Bakhiya A, Bahn A, Burckhardt G and Wolff N (2003) Human organic anion 
transporter 3 (hOAT3) can operate as an exchanger and mediate secretory 
urate flux. Cell Physiol Biochem 13:249-256. 
Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F and Marin JJ 
(2006) Expression of transporters potentially involved in the targeting of 
cytostatic bile acid derivatives to colon cancer and polyps. Biochem 
Pharmacol 72:729-738. 
Banerjee A, Ray A, Chang C and Swaan PW (2005) Site-directed mutagenesis and 
use of bile acid-MTS conjugates to probe the role of cysteines in the human 
 163
 apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 
44:8908-8917. 
Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, Burk RD, Bai S, Novikoff 
PM, Stieger B, Meier PJ, Schuster VL and Wolkoff AW (1996) Immunologic 
distribution of an organic anion transport protein in rat liver and kidney. Am J 
Physiol 271:G231-238. 
Bressler R (2006) Grapefruit juice and drug interactions. Exploring mechanisms of 
this interaction and potential toxicity for certain drugs. Geriatrics 61:12-18. 
Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San 
Martin FG and Marin JJ (2006) OATP8/1B3-mediated cotransport of bile 
acids and glutathione: an export pathway for organic anions from 
hepatocytes? J Biol Chem 281:30326-30335. 
Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J and Marin JJ (2003) Role of 
organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in 
the human placenta-maternal liver tandem excretory pathway for foetal 
bilirubin. Biochem J 371:897-905. 
Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler 
D and Nies AT (2005) ABCC drug efflux pumps and organic anion uptake 
transporters in human gliomas and the blood-tumor barrier. Cancer Res 
65:11419-11428. 
 164
 Buist SC, Cherrington NJ, Choudhuri S, Hartley DP and Klaassen CD (2002) 
Gender-specific and developmental influences on the expression of rat organic 
anion transporters. J Pharmacol Exp Ther 301:145-151. 
Butenhoff JL, Kennedy GL, Jr., Hinderliter PM, Lieder PH, Jung R, Hansen KJ, 
Gorman GS, Noker PE and Thomford PJ (2004) Pharmacokinetics of 
perfluorooctanoate in cynomolgus monkeys. Toxicol Sci 82:394-406. 
Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DKF, Winterhalter KE, 
Meier PJ and Hagenbuch B (2001) Localization of organic anion transporting 
polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity 
with Oatp1, Oatp2 and Oatp3. Pflügers Arch. 443:188-195. 
Cerrutti JA, Brandoni A, Quaglia NB and Torres AM (2002) Sex differences in p-
aminohippuric acid transport in rat kidney: role of membrane fluidity and 
expression of OAT1. Mol Cell Biochem 233:175-179. 
Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y and 
Endou H (2000) Molecular cloning and characterization of multispecific 
organic anion transporter 4 expressed in the placenta. J Biol Chem 275:4507-
4512. 
Chan BS, Bao Y and Schuster VL (2002) Role of conserved transmembrane cationic 
amino acids in the prostaglandin transporter PGT. Biochemistry 41:9215-
9221. 
 165
 Chan BS, Satriano JA and Schuster VL (1999) Mapping the substrate binding site of 
the prostaglandin transporter PGT by cysteine scanning mutagenesis. J. Biol. 
Chem. 274:25564-25570. 
Chang C, Pang KS, Swaan PW and Ekins S (2005) Comparative pharmacophore 
modeling of organic anion transporting polypeptides: a meta-analysis of rat 
Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 314:533-541. 
Chang C and Swaan PW (2006) Computational approaches to modeling drug 
transporters. Eur J Pharm Sci 27:411-424. 
Chang S, Das K, Ehresman DJ, Ellefson ME, Gorman GS, Hart JA, Noker PE, Tan 
YM, Lieder PH, Lau C, Olsen GW and Butenhoff JL (2008) Comparative 
Pharmacokinetics of Perfluorobutyrate (PFBA) in Rats, Mice, Monkeys, and 
Humans and Relevance to Human Exposure via Drinking Water. Tox Sci 
104:40-53. 
Cheng X and Klaassen CD (2006) Regulation of mRNA expression of xenobiotic 
transporters by the pregnane x receptor in mouse liver, kidney, and intestine. 
Drug Metab Dispos 34:1863-1867. 
Cheng X and Klaassen CD (2008) Critical role of PPAR-alpha in perfluorooctanoic 
acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake 
transporters in mouse livers. Toxicol Sci 106:37-45. 
Cheng X and Klaassen CD (2009) Tissue distribution, ontogeny, and hormonal 
regulation of xenobiotic transporters in mouse kidneys. Drug Metab Dispos 
37:2178-2185. 
 166
 Cheng X, Maher J, Dieter MZ and Klaassen CD (2005) Regulation of mouse organic 
anion-transporting polypeptides (Oatps) in liver by prototypical microsomal 
enzyme inducers that activate distinct transcription factor pathways. Drug 
Metab Dispos 33:1276-1282. 
Cheng X, Maher J, Lu H and Klaassen CD (2006) Endocrine regulation of gender-
divergent mouse organic anion-transporting polypeptide (Oatp) expression. 
Mol Pharmacol 70:1291-1297. 
Chengelis CP, Kirkpatrick JB, Myers NR, Shinohara M, Stetson PL and Sved DW 
(2009) Comparison of the Toxicokinetic Behavior of Perfluorohexanoic Acid 
(PFHxA) and Nonafluorobutane-1-Sulfonic Acid (PFBS) in Cynomolgus 
Monkeys and Rats. Reproductive Toxicology 27:400-406. 
Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG 
and Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the 
pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 
78:342-350. 
Costa G, Sartori S and Consonni D (2009) Thirty years of medical surveillance in 
perfluooctanoic acid production workers. J Occup Environ Med 51:364-372. 
Cui Y, Konig J, Leier I, Buchholz U and Keppler D (2001) Hepatic uptake of 
bilirubin and its conjugates by the human organic anion transporter SLC21A6. 
J Biol Chem 276:9626-9630. 
 167
 Cvetkovic M, Leake B, Fromm MF, Wilkinson GR and Kim RB (1999) OATP and P-
glycoprotein transporters mediate the cellular uptake and excretion of 
fexofenadine. Drug Metab Dispos 27:866-871. 
D'Eon JC, Hurley MD, Wallington TJ and Mabury SA (2006) Atmospheric chemistry 
of N-methyl perfluorobutane sulfonamidoethanol, 
C4F9SO2N(CH3)CH2CH2OH: kinetics and mechanism of reaction with OH. 
Environ Sci Technol 40:1862-1868. 
D'Eon JC and Mabury SA (2007) Production of perfluorinated carboxylic acids 
(PFCAs) from the biotransformation of polyfluoroalkyl phosphate surfactants 
(PAPS): exploring routes of human contamination. Environ Sci Technol 
41:4799-4805. 
De Silva AO, Benskin JP, Martin LJ, Arsenault G, McCrindle R, Riddell N, Martin 
JW and Mabury SA (2009) Disposition of perfluorinated acid isomers in 
Sprague-Dawley rats; part 2: subchronic dose. Environ Toxicol Chem 28:555-
567. 
Dresser GK and Bailey DG (2003) The effects of fruit juices on drug disposition: a 
new model for drug interactions. Eur J Clin Invest 33 Suppl 2:10-16. 
Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ and Kim 
RB (2002) Fruit juices inhibit organic anion transporting polypeptide-
mediated drug uptake to decrease the oral availability of fexofenadine. Clin 
Pharmacol Ther 71:11-20. 
 168
 Dresser GK, Kim RB and Bailey DG (2005) Effect of grapefruit juice volume on the 
reduction of fexofenadine bioavailability: possible role of organic anion 
transporting polypeptides. Clin Pharmacol Ther 77:170-177. 
Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ and 
Hagenbuch B (1999) Polyspecific substrate uptake by the hepatic organic 
anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol 
276:G1037-1042. 
Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, 
Sophasan S and Endou H (2004) Human organic anion transporter 4 is a renal 
apical organic anion/dicarboxylate exchanger in the proximal tubules. J 
Pharmacol Sci 94:297-304. 
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada 
M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, 
Hosoya T, Shimokata K, Niwa T, Kanai Y and Endou H (2002a) Molecular 
identification of a renal urate anion exchanger that regulates blood urate 
levels. Nature 417:447-452. 
Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, 
Yamamoto T, Sekine T, Cha SH, Niwa T and Endou H (2002b) Interaction of 
human organic anion transporters 2 and 4 with organic anion transport 
inhibitors. J Pharmacol Exp Ther 301:797-802. 
Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg 
T, Truong DM, Long JM, Barshop BA, Kaler G and Nigam SK (2006) 
 169
 Decreased renal organic anion secretion and plasma accumulation of 
endogenous organic anions in OAT1 knock-out mice. J Biol Chem 281:5072-
5083. 
Fahrmayr C, Fromm MF and Konig J (2010) Hepatic OATP and OCT uptake 
transporters: their role for drug-drug interactions and pharmacogenetic 
aspects. Drug Metab Rev Jan 25. [Epub ahead of print]. 
Fasano WJ, Carpenter SC, Gannon SA, Snow TA, Stadler JC, Kennedy GL, Buck 
RC, Korzeniowski SH, Hinderliter PM and Kemper RA (2006) Absorption, 
distribution, metabolism, and elimination of 8-2 fluorotelomer alcohol in the 
rat. Toxicol Sci 91:341-355. 
Fattinger K, Cattori V, Hagenbuch B, Meier PJ and Stieger B (2000) Rifamycin SV 
and rifampicin exhibit differential inhibition of the hepatic rat organic anion 
transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86. 
Feng B, Dresser MJ, Shu Y, Johns SJ and Giacomini KM (2001) Arginine 454 and 
lysine 370 are essential for the anion specificity of the organic anion 
transporter, rOAT3. Biochemistry 40:5511-5520. 
Feng B, Shu Y and Giacomini KM (2002) Role of aromatic transmembrane residues 
of the organic anion transporter, rOAT3, in substrate recognition. 
Biochemistry 41:8941-8947. 
Fischer WJ, Altheimer S, Cattori V, Meier PJ, Dietrich DR and Hagenbuch B (2005) 
Organic anion transporting polypeptides expressed in liver and brain mediate 
uptake of microcystin. Toxicol Appl Pharmacol 203:257-263. 
 170
 Frillingos S, Sahin-Toth M, Wu J and Kaback HR (1998) Cys-scanning mutagenesis: 
a novel approach to structure function relationships in polytopic membrane 
proteins. Faseb J 12:1281-1299. 
Fujita T, Brown C, Carlson EJ, Taylor T, de la Cruz M, Johns SJ, Stryke D, 
Kawamoto M, Fujita K, Castro R, Chen CW, Lin ET, Brett CM, Burchard 
EG, Ferrin TE, Huang CC, Leabman MK and Giacomini KM (2005) 
Functional analysis of polymorphisms in the organic anion transporter, 
SLC22A6 (OAT1). Pharmacogenet Genomics 15:201-209. 
Furihata T, Satoh N, Ohishi T, Ugajin M, Kameyama Y, Morimoto K, Matsumoto S, 
Yamashita K, Kobayashi K and Chiba K (2009) Functional analysis of a 
mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient 
with pravastatin-induced myopathy. Pharmacogenomics J 9:185-193. 
Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A and Meier PJ (2000) 
Organic anion-transporting polypeptides mediate transport of opioid peptides 
across blood-brain barrier. J Pharmacol Exp Ther 294:73-79. 
Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao 
ZS, Manser E, Biber J and Murer H (2003) PDZK1: I. a major scaffolder in 
brush borders of proximal tubular cells. Kidney Int 64:1733-1745. 
Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur 
E, Lee W, Leake BF, Tirona RG and Kim RB (2007) Intestinal drug 
transporter expression and the impact of grapefruit juice in humans. Clin 
Pharmacol Ther 81:362-370. 
 171
 Glaeser H, Mandery K, Sticht H, Fromm MF and Konig J (2010) Relevance of 
conserved lysine and arginine residues in transmembrane helices for the 
transport activity of organic anion transporting polypeptide 1B3. Br J 
Pharmacol. 
Glavy JS, Wu SM, Wang PJ, Orr GA and Wolkoff AW (2000) Down-regulation by 
extracellular ATP of rat hepatocyte organic anion transport is mediated by 
serine phosphorylation of oatp1. J Biol Chem 275:1479-1484. 
Greenblatt DJ (2009) Analysis of Drug Interactions Involving Fruit Beverages and 
Organic Anion-Transporting Polypeptides. J Clin Pharmacol. 
Gui C and Hagenbuch B (2008) Amino acid residues in transmembrane domain 10 of 
organic anion transporting polypeptide 1B3 are critical for cholecystokinin 
octapeptide transport. Biochemistry 47:9090-9097. 
Gui C and Hagenbuch B (2009) Role of transmembrane domain 10 for the function of 
organic anion transporting polypeptide 1B1. Protein Sci. 
Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B and Hagenbuch B 
(2008) Effect of pregnane X receptor ligands on transport mediated by human 
OATP1B1 and OATP1B3. Eur J Pharmacol 584:57-65. 
Gui C, Wahlgren B, Lushington GH and Hagenbuch B (2009) Identification, Ki 
determination and CoMFA analysis of nuclear receptor ligands as competitive 
inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. 
Pharmacol Res 60:50-56. 
 172
 Guo GL, Choudhuri S and Klaassen CD (2002) Induction profile of rat organic anion 
transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme 
inducers that activate gene expression through ligand-activated transcription 
factor pathways. J Pharmacol Exp Ther 300:206-212. 
Guo GL and Klaassen CD (2001) Protein kinase C suppresses rat organic anion 
transporting polypeptide 1- and 2-mediated uptake. J Pharmacol Exp Ther 
299:551-557. 
Hagenbuch B (2007) Cellular entry of thyroid hormones by organic anion 
transporting polypeptides. Best Pract Res Clin Endocrinol Metab 21:209-221. 
Hagenbuch B (2010) Drug uptake systems in liver and kidney: a historic perspective. 
Clin Pharmacol Ther 87:39-47. 
Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion 
transporting polypeptides (OATP) family. Xenobiotica 38:778-801. 
Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting 
polypeptides. Biochim Biophys Acta 1609:1-18. 
Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the 
OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO 
superfamily, new nomenclature and molecular/functional properties. Pflugers 
Arch 447:653-665. 
Hagenbuch B, Scharschmidt BF and Meier PJ (1996) Effect of antisense 
oligonucleotides on the expression of hepatocellular bile acid and organic 
anion uptake systems in Xenopus laevis oocytes. Biochem J 316:901-904. 
 173
 Hagenbuch B, Stieger B, Foguet M, Lübbert H and Meier PJ (1991) Functional 
expression cloning and characterization of the hepatocyte Na+/bile acid 
cotransport system. Proc Natl Acad Sci USA 88:10629-10633. 
Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda 
K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL and Figg WD (2008) 
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome 
in caucasian patients with androgen-independent prostatic cancer. Clin Cancer 
Res 14:3312-3318. 
Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT and Lee JS (2008) 
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) 
polymorphisms on irinotecan-pharmacokinetics and clinical outcome of 
patients with advanced non-small cell lung cancer. Lung Cancer 59:69-75. 
Han X, Snow TA, Kemper RA and Jepson GW (2003) Binding of perfluorooctanoic 
acid to rat and human plasma proteins. Chem Res Toxicol 16:775-781. 
Hanggi E, Grundschober AF, Leuthold S, Meier PJ and St-Pierre MV (2006) 
Functional analysis of the extracellular cysteine residues in the human organic 
anion transporting polypeptide, OATP2B1. Mol Pharmacol 70:806-817. 
Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H and Bruford EA (2004) 
The ABCs of solute carriers: physiological, pathological and therapeutic 
implications of human membrane transport proteinsIntroduction. Pflugers 
Arch 447:465-468. 
 174
 Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 
(OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in 
humans. J Pharmacol Exp Ther 311:139-146. 
Hirano M, Maeda K, Shitara Y and Sugiyama Y (2006) Drug-drug interaction 
between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 
34:1229-1236. 
Hong M, Zhou F, Lee K and You G (2007) The putative transmembrane segment 7 of 
human organic anion transporter hOAT1 dictates transporter substrate binding 
and stability. J Pharmacol Exp Ther 320:1209-1215. 
Hong M, Zhou F and You G (2004) Critical amino acid residues in transmembrane 
domain 1 of the human organic anion transporter hOAT1. J Biol Chem 
279:31478-31482. 
Hosoyamada M, Sekine T, Kanai Y and Endou H (1999) Molecular cloning and 
functional expression of a multispecific organic anion transporter from human 
kidney. Am J Physiol 276:F122-128. 
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP and Kirchgessner TG 
(1999) A novel human hepatic organic anion transporting polypeptide 
(OATP2). Identification of a liver-specific human organic anion transporting 
polypeptide and identification of rat and human hydroxymethylglutaryl-CoA 
reductase inhibitor transporters. J Biol Chem 274:37161-37168. 
 175
 Huang Y, Lemieux MJ, Song J, Auer M and Wang DN (2003) Structure and 
mechanism of the glycerol-3-phosphate transporter from Escherichia coli. 
Science 301:616-620. 
Hussainzada N, Da Silva TC, Zhang EY and Swaan PW (2008) Conserved aspartic 
acid residues lining the extracellular loop 1 of sodium-coupled bile acid 
transporter ASBT Interact with Na+ and 7alpha-OH moieties on the ligand 
cholestane skeleton. J Biol Chem 283:20653-20663. 
Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, 
Higuchi S, Otsubo K and Sugiyama Y (2004) Influence of common variants 
in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum 
bilirubin levels in healthy subjects. Hepatol Res 30:91-95. 
Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ and Kullak-Ublick 
GA (2001) Hepatic uptake of cholecystikinin octapeptide by organic anion-
transporting polypeptides OATP4 and OATP8 of rat and human liver. 
Gastroenterology 121:1185-1190. 
Iwai M, Suzuki H, Ieiri I, Otsubo K and Sugiyama Y (2004) Functional analysis of 
single nucleotide polymorphisms of hepatic organic anion transporter 
OATP1B1 (OATP-C). Pharmacogenetics 14:749-757. 
Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW and Meier PJ (1994) Expression 
cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl 
Acad Sci U S A 91:133-137. 
 176
 Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y and Fardel O (2006) 
Differential regulation of sinusoidal and canalicular hepatic drug transporter 
expression by xenobiotics activating drug-sensing receptors in primary human 
hepatocytes. Drug Metab Dispos 34:1756-1763. 
Jones PM and George AM (2004) The ABC transporter structure and mechanism: 
perspectives on recent research. Cell Mol Life Sci 61:682-699. 
Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ and Kullak-Ublick GA 
(2001) Characterization of the human OATP-C (SLC21A6) gene promoter 
and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 
alpha. J Biol Chem 276:37206-37214. 
Kaback HR, Sahin-Toth M and Weinglass AB (2001) The kamikaze approach to 
membrane transport. Nat Rev Mol Cell Biol 2:610-620. 
Kakyo M, Sakagami H, Nishio T, Nakai D, Nakagomi R, Tokui T, Naitoh T, 
Matsuno S, Abe T and Yawo H (1999) Immunohistochemical distribution and 
functional characterization of an organic anion transporting polypeptide 2 
(oatp2). FEBS Lett 445:343-346. 
Kaler G, Truong DM, Sweeney DE, Logan DW, Nagle M, Wu W, Eraly SA and 
Nigam SK (2006) Olfactory mucosa-expressed organic anion transporter, 
Oat6, manifests high affinity interactions with odorant organic anions. 
Biochem Biophys Res Commun 351:872-876. 
Kamath AV, Yao M, Zhang Y and Chong S (2005) Effect of fruit juices on the oral 
bioavailability of fexofenadine in rats. J Pharm Sci 94:233-239. 
 177
 Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M and Chiba K (2005) 
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, 
SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression 
systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. 
Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M and Schuster VL (1996) Estradiol 17 
beta-D-glucuronide is a high-affinity substrate for oatp organic anion 
transporter. Am J Physiol 270:F326-331. 
Karlin A and Akabas MH (1998) Substituted-cysteine accessibility method. Methods 
Enzymol 293:123-145. 
Kasahara T, Ishiguro M and Kasahara M (2004) Comprehensive chimeric analysis of 
amino acid residues critical for high affinity glucose transport by Hxt2 of 
Saccharomyces cerevisiae. J Biol Chem 279:30274-30278. 
Katakura M, Kudo N, Tsuda T, Hibino Y, Mitsumoto A and Kawashima Y (2007) 
Rat organic anion transporter 3 and organic anion transporting polypeptide 1 
mediate perfluorooctanoic acid transport. J. Health Sci. 53:77-83. 
Kato Y, Kuge K, Kusuhara H, Meier PJ and Sugiyama Y (2002) Gender difference in 
the urinary excretion of organic anions in rats. J Pharmacol Exp Ther 
302:483-489. 
Kennedy GL, Jr., Butenhoff JL, Olsen GW, O'Connor JC, Seacat AM, Perkins RG, 
Biegel LB, Murphy SR and Farrar DG (2004) The toxicology of 
perfluorooctanoate. Crit Rev Toxicol 34:351-384. 
 178
 Khantwal CM and Swaan PW (2008) Cytosolic half of transmembrane domain IV of 
the human bile acid transporter hASBT (SLC10A2) forms part of the substrate 
translocation pathway. Biochemistry 47:3606-3614. 
Kikuchi A, Nozawa T, Wakasawa T, Maeda T and Tamai I (2006) Transporter-
mediated intestinal absorption of fexofenadine in rats. Drug Metab 
Pharmacokinet 21:308-314. 
Kitamura S, Maeda K, Wang Y and Sugiyama Y (2008) Involvement of multiple 
transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 
36:2014-2023. 
Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A and Tamai I (2003) Involvement of 
human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-
dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 
306:703-708. 
Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N and Yamamoto T 
(2005) Transport mechanism and substrate specificity of human organic anion 
transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57:573-578. 
Kocher O, Pal R, Roberts M, Cirovic C and Gilchrist A (2003) Targeted disruption of 
the PDZK1 gene by homologous recombination. Mol Cell Biol 23:1175-1180. 
Kock K, Koenen A, Giese B, Fraunholz M, May K, Siegmund W, Hammer E, Volker 
U, Jedlitschky G, Kroemer HK and Grube M (2010) Rapid modulation of the 
organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function 
by protein kinase C-mediated internalization. J Biol Chem. 
 179
 Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y and Endou H (2002) 
Immunolocalization of multispecific organic anion transporters, OAT1, 
OAT2, and OAT3, in rat kidney. J Am Soc Nephrol 13:848-857. 
Konig J, Cui Y, Nies AT and Keppler D (2000) A novel human organic anion 
transporting polypeptide localized to the basolateral hepatocyte membrane. 
Am J Physiol Gastrointest Liver Physiol 278:G156-164. 
König J, Cui Y, Nies AT and Keppler D (2000) Localization and genomic 
organization of a new hepatocellular organic anion transporting polypeptide. 
J. Biol. Chem. 275:23161-23168. 
Konig J, Seithel A, Gradhand U and Fromm MF (2006) Pharmacogenomics of human 
OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432-443. 
Kudo N, Katakura M, Sato Y and Kawashima Y (2002) Sex hormone-regulated renal 
transport of perfluorooctanoic acid. Chem Biol Interact 139:301-316. 
Kudo N and Kawashima Y (2003) Toxicity and toxicokinetics of perfluorooctanoic 
acid in humans and animals. J Toxicol Sci 28:49-57. 
Kudo N, Suzuki E, Katakura M, Ohmori K, Noshiro R and Kawashima Y (2001) 
Comparison of the elimination between perfluorinated fatty acids with 
different carbon chain length in rats. Chem Biol Interact 134:203-216. 
Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff 
AW and Meier PJ (1995) Molecular and functional characterization of an 
organic anion transporting polypeptide cloned from human liver. 
Gastroenterology 109:1274-1282. 
 180
 Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, 
Fattinger K, Meier PJ and Hagenbuch B (2001) Organic anion-transporting 
polypeptide B (OATP-B) and its functional comparison with three other 
OATPs of human liver. Gastroenterology 120:525-533. 
Kwak JO, Kim HW, Oh KJ, Ko CB, Park H and Cha SH (2005) Characterization of 
mouse organic anion transporter 5 as a renal steroid sulfate transporter. J 
Steroid Biochem Mol Biol 97:369-375. 
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A and Seed J (2007) 
Perfluoroalkyl Acids: A Review of Monitoring  and Toxicological Findings. 
Tox Sci 99:366-394. 
Le Vee M, Jouan E, Moreau A and Fardel O (2010) Regulation of drug transporter 
mRNA expression by interferon-gamma in primary human hepatocytes. 
Fundam Clin Pharmacol. 
Le Vee M, Lecureur V, Moreau A, Stieger B and Fardel O (2009) Differential 
regulation of drug transporter expression by hepatocyte growth factor in 
primary human hepatocytes. Drug Metab Dispos 37:2228-2235. 
Lee TK, Koh AS, Cui Z, Pierce RH and Ballatori N (2003) N-glycosylation controls 
functional activity of Oatp1, an organic anion transporter. Am J Physiol 
Gastrointest Liver Physiol 285:G371-381. 
Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington 
MK, Brunt EM, Zaika A, Kim RB and El-Rifai W (2008) Overexpression of 
 181
 OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 68:10315-
10323. 
Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF and 
Kim RB (2005) Polymorphisms in human organic anion-transporting 
polypeptide 1A2 (OATP1A2): implications for altered drug disposition and 
central nervous system drug entry. J Biol Chem 280:9610-9617. 
Lemal DM (2004) Perspective on fluorocarbon chemistry. J Org Chem 69:1-11. 
Letschert K, Keppler D and Konig J (2004) Mutations in the SLCO1B3 gene 
affecting the substrate specificity of the hepatocellular uptake transporter 
OATP1B3 (OATP8). Pharmacogenetics 14:441-452. 
Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ and Stieger B (2009) 
Mechanisms of pH-gradient driven transport mediated by organic anion 
polypeptide transporters. Am J Physiol Cell Physiol 296:C570-582. 
Li L, Lee TK, Meier PJ and Ballatori N (1998) Identification of glutathione as a 
driving force and leukotriene C4 as a substrate for oatp1, the hepatic 
sinusoidal organic solute transporter. J Biol Chem 273:16184-16191. 
Li L, Meier PJ and Ballatori N (2000) Oatp2 mediates bidirectional organic solute 
transport: a role for intracellular glutathione. Mol Pharmacol 58:335-340. 
Li N, Choudhuri S, Cherrington NJ and Klaassen CD (2004) Down-regulation of 
mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) 
mRNA by lipopolysaccharide through the toll-like receptor 4 (TLR4). Drug 
Metab Dispos 32:1265-1271. 
 182
 Lickteig AJ, Slitt AL, Arkan MC, Karin M and Cherrington NJ (2007) Differential 
regulation of hepatic transporters in the absence of tumor necrosis factor-
alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two 
models of cholestasis. Drug Metab Dispos 35:402-409. 
Ljubojevic M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, Burckhardt G and 
Sabolic I (2007) Renal expression of organic anion transporter OAT2 in rats 
and mice is regulated by sex hormones. Am J Physiol Renal Physiol 
292:F361-372. 
Ljubojevic M, Herak-Kramberger CM, Hagos Y, Bahn A, Endou H, Burckhardt G 
and Sabolic I (2004) Rat renal cortical OAT1 and OAT3 exhibit gender 
differences determined by both androgen stimulation and estrogen inhibition. 
Am J Physiol Renal Physiol 287:F124-138. 
Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X, Song PZ and Klaassen 
CD (2008) Characterization of organic anion transporting polypeptide 1b2-
null mice: essential role in hepatic uptake/toxicity of phalloidin and 
microcystin-LR. Toxicol Sci 103:35-45. 
Lu H and Klaassen C (2008) Gender differences in mRNA expression of ATP-
binding cassette efflux and bile acid transporters in kidney, liver, and intestine 
of 5/6 nephrectomized rats. Drug Metab Dispos 36:16-23. 
Lu R, Kanai N, Bao Y, Wolkoff AW and Schuster VL (1996) Regulation of renal 
oatp mRNA expression by testosterone. Am J Physiol 270:F332-337. 
 183
 Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, 
Kitamura Y, Kusuhara H and Sugiyama Y (2006) Effects of organic anion 
transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, 
valsartan, and temocapril. Clin Pharmacol Ther 79:427-439. 
Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R and Tamai I (2007) 
Identification of influx transporter for the quinolone antibacterial agent 
levofloxacin. Mol Pharm 4:85-94. 
Mahagita C, Grassl SM, Piyachaturawat P and Ballatori N (2007) Human organic 
anion transporter 1B1 and 1B3 function as bidirectional carriers and do not 
mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 
293:G271-278. 
Matsushima S, Maeda K, Ishiguro N, Igarashi T and Sugiyama Y (2008) 
Investigation of the inhibitory effects of various drugs on the hepatic uptake of 
fexofenadine in humans. Drug Metab Dispos 36:663-669. 
Meier-Abt F, Mokrab Y and Mizuguchi K (2005) Organic anion transporting 
polypeptides of the OATP/SLCO superfamily: identification of new members 
in nonmammalian species, comparative modeling and a potential transport 
mode. J Membr Biol 208:213-227. 
Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH and Kim RB (2008) 
Interplay between the nuclear receptor pregnane X receptor and the uptake 
transporter organic anion transporter polypeptide 1A2 selectively enhances 
estrogen effects in breast cancer. Cancer Res 68:9338-9347. 
 184
 Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, 
Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, 
Ito S, Goto J and Abe T (2004) Isolation and characterization of a digoxin 
transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci 
U S A 101:3569-3574. 
Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T and Habuchi T 
(2007) Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms 
on mycophenolic acid pharmacokinetics in Japanese renal transplant 
recipients. Eur J Clin Pharmacol 63:1161-1169. 
Miyagawa M, Maeda K, Aoyama A and Sugiyama Y (2009) The eighth and ninth 
transmembrane domains in organic anion transporting polypeptide 1B1 affect 
the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide. 
J Pharmacol Exp Ther 329:551-557. 
Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He 
X, Nonoguchi H, Tomita K, Kanai Y and Endou H (2005) Modulation of 
renal apical organic anion transporter 4 function by two PDZ domain-
containing proteins. J Am Soc Nephrol 16:3498-3506. 
Monte JC, Nagle MA, Eraly SA and Nigam SK (2004) Identification of a novel 
murine organic anion transporter family member, OAT6, expressed in 
olfactory mucosa. Biochem Biophys Res Commun 323:429-436. 
 185
 Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M and Chiba K (2004) A novel 
variant allele of OATP-C (SLCO1B1) found in a Japanese patient with 
pravastatin-induced myopathy. Drug Metab Pharmacokinet 19:453-455. 
Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa 
O and Inui K (2002) Gene expression levels and immunolocalization of 
organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874. 
Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, Ohuchi N, 
Sasano H, Abe T and Unno M (2007) Human liver-specific organic anion 
transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer 
Sci 98:1570-1576. 
Mwinyi J, Johne A, Bauer S, Roots I and Gerloff T (2004) Evidence for inverse 
effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. 
Clin Pharmacol Ther 75:415-421. 
Nakagawa H, Hirata T, Terada T, Jutabha P, Miura D, Harada KH, Inoue K, Anzai N, 
Endou H, Inui K, Kanai Y and Koizumi A (2008) Roles of organic anion 
transporters in the renal excretion of perfluorooctanoic acid. Basic Clin 
Pharmacol Toxicol 103:1-8. 
Nakagawa H, Terada T, Harada KH, Hitomi T, Inoue K, Inui K and Koizumi A 
(2009) Human organic anion transporter hOAT4 is a transporter of 
perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 105:136-138. 
 186
 Neuvonen PJ, Backman JT and Niemi M (2008) Pharmacokinetic comparison of the 
potential over-the-counter statins simvastatin, lovastatin, fluvastatin and 
pravastatin. Clin Pharmacokinet 47:463-474. 
Newell JG and Czajkowski C (2007) Cysteine Scanning Mutagenesis: Mapping and 
Binding Sites of Ligand‐Gated Ion Channels, in Handbook of 
Neurochemistry Molecular Neurobiology Practical Neurochemistry Methods 
(Lajtha A, Baker G, Dunn S and Holt A eds) pp 439-454, Springer US. 
Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman 
JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M and Kivisto KT (2004) 
High plasma pravastatin concentrations are associated with single nucleotide 
polymorphisms and haplotypes of organic anion transporting polypeptide-C 
(OATP-C, SLCO1B1). Pharmacogenetics 14:429-440. 
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, 
Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K and Sugiyama Y 
(2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: 
consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-
565. 
Noe B, Hagenbuch B, Stieger B and Meier PJ (1997) Isolation of a multispecific 
organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad 
Sci U S A 94:10346-10350. 
Noe J, Portmann R, Brun ME and Funk C (2007) Substrate-dependent drug-drug 
interactions between gemfibrozil, fluvastatin and other organic anion-
 187
 transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and 
OATP1B3. Drug Metab Dispos 35:1308-1314. 
Nozawa T, Imai K, Nezu J, Tsuji A and Tamai I (2004) Functional characterization of 
pH-sensitive organic anion transporting polypeptide OATP-B in human. J 
Pharmacol Exp Ther 308:438-445. 
Nozawa T, Minami H, Sugiura S, Tsuji A and Tamai I (2005) Role of organic anion 
transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active 
metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of 
single nucleotide polymorphisms. Drug Metab Dispos 33:434-439. 
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A and Yokoi T 
(2002) Genetic polymorphisms of human organic anion transporters OATP-C 
(SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese 
population and functional analysis. J Pharmacol Exp Ther 302:804-813. 
Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL and 
Zobel LR (2007) Half-life of serum elimination of 
perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in 
retired fluorochemical production workers. Environ Health Perspect 
115:1298-1305. 
Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C, 
Rosskopf D, Fromm MF and Siegmund W (2008) Disposition of ezetimibe is 
influenced by polymorphisms of the hepatic uptake carrier OATP1B1. 
Pharmacogenet Genomics 18:559-568. 
 188
 Palermo DP, DeGraaf ME, Marotti KR, Rehberg E and Post LE (1991) Production of 
analytical quantities of recombinant proteins in Chinese hamster ovary cells 
using sodium butyrate to elevate gene expression. J Biotechnol 19:35-47. 
Pao SS, Paulsen IT and Saier MH, Jr. (1998) Major facilitator superfamily. Microbiol 
Mol Biol Rev 62:1-34. 
Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ and Niemi M (2008) 
Polymorphism of the hepatic influx transporter organic anion transporting 
polypeptide 1B1 is associated with increased cholesterol synthesis rate. 
Pharmacogenet Genomics 18:921-926. 
Perry JL, Dembla-Rajpal N, Hall LA and Pritchard JB (2006) A three-dimensional 
model of human organic anion transporter 1: aromatic amino acids required 
for substrate transport. J Biol Chem 281:38071-38079. 
Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G and Meier PJ (2002) 
Identification of a novel human organic anion transporting polypeptide as a 
high affinity thyroxine transporter. Mol Endocrinol 16:2283-2296. 
Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ and St-Pierre MV (2003) 
Identification of steroid sulfate transport processes in the human mammary 
gland. J Clin Endocrinol Metab 88:3902-3912. 
Pucci ML, Bao Y, Chan B, Itoh S, Lu R, Copeland NG, Gilbert DJ, Jenkins NA and 
Schuster VL (1999) Cloning of mouse prostaglandin transporter PGT cDNA: 
species-specific substrate affinities. Am. J. Physiol. 299:R734-741. 
 189
 Qiang F, Lee BJ, Lee W and Han HK (2009) Pharmacokinetic drug interaction 
between fexofenadine and fluvastatin mediated by organic anion-transporting 
polypeptides in rats. Eur J Pharm Sci 37:413-417. 
Race JE, Grassl SM, Williams WJ and Holtzman EJ (1999) Molecular cloning and 
characterization of two novel human renal organic anion transporters (hOAT1 
and hOAT3). Biochem Biophys Res Commun 255:508-514. 
Reichel C, Gao B, van Montfoort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, 
Kamisako T and Meier PJ (1999) Localization and function of the organic 
anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 117:688-
695. 
Rizwan AN and Burckhardt G (2007) Organic anion transporters of the SLC22 
family: biopharmaceutical, physiological, and pathological roles. Pharm Res 
24:450-470. 
Rizwan AN, Krick W and Burckhardt G (2007) The chloride dependence of the 
human organic anion transporter 1 (hOAT1) is blunted by mutation of a single 
amino acid. J Biol Chem 282:13402-13409. 
Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G and Lotsch J (2006) Rapid 
identification of three functionally relevant polymorphisms in the OATP1B1 
transporter gene using Pyrosequencing. Pharmacogenomics 7:167-176. 
Rost D, Kopplow K, Gehrke S, Mueller S, Friess H, Ittrich C, Mayer D and Stiehl A 
(2005) Gender-specific expression of liver organic anion transporters in rat. 
Eur J Clin Invest 35:635-643. 
 190
 Saier MH, Jr. (2000) A functional-phylogenetic classification system for 
transmembrane solute transporters. Microbiol Mol Biol Rev 64:354-411. 
Satlin LM, Amin V and Wolkoff AW (1997) Organic anion transporting polypeptide 
mediates organic anion/HCO3- exchange. J Biol Chem 272:26340-26345. 
Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W and Keppler D 
(1997) Expression of the conjugate export pump encoded by the mrp2 gene in 
the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8:1213-
1221. 
Schnabolk GW, Youngblood GL and Sweet DH (2006) Transport of estrone sulfate 
by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal 
Physiol 291:F314-321. 
Schuster VL (2002) Prostaglandin transport. Prostaglandins Other Lipid Mediat 68-
69:633-647. 
Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dorje F, Fromm MF 
and Konig J (2007) The influence of macrolide antibiotics on the uptake of 
organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab 
Dispos 35:779-786. 
Sekine T, Miyazaki H and Endou H (2006) Molecular physiology of renal organic 
anion transporters. Am J Physiol Renal Physiol 290:F251-261. 
Sekine T, Watanabe N, Hosoyamada M, Kanai Y and Endou H (1997) Expression 
cloning and characterization of a novel multispecific organic anion 
transporter. J Biol Chem 272:18526-18529. 
 191
 Shi X, Bai S, Ford AC, Burk RD, Jacquemin E, Hagenbuch B, Meier PJ and Wolkoff 
AW (1995) Stable inducible expression of a functional rat liver organic anion 
transport protein in HeLa cells. J Biol Chem 270:25591-25595. 
Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H and Sugiyama 
Y (2005) Contribution of OATP (organic anion-transporting polypeptide) 
family transporters to the hepatic uptake of fexofenadine in humans. Drug 
Metab Dispos 33:1477-1481. 
Shin HJ, Anzai N, Enomoto A, He X, Kim do K, Endou H and Kanai Y (2007) Novel 
liver-specific organic anion transporter OAT7 that operates the exchange of 
sulfate conjugates for short chain fatty acid butyrate. Hepatology 45:1046-
1055. 
Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS 
and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant 
recipients administered an antirejection regimen including cyclosporine. Clin 
Pharmacol Ther 76:167-177. 
Smith NF, Acharya MR, Desai N, Figg WD and Sparreboom A (2005) Identification 
of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. 
Cancer Biol Ther 4:815-818. 
Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, 
Verweij J, McLeod HL and Sparreboom A (2007) Variants in the SLCO1B3 
gene: interethnic distribution and association with paclitaxel 
pharmacokinetics. Clin Pharmacol Ther 81:76-82. 
 192
 Sours R and Swift J (2004) The relationship between uric acid crystals and kidney 
stone disease. ACA Transactions 39:83-89. 
Sugiyama D, Kusuhara H, Shitara Y, Abe T and Sugiyama Y (2002) Effect of 17 
beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting 
polypeptide 2-mediated transport differs depending on substrates. Drug Metab 
Dispos 30:220-223. 
Sun W, Wu RR, van Poelje PD and Erion MD (2001) Isolation of a family of organic 
anion transporters from human liver and kidney. Biochem Biophys Res 
Commun 283:417-422. 
Sweet DH, Chan LM, Walden R, Yang XP, Miller DS and Pritchard JB (2003) 
Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly 
coupled to the Na+ gradient. Am J Physiol Renal Physiol 284:F763-769. 
Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR and Nigam SK (2002) 
Impaired organic anion transport in kidney and choroid plexus of organic 
anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 277:26934-
26943. 
Sweet DH, Wolff NA and Pritchard JB (1997) Expression cloning and 
characterization of ROAT1. The basolateral organic anion transporter in rat 
kidney. J Biol Chem 272:30088-30095. 
Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, 
Tokunaga K, Kondo I, Sugiyama Y and Miki T (2004) Effect of genetic 
 193
 polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-
CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375-380. 
Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y and Tsuji A (2001) Functional 
characterization of human organic anion transporting polypeptide B (OATP-
B) in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269. 
Tan YM, Clewell HJ, 3rd and Andersen ME (2008) Time Dependencies in 
Perfluorooctylacids Disposition in Rat and Monkeys: A Kinetic Analysis. 
Toxicol Lett 177:38-47. 
Tanaka K, Xu W, Zhou F and You G (2004) Role of glycosylation in the organic 
anion transporter OAT1. J Biol Chem 279:14961-14966. 
Tirona RG, Leake BF, Merino G and Kim RB (2001) Polymorphisms in OATP-C: 
identification of multiple allelic variants associated with altered transport 
activity among European- and African-Americans. J Biol Chem 276:35669-
35675. 
Tirona RG, Leake BF, Wolkoff AW and Kim RB (2003) Human organic anion 
transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-
mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228. 
Tojo A, Sekine T, Nakajima N, Hosoyamada M, Kanai Y, Kimura K and Endou H 
(1999) Immunohistochemical localization of multispecific renal organic anion 
transporter 1 in rat kidney. J Am Soc Nephrol 10:464-471. 
Treiber A, Schneiter R, Hausler S and Stieger B (2007) Bosentan is a substrate of 
human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common 
 194
 mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. 
Drug Metab Dispos 35:1400-1407. 
Tsujimoto M, Dan Y, Hirata S, Ohtani H and Sawada Y (2008) Influence of 
SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal 
renal failure. Drug Metab Pharmacokinet 23:406-411. 
Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, 
Dieterich HA, Howard D and Dole WP (2008) Pharmacokinetics of the oral 
direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and 
ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition 
of aliskiren. J Clin Pharmacol 48:1323-1338. 
van Aubel RA, Smeets PH, Peters JG, Bindels RJ and Russel FG (2002) The 
MRP4/ABCC4 gene encodes a novel apical organic anion transporter in 
human kidney proximal tubules: putative efflux pump for urinary cAMP and 
cGMP. J Am Soc Nephrol 13:595-603. 
van der Deure WM, Friesema EC, de Jong FJ, de Rijke YB, de Jong FH, Uitterlinden 
AG, Breteler MM, Peeters RP and Visser TJ (2008) Organic anion transporter 
1B1: an important factor in hepatic thyroid hormone and estrogen transport 
and metabolism. Endocrinology 149:4695-4701. 
van Giersbergen PL, Treiber A, Schneiter R, Dietrich H and Dingemanse J (2007) 
Inhibitory and inductive effects of rifampin on the pharmacokinetics of 
bosentan in healthy subjects. Clin Pharmacol Ther 81:414-419. 
 195
 Vanden Heuvel JP (1996) Perfluorodecanoic acid as a useful pharmacologic tool for 
the study of peroxisome proliferation. Gen Pharmacol 27:1123-1129. 
Vanden Heuvel JP, Kuslikis BI, Van Rafelghem MJ and Peterson RE (1991) Tissue 
distribution, metabolism, and elimination of perfluorooctanoic acid in male 
and female rats. J Biochem Toxicol 6:83-92. 
Vardy E, Arkin IT, Gottschalk KE, Kaback HR and Schuldiner S (2004) Structural 
conservation in the major facilitator superfamily as revealed by comparative 
modeling. Protein Sci 13:1832-1840. 
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ and Fattinger K (2002) Interactions 
of rifamycin SV and rifampicin with organic anion uptake systems of human 
liver. Hepatology 36:164-172. 
Vee ML, Lecureur V, Stieger B and Fardel O (2009) Regulation of drug transporter 
expression in human hepatocytes exposed to the proinflammatory cytokines 
tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37:685-693. 
Wallington TJ, Hurley MD, Xia J, Wuebbles DJ, Sillman S, Ito A, Penner JE, Ellis 
DA, Martin J, Mabury SA, Nielsen OJ and Sulbaek Andersen MP (2006) 
Formation of C7F15COOH (PFOA) and other perfluorocarboxylic acids 
during the atmospheric oxidation of 8:2 fluorotelomer alcohol. Environ Sci 
Technol 40:924-930. 
Walters HC, Craddock AL, Fusegawa H, Willingham MC and Dawson PA (2000) 
Expression, transport properties, and chromosomal location of organic anion 
 196
 transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 279:G1188-
1200. 
Wang P, Hata S, Xiao Y, Murray JW and Wolkoff AW (2008) Topological 
assessment of oatp1a1: a 12-transmembrane domain integral membrane 
protein with three N-linked carbohydrate chains. Am J Physiol Gastrointest 
Liver Physiol 294:G1052-1059. 
Wang P, Wang JJ, Xiao Y, Murray JW, Novikoff PM, Angeletti RH, Orr GA, Lan D, 
Silver DL and Wolkoff AW (2005) Interaction with PDZK1 is required for 
expression of organic anion transporting protein 1A1 on the hepatocyte 
surface. J Biol Chem 280:30143-30149. 
Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR and Anderson GW (2009) 
Competitive inhibition of organic anion transporting polypeptide 1c1-
mediated thyroxine transport by the fenamate class of nonsteroidal 
antiinflammatory drugs. Endocrinology 150:1025-1032. 
Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G and Jaeger W (2008) 
Altered expression of organic anion transporter polypeptide (OATP) genes in 
human breast carcinoma. Cancer Biol Ther 7:1450-1455. 
Wolff NA, Werner A, Burkhardt S and Burckhardt G (1997) Expression cloning and 
characterization of a renal organic anion transporter from winter flounder. 
FEBS Lett 417:287-291. 
 197
 Wood M, Ananthanarayanan M, Jones B, Wooton-Kee R, Hoffman T, Suchy FJ and 
Vore M (2005) Hormonal regulation of hepatic organic anion transporting 
polypeptides. Mol Pharmacol 68:218-225. 
Xu W, Tanaka K, Sun AQ and You G (2006) Functional role of the C terminus of 
human organic anion transporter hOAT1. J Biol Chem 281:31178-31183. 
Yang CH, Glover KP and Han X (2009) Organic anion transporting polypeptide 
(Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal 
reabsorption mechanism of Oatp1a1 in renal elimination of 
perfluorocarboxylates in rats. Toxicol Lett. 
Yarim M, Moro S, Huber R, Meier PJ, Kaseda C, Kashima T, Hagenbuch B and 
Folkers G (2005) Application of QSAR analysis to organic anion transporting 
polypeptide 1a5 (Oatp1a5) substrates. Bioorg Med Chem 13:463-471. 
Yin Y, He X, Szewczyk P, Nguyen T and Chang G (2006) Structure of the multidrug 
transporter EmrD from Escherichia coli. Science 312:741-744. 
You G (2004) Towards an understanding of organic anion transporters: structure-
function relationships. Med Res Rev 24:762-774. 
Youngblood GL and Sweet DH (2004) Identification and functional assessment of the 
novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. 
Am J Physiol Renal Physiol 287:F236-244. 
Zaher H, zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, 
Palandra J, Stock JL, Kim RB and Ware JA (2008) Targeted disruption of 
murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) 
 198
 significantly alters disposition of prototypical drug substrates pravastatin and 
rifampin. Mol Pharmacol 74:320-329. 
Zhang EY, Phelps MA, Banerjee A, Khantwal CM, Chang C, Helsper F and Swaan 
PW (2004) Topology scanning and putative three-dimensional structure of the 
extracellular binding domains of the apical sodium-dependent bile acid 
transporter (SLC10A2). Biochemistry 43:11380-11392. 
Zhang EY, Phelps MA, Cheng C, Ekins S and Swaan PW (2002) Modeling of active 
transport systems. Adv Drug Deliv Rev 54:329-354. 
Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY 
and Zhou HH (2007) OATP1B1 polymorphism is a major determinant of 
serum bilirubin level but not associated with rifampicin-mediated bilirubin 
elevation. Clin Exp Pharmacol Physiol 34:1240-1244. 
Zhou F, Pan Z, Ma J and You G (2004a) Mutational analysis of histidine residues in 
human organic anion transporter 4 (hOAT4). Biochem J 384:87-92. 
Zhou F, Tanaka K, Pan Z, Ma J and You G (2004b) The role of glycine residues in 
the function of human organic anion transporter 4. Mol Pharmacol 65:1141-
1147. 
Zhou F, Xu W, Hong M, Pan Z, Sinko PJ, Ma J and You G (2005) The role of N-
linked glycosylation in protein folding, membrane targeting, and substrate 
binding of human organic anion transporter hOAT4. Mol Pharmacol 67:868-
876. 
 199
 Zhou F and You G (2007) Molecular insights into the structure-function relationship 
of organic anion transporters OATs. Pharm Res 24:28-36. 
Zhou JJ, Fatehi M and Linsdell P (2008) Identification of positive charges situated at 
the outer mouth of the CFTR chloride channel pore. Pflugers Arch 457:351-
360. 
 
 
 200
 APPENDICES 
Appendix I: Citations of Publication 
1. Gui, C., Miao, Y., Thompson, L., Wahlgren, B., Mock, M., Stieger, B., and 
Hagenbuch, B. (2008). Effect of pregnane X receptor ligands on transport 
mediated by human OATP1B1 and OATP1B3. European journal of 
pharmacology 584, 57-65. 
2. Cui, Y. J., Cheng, X., Weaver, Y. M., and Klaassen, C. D. (2009). Tissue 
distribution, gender-divergent expression, ontogeny, and chemical induction 
of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. 
Drug metabolism and disposition: the biological fate of chemicals 37, 203-10. 
3. Weaver, Y. M., Ehresman, D. J., Butenhoff, J. L., and Hagenbuch, B. (2010). 
Roles  of rat renal organic anion transporters in transporting perfluorinated 
carboxylates with different chain lengths. Toxicol Sci 113, 305-14. 
4. Weaver, Y. M., and Hagenbuch, B. The role of conserved positively charged 
amino acids in OATP1B1 mediated transport. J Membr Biol submitted. 
5. Weaver, Y. M., Hammann-Hänni, A., van Montfoort, J., Meier-Abt, F., 
Grütter, M. G., Meier, P. J., and Hagenbuch, B. The role of extracellular loop 
4 and transmembrane domain 8 in Oatp1a4 mediated transport of mutiple 
substrates. In preparation. 
6. Weaver, Y. M., Ehresman, D. J., Chang, S., Butenhoff, J. L., and Hagenbuch, 
B. The roles of organic anion transporters in renal elimination of branched and 
linear perfluorobutyrate in rats. In preparation  
 201
   
Appendix II: Citations of Peer-reviewed Presentation/Poster Abstracts 
 
1. Miao, Y. and Hagenbuch B. Conserved Positively Charged Amino Acid 
Residues in the Putative Binding Pocket are Important for OATP1B1 
Function. Experimental Biology Meeting, April 2007, Washington D.C.  
Symposia Presentation.  
2. Weaver, Y. M.  and Hagenbuch, B. Identification of transporters involved in 
renal elimination of perfluorinated carboxylates in rats.  Central State SOT 
Meeting,   September, 2008, University of Kansas Medical Center, Kansas 
City, KS.  Poster. 
3. Weaver, Y. M.  Conserved Positively Charged Amino Acid Residues Facing 
the Putative Binding Pocket Are Important for OATP1B1 Function.  
Biomedical Research Training Program. May 2009, University of Kansas 
Medical Center, Kansas City, KS.  Presentation. 
4. Weaver, Y. M.  and Hagenbuch, B. . Identification of transporters involved in 
renal elimination of perfluorinated carboxylates in rats.  SOT Annual 
Meeting, March 2009, Baltimore, MD.  Poster. 
5. Weaver, Y. M. , Ehresman, D. J.,  Chang, S., Butenhoff, J. L. and 
Hagenbuch, B. . The roles of organic anion transporters in renal elimination of 
branched and linear perfluorobutyrate in rats. SOT Annual Meeting, March 
2010, Salt Lake City, UT.  Poster. 
 202
 Appendix III:  List of License Agreements for Copyrighted Materials 
 
License Agreement for Figure 1-1 
 
  License number:  2324860778780 
  License date: December 9, 2009 
  License content publisher:  Elsevier 
  Licensed content publication:  Biophysica Acta (BBA) -Biomembranes 
  Licensed content title:  The superfamily of organic anion transporting 
polypeptides 
  Licensed content author:  B. Hagenbuch and P.J. Meier 
  Licensed content date:  January 10,  2003 
  Volume number:  1609 
  Issue number:  1 
  Pages:  1-18 
  Type of use:  Thesis/Dissertation 
  Details of use:  Print 
  Portion of the article:  Figures 
 203
 License Agreement for Table 1-1 
 
  License number:  2324870536357 
  License date: December 9, 2009 
  License content publisher:  Springer 
  Licensed content publication:  Pflügers Archiv 
  Licensed content title:  The ABCs of solute carriers: physiological, 
pathological and therapeutic implications of human membrane transport 
protein 
            Licensed content author:  MatthiasA. Hediger 
  Licensed content date: February 1, 2004 
  Volume number:  447 
  Issue number:  5 
  Pages:  465-468 
  Type of use:  Thesis/Dissertation 
  Details of use:  Print 
  Portion of the article:  Table 
 
 
 
 204
 License Agreement for Table 1-2 
 
  License number:  2324891475791 
  License date: December 9, 2009 
  License content publisher:  Springer 
  Licensed content publication:  Pflügers Archiv 
  Licensed content title:  Organic anion transporting polypeptides of the OATP/ 
SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new 
nomenclature and molecular/functional properties 
            Licensed content author:  Bruno Hagenbuch 
  Licensed content date: February 1, 2004 
  Volume number:  447 
  Issue number:  5 
  Pages:  653-665 
  Type of use:  Thesis/Dissertation 
  Details of use:  Print 
  Portion of the article:  Table 
 
 
 
 
 205
